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Summary 
This research work focuses on the exploration and analysis of the database 
of the National Study of Health, Well-Being and Aging, SABE Colombia 2015, 
especially in what has to do with the prevalence of Metabolic Syndrome in the 
elderly, and its associated factors. The definition of cohort points of handgrip 
strength, by sex and age in older adults; as well as the probabilities of adverse events 
for each of the domains of intrinsic capacity. And the mediating role of the speed of 
gait of the effect of sarcopenia on activities of daily living. 
The SABE Colombia 2015 survey aims to investigate the current situation, in 
the rural and urban environment, of the elderly, from a social determinants of health 
approach. Within this interest, three secondary studies related to the characteristics 
concerning the determinants of health, care and of individual, sociodemographic and 
environmental factors are proposed. 
Study 1 (Chapter 2) 
The purpose of this study to analyze the prevalence of metabolic syndrome 
and associated risk factors in older individuals aged ≥60 years in Colombia. The data 
for this study came from a secondary cross-sectional, nationally representative 
SABE study Survey on Health, Well-Being, and Aging in Colombia, 2015. Setting 
and participants: A total of 1637 participants (60.7% women, 70.5±7.9 years) from 
86 Colombian municipalities participated. A structured questionnaire was used to 
collect data on socio-demography, lifestyle, and medical conditions. Measurements 
included anthropometric variables, handgrip strength, high-density lipoprotein 
cholesterol, triglycerides, fasting glucose, and blood pressure. Univariate and 
multivariate regression models were established as part of the main analysis. Using 
the harmonized Joint Scientific Statement criteria, metabolic syndrome was present 
in 54.9% of the study population, with a higher prevalence among females than 
males (59.8% vs. 47.3%). Smoking (odds ratio [OR] = 1.59; 95% confidence interval 
[CI] = 1.03–2.44; p=.034), male gender (OR = 1.38; 95% CI = 1.05–1.82; p=.020)
and sarcopenia (OR = 1.63; 95% CI = 1.06–2.52; p=.026) were associated with
increased odds of metabolic syndrome. Metabolic syndrome is prevalent in this study
population. Smoking, male gender, and sarcopenia are associated with metabolic
syndrome. Screening for promotion of healthy lifestyle and nutrition counselling
should be offered routinely among this nationally representative sample of
Colombian older adults.
Study 2 (Chapter 3) 
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The purposes of this study were three-fold: (1) to describe handgrip strength 
in older individuals aged ≥ 60 years in Colombia; (2) to identify sex- and age-specific 
muscle weakness cut-off points in older adults; and (3) to determine the odds of 
adverse events for each of the intrinsic capacity domains for individuals with 
handgrip strength greater than the muscle weakness cut-off points, as compared 
with their weaker counterparts. Methods: A cross-sectional study was conducted in 
Colombia, among 5,237 older adults aged ≥60 years old (58.5% women, 70.5±7.8 
years), according to “SABE Survey 2015”. Handgrip strength data were obtained 
with a Takei dynamometer. Sociodemographic variables, five domains of intrinsic 
capacity (i.e., locomotion, vitality, cognition, psychological, and sensory), and 
medical conditions were assessed and analyzed. Adjustments variables were age, 
ethnicity, socioeconomic status, urbanicity, body-mass index, smoking status, 
alcohol intake, drug use, physical activity, and comorbid chronic diseases. Sex-
stratified analyses were conducted with logistic regression models. Handgrip 
strength was greater among men than among women (26.7 ± 8.5 kg vs 16.7 ± 5.7 
kg, respectively, p<0.001) at all ages. Weak handgrip strength cut-off points ranged 
from 17.4 to 8.6 and 10.1 to 4.9 in men and women, respectively. Overall, 
participants with optimal handgrip strength had better intrinsic capacity (in men, odds 
ratio [OR]=0.62, 95% confidence interval [CI] 0.53 to 0.71; p<0.001; and in women, 
OR=0.79, 95%CI 0.68 to 0.92; p=0.002) than their weaker counterparts. Also, men 
with optimal handgrip strength had a lower risk of hospitalization (OR=0.47, 95%CI 
0.29 to 0.78; p=0.004) than their weaker counterparts. This study is the first to 
describe handgrip strength values and cut-off points for muscle weakness among a 
nationally representative sample of Colombian older adults by age and sex. After 
categorizing older adults as weak or not weak based on the handgrip cut-off points, 
non-weakness was associated with a decreased odds of intrinsic capacity 
impairments. These cut-off points may be good candidates for clinical assessment 
of risks to physical and mental health in older Colombian adults. 
Study 3 (Chapter 4) 
The purposes of this study were three-fold: (1) to describe handgrip strength 
in older individuals aged ≥ 60 years in Colombia; (2) to identify sex- and age-specific 
muscle weakness cut-off points in older adults; and (3) to determine the odds of 
adverse events for each of the intrinsic capacity domains for individuals with 
handgrip strength greater than the muscle weakness cut-off points, as compared 
with their weaker counterparts. A cross-sectional study was conducted in Colombia, 
among 5,237 older adults aged ≥60 years old (58.5% women, 70.5±7.8 years), 
according to “SABE Survey 2015”. Handgrip strength data were obtained with a 
Takei dynamometer. Sociodemographic variables, five domains of intrinsic capacity 
(i.e., locomotion, vitality, cognition, psychological, and sensory), and medical 
conditions were assessed and analyzed. Adjustments variables were age, ethnicity, 
socioeconomic status, urbanicity, body-mass index, smoking status, alcohol intake, 
drug use, physical activity, and comorbid chronic diseases. Sex-stratified analyses 
were conducted with logistic regression models. Results: Handgrip strength was 
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greater among men than among women (26.7 ± 8.5 kg vs 16.7 ± 5.7 kg, respectively, 
p<0.001) at all ages. Weak handgrip strength cut-off points ranged from 17.4 to 8.6 
and 10.1 to 4.9 in men and women, respectively. Overall, participants with optimal 
handgrip strength had better intrinsic capacity (in men, odds ratio [OR]=0.62, 95% 
confidence interval [CI] 0.53 to 0.71; p<0.001; and in women, OR=0.79, 95%CI 0.68 
to 0.92; p=0.002) than their weaker counterparts. Also, men with optimal handgrip 
strength had a lower risk of hospitalization (OR=0.47, 95%CI 0.29 to 0.78; p=0.004) 
than their weaker counterparts. This study is the first to describe handgrip strength 
values and cut-off points for muscle weakness among a nationally representative 
sample of Colombian older adults by age and sex. After categorizing older adults as 
weak or not weak based on the handgrip cut-off points, non-weakness was 
associated with a decreased odds of intrinsic capacity impairments. These cut-off 
points may be good candidates for clinical assessment of risks to physical and 
mental health in older Colombian adults. 
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RESUMEN 
El presente trabajo de investigación se centra en la exploración y análisis de 
la base de datos del Estudio Nacional de Salud, Bienestar y Envejecimiento, SABE 
Colombia 2015, en especial, en lo que tiene que ver con la prevalencia de Síndrome 
Metabólico en personas mayores, y sus factores asociados. La definición de puntos 
de cohorte de la fuerza prensil, por sexo y edad en adultos mayores; así como las 
probabilidades de eventos adversos para cada uno de los dominios de capacidad 
intrínseca. Y el papel mediador de la velocidad de la marcha del efecto de la 
sarcopenia en actividades de la vida diaria. 
La encuesta SABE Colombia 2015 tiene como propósito indagar sobre la 
situación actual, en el entorno rural y urbano, de las personas adultas mayores, 
desde un enfoque de determinantes sociales de la salud. Dentro de este interés se 
proponen tres estudios secundarios relacionados con las características 
concernientes con los determinantes de la salud, el cuidado y de los factores 
individuales, sociodemográficos y del entorno. 
Estudio 1 (Capítulo 2) 
En este primer estudio se analizó la prevalencia del síndrome metabólico y 
los factores de riesgo asociados en personas mayores de 60 años o más. Los datos 
provienen de una encuesta secundaria, representativa a nivel nacional, del estudio 
SABE, sobre salud, bienestar y envejecimiento en Colombia, 2015. Se incluyeron 
1637 participantes (60.7% mujeres, 70.5 ± 7.9 años) de 86 municipios colombianos. 
Se recopilaron datos sociodemográficos, estilo de vida y condiciones médicas. Las 
mediciones incluyeron variables antropométricas, fuerza de agarre, colesterol de 
lipoproteínas de alta densidad, triglicéridos, glucosa en ayunas y presión arterial. Se 
utilizaron modelos de regresión univariada y multivariada. El síndrome metabólico 
estuvo presente en el 54,9% de la población del estudio, con una prevalencia más 
alta entre mujeres que entre hombres (59,8% frente a 47,3%). El Fumar (cociente 
de probabilidad [OR] = 1.59; intervalo de confianza del 95% [CI] = 1.03–2.44; p = 
.034), ser de sexo masculino (OR = 1.38; IC del 95% = 1.05–1.82; p = .020) y poseer 
sarcopenia (OR = 1,63; IC del 95% = 1,06-2,52; p = 0,026) se asociaron con 
mayores probabilidades de tener síndrome metabólico.  
Estudio 2 (Capítulo 3) 
El propósito de este segundo estudio fue describir la fuerza prensil en 
personas mayores de 60 años o más en Colombia; determinando los puntos de 
corte de la fuerza por sexo y edad en adultos mayores; así como las probabilidades 
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de eventos adversos para cada uno de los dominios de capacidad intrínseca para 
individuos con una fuerza prensil mayor, en comparación con sus contrapartes más 
débiles. Se realizó un estudio transversal con datos de 5237 adultos mayores de 60 
años o más (58,5% mujeres, 70,5 ± 7,8 años), según la Encuesta SABE 2015. Los 
datos de fuerza prensil se obtuvieron con un dinamómetro Takei. Se evaluaron y 
analizaron las variables sociodemográficas, los dominios de capacidad intrínseca 
(es decir, locomoción, vitalidad, cognición, psicológica y sensorial) y condiciones 
médicas. Las variables de ajuste fueron la edad, el origen étnico, el estado 
socioeconómico, la urbanidad, el índice de masa corporal, el estado de fumador, el 
consumo de alcohol, el consumo de drogas, la actividad física y las comorbilidades. 
Se realizaron análisis estratificados por sexo con modelos de regresión logística. La 
fuerza prensil fue mayor entre los hombres que entre las mujeres (26.7 ± 8.5 vs. 
16.7 ± 5.7 kg, respectivamente, P <0.001) en todas las edades. Los puntos de corte 
de fuerza prensil baja oscilaron entre 17,4 y 8,6 y entre 10,1 y 4,9 en hombres y 
mujeres, respectivamente. En general, los participantes con una fuerza prensil 
óptima tenían mejor capacidad intrínseca [en hombres, cociente de probabilidad 
(OR) = 0,62, 95% de intervalo de confianza (IC) de 0,53 a 0,71; P <0,001; y en 
mujeres, OR = 0,79, IC del 95%: 0,68 a 0,92; P = 0.002] que sus contrapartes más 
débiles. Además, los hombres con una fuerza prensil óptima tenían un menor riesgo 
de hospitalización (OR = 0,47; IC del 95%: 0.29 a 0.78; P = 0.004) que sus 
contrapartes más débiles. Este estudio es el primero en describir los valores de 
fuerza prensil y los puntos de corte para la debilidad muscular en una muestra 
representativa a nivel nacional de adultos mayores colombianos por edad y sexo. 
Después de clasificar a los adultos mayores como débiles o fuertes según los puntos 
de corte de la fuerza, la fuerza se asoció con una disminución de las probabilidades 
de deterioro de la capacidad intrínseca. 
Estudio 3 (Capítulo 4) 
En el tercer estudio planteamos explorar el papel mediador de la velocidad 
de la marcha en la relación entre la sarcopenia y la dependencia en las ADL. Un 
total de 19,705 adultos mayores con una edad media de 70 años, 55.6% mujeres, 
16.1% con sarcopenia y 14.7% dependencia leve, moderada o severa en ADL. La 
sarcopenia se evaluó mediante la circunferencia de la pantorrilla y la dependencia 
de ADL a través del Índice de Barthel. La velocidad de la marcha se midió en una 
distancia de 3 m. El análisis de covarianza se utilizó para explorar las diferencias en 
la velocidad de la marcha y el índice de Barthel entre los grupos de sarcopenia y no 
sarcopenia. Se realizo una mediación para examinar si la velocidad de la marcha 
mediaba la asociación entre la sarcopenia y los componentes de dependencia de la 
función física. Se encontraron diferencias significativas (p <0.05) en la velocidad de 
la marcha y la dependencia en ADL entre los grupos de sarcopenia y no sarcopenia 
después de ajustar por edad, sexo e índice de masa corporal. Los resultados del 
análisis de regresión del modelo de mediación indicaron un efecto perjudicial 
significativo y directo de la sarcopenia sobre la dependencia en ADL (ß= −0.05; P = 
0.000), y un efecto indirecto significativo de la velocidad de la marcha sobre el efecto 
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directo (−0.009 a −0.004). El efecto negativo de la sarcopenia sobre la dependencia 
funcional fue mediado por la velocidad de la marcha. 
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1. Global and regional aging in numbers 
 
Aging is a global phenomenon. It is estimated that the adult population over 
60 years of age reached 962-million people in 2017. It is expected for this number 
to duplicate in the next 30 years, estimating that by 2050 this figure can reach 2.1-
billion elderly people throughout the world (1,2). According to global epidemiological 
analyses, growth of the elderly population is not equal in each of the regions of the 
world, given that this population growth depends on the economic development in 
each of the world´s regions. It is estimated that 71-million people (>60 years of age) 
live in Latin America, which represents 11.2% of the region’s population. In the 
Caribbean, this figure reaches 13.2%. By 2100, the population in Latin America and 
the Caribbean will be comprised of 32% elderly adults (3,4).  
 
Rapid global epidemiological growth of the elderly population is justified by 
progress in the control and treatment of chronic disease, pandemic control, reduction 
of military conflicts, progress in agriculture, technological development, access to 
better public services, aspects that have contributed to reduced all-cause mortality 
in the world (5) and a five-year increase in life expectancy of the global population in 
the last 18 years (6).   
 
2. Aging, health, and wellbeing in Colombia 
 
The 2018 Colombian National Census reported that 13.4% of the population 
is composed of elderly individuals (>60 years of age); where women represent a 
higher proportion with 54.2% against men with 45.8%, respectively (7). The trend in 
Colombia is of rapid elderly population growth, expecting by 2021, to have an elderly 
individual for every two Colombian adolescents (8). Added to this, it should be 
considered that Colombia is one of the countries in the region with greater social 
inequality in this population, which is why conditions to access healthcare services, 
education, pension, and quality of life are low (9,10).  
 
In response to this situation, the national government has been consolidating 
the National Policy on Aging and Old Age (8). This policy was formulated in late 
2007, seeking to protect, promote, and defend the rights of elderly individuals in 
compliance with that mandated by Legislation 1151 of 2007 (11). Another important 
norm is Legislation 1315 of 2009 (12), which determines the minimum conditions to 
guarantee care and provide quality comprehensive services to the elderly. This 
normative framework seeks to improve conditions of equality, autonomous life, 
dignity, and health in the elderly in Colombia (8).  
 
Thereafter, the Ten-Year Public Health Plan for 2012 – 2021 (PDSP, 2012-
2021) was proposed (13) in which aging is a priority from an approach of health 
determinants. One of the strategies proposed by the (PDSP, 2012-2021) is that of 
designing an information structure that permits characterizing the population aging 
process at national and territorial levels, given that Colombia needs up-to-date data 
21 
 
and primary sources of information on the situation of the elderly (14). To meet this 
need, the Ministry of Health and Social Protection and COLCIENCIAS have 
promoted the SABE Temporary Union, conformed by diverse research groups from 
Universidad del Valle and Universidad de Caldas, with collaboration from the 
National Consulting Center (CNC, for the term in Spanish) to develop the Survey on 
Health, Wellbeing, and Aging (SABE-Colombia) between 2014 and 2015 (14,15). 
 
The SABE-Colombia survey sought to know the current situation, in the rural 
and urban settings, of the elderly population in Colombia through interdisciplinary in-
depth exploration and evaluation of old age and aging, within the framework of the 
determinants of active aging and from the model of Social Health Determinants (15).  
 
The sample was comprised of 24,553 people and, supposing an 80% 
response, the objective sample was made up of 30,691 individuals from 32 
departments (16). However, during the field work and after implementing various 
strategies to achieve the general sample, the response proportion was of 
approximately 70%, which varied according to the regional and urban/rural 
distribution. The final sample size (including 244 municipalities) was of 23,694 
elderly individuals (16). 
 
The survey reported information on socioeconomic aspects, the physical and 
social environment, behavior, cognition and affect, functionality, mental wellbeing, 
health conditions, and use and access to health services. Likewise, biochemical 
tests were taken to measure levels of glucose, lipid profile, and hemoglobin. 
Anthropometric measurements were taken, like weight, height, circumference of the 
waist, calf, and arm. In addition, blood pressure was measured and functionality tests 
were performed, like handgrip strength, gait rate, balance and time of incorporation 
from a chair (14,15). 
 
The 2015 SABE-Colombia is part of the multicentric project by the Pan 
American Health Organization (PAHO), the Survey on Health, Wellbeing, and Aging 
by SABE 2015 in Latin America and the Caribbean (16–18). This project was 
conducted in seven capital cities of Latin America and the Caribbean (17). The SABE 
survey becomes a starting point in the systematic study of aging in urban zones in 
the region of Latin America and the Caribbean (19). This regional effort has permitted 
achieving specialized databases between countries that are comparative and 
compatible to each other; likewise, it has permitted development of expertise among 
professionals from different areas and has favored profound reflection on the 
conditions of the elderly in the region. 
 
Another antecedent of the 2015 SABE-Colombia is the SABE Bogotá study 
conducted in 2012, with a sample of 2,000 elderly individuals from urban and rural 
zones in the city, ranging between 60 and 100 years of age, with this being a 
representative sample of over 700,000 people 60 years of age or more living in the 
city (19). The results obtained permitted characterizing conditions of sarcopenia in 
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adults with COPD/Asthma (20), the frequency of vaccinations in the elderly 
population, and the association with socioeconomic and health factors (21), 
prevalence and frailty and sarcopenia and its associated factors (22); along with the 
report of the prevalence of multi-morbidity and depression symptoms in the elderly 
in the city (23). This work of SABE Bogotá was considered a preparation exercise 
for the national survey. This PhD work was based on performing secondary analyses 
of the data from this national survey. 
 
3. Healthy Aging 
 
Aging has been described as a multifactor phenomenon of decline or 
progressive, non-linear and irreversible loss of the individual’s capacities occurring 
throughout life (24). This phenomenon is conditioned by different cultural, social, 
intrapersonal, biological processes and by the life story of each individual, added to 
the development of risk factors against chronic disease and exposure to 
environmental conditions. In light of this fact, the aging phenomenon is a process 
inherent to life itself (25). It can be optimized by improving health and reinforcing 
social, productive, learning, wellbeing, and quality-of-life opportunities. 
Different theoretical and conceptual models of psychosocial and biomedical 
origin have been proposed to understand and promote a better way of aging (26). 
Among these, the successful aging model proposed by Rowe and Kahn (27) is 
highlighted. This is understood as the actions carried out to reach a high level of 
satisfaction and happiness upon processes of life changes. Therefore, with sufficient 
levels of physical activity, maintenance of cognitive functions, and preservation of 
interpersonal relationships, the possibility of getting sick can be reduced (28). 
Another model is that of Selection, Optimization, and Compensation (SOC) by Baltes 
& Baltes (29). It centers on the strategies people use to compensate for losses due 
to aging, generating compensations that permit maintaining a sufficient level of 
functionality with a high degree of perception of wellbeing. In this same line, there is 
the model proposed by Kahana & Kahana (30), which is based on the 
implementation of prior strategies to prevent and control stressful factors or their 
effects that can alter the perception of wellbeing. Recently, other proposals have 
emerged, like: the productive aging (31), positive aging (32), optimal aging (33), and 
independent aging (34). Concepts formulated from the positive view of aging, 
counteracting the focus of decline or functional loss of the pathological elderly 
individual, resulting from the disease burden (35).  
Based on the aforementioned, since the 1990s, the World Health 
Organization (WHO) has promoted the concept of Active Aging, proposed from an 
approach of equality of rights for the elderly, prioritizing independence, participation, 
dignity, assistance, and performance of their own desires. The concept of healthy 
aging is understood as a process of development and maintenance of the functional 
capacity in individuals, which permits achieving wellbeing in old age (36,37), where 
functionality is the determinant of the interaction with the environment, independent 
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from the presence or not of disease. What it seeks is to have a higher number of 
years of life with a good state of health to continue with life’s purposes. Hence, 
healthy aging focuses on an individual’s functional capacity, on their physical and 
mental capacities and how these allow them to interact in the environments they 
inhabit (38).  
From this logic, in 2016, the Global Strategy and Action Plan on Aging and 
Health (GSAP) was first proposed as a commitment by the member states of the 
world health assembly to adopt measures to trigger the creation of the next ten-year 
plan for active and healthy aging, 2020 – 2030 (39). Among the multi-sector actions 
proposed there is active aging, as a way of recognizing and exalting the capabilities 
and experience of the elderly in social, economic, cultural, spiritual activities and as 
a citizen in the possibilities of participating and contributing to society (40). What 
active aging provides are opportunities of social integration, health, and wellbeing 
through maintaining and improving the functional and intrinsic capacity in the elderly 
(34,41).  
In contrast to the aforementioned, one of the principal problems the elderly 
have is physical inactivity (PI), which has been increasing significantly in the last 20 
years globally (42). Due to its rapid spread, PI is considered a pandemic, which is 
strongly associated with the presence of non-communicable diseases (NCD) in 
adults and in the elderly (43). Within this context, recent cross-sectional studies 
indicate that the prevalence of PI in the elderly is above 50%, as reported by Chan 
et al.,(44) after analyzing adults ≥60 years of age (n = 3,790) from the National 
Health and Morbidity Survey (NHMS) in Malaysia, demonstrating 48.8% PI 
prevalence. Likewise, higher prevalence has been reported, like those in the United 
States (45) and Brazil (46) with 73% and 62%, respectively. In Europe, (47), PI 
prevalence is at 12.5%, according to the Survey of Health, Aging, and Retirement in 
Europe (SHARE), which analyzed people over 55 years of age (n = 19,298) from a 
total of 58,489 people from 16 countries. The PI prevalence varied among different 
European countries, ranging between 4.9% in Sweden and 29% in Portugal.  
These prevalence studies also suggest various factors associated with PI in 
the elderly, like gender, where PI is more prevalent in women, in elderly people, in 
adults with higher income, in people who consume less fruits and vegetables (<5 
portions/day), in people who remain mostly seated, and with presence of NCD, like 
diabetes, and with mobility limitations. Similarly, several authors (48–50) have shown 
how PI is a risk factor associated with suffering from NCD, like type II diabetes, 
cardiovascular disease, and premature mortality. Additionally, nearly 92% of the 
elderly live with a chronic disease (51) and 62% of the elderly live with two or more 
co-morbidities (52). 
3. Benefits of physical activity in the elderly 
 
Physical activity (PA) is considered one of the most important strategies to 
control and prevent NCD. Organizations, like the American College of Sports 
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Medicine) (53) and the American Heart Association (54) coincide on recommending 
for the elderly to engage in at least 150 minutes (2 hours and 30 minutes) to 300 
minutes (5 hours) of moderate-intensity PA per week, or 75 minutes (1 hour and 15 
minutes) to 150 minutes (2 hours and 30 minutes) of vigorous-intensity PA, or an 
equivalent combination between both intensities, accompanied by at least two days 
of muscle strengthening activities per week, as proposed by the Physical Activity 
Guidelines for Americans (55,56). 
Together with the aforementioned, consistent epidemiological and 
experimental evidence exists on the benefits of PA on health and on the physical 
and mental function in the elderly (57–61). An example of this is found in a recent 
meta-analysis proposed by Northey et al., (62) which analyzed 39 clinical trials with 
interventions of aerobic physical exercise, endurance training, multi-component 
training, and Tai chi in adults over 50 years of age. The exercise interventions were 
conducted in 45- to 60-min sessions with moderate intensity. The results reported 
significant association (0.29; 95%CI: 0.17 to 0.41; p <0.01) among the subjects who 
exercised with improvement in the cognitive function.  
Other studies also confirm how PA can delay brain aging (63–66). Raichlen 
et al., (67) examined neuro images from the National Biobank of the United Kingdom 
in (n = 7,148 subjects; male = 3,062; female = 4,086; age = 62.14 ± 7.40 years), 
crossing such with variables, like moderate to vigorous physical activity (MVPA) and 
cardiorespiratory fitness (CRF). These authors reported how MVPA and CRF 
associated positively with changes in the general volume of grey matter (p = 1.28 E-
05). Likewise, when data were adjusted first by CRF, followed by MVPA, these 
associated positively with changes in the volumes of the left and right hippocampus 
(p left = 0.01; p right = 0.02), but without changes in the general volume of grey 
matter. These results suggest that MVPA and CRF are powerful neuro-physiological 
stimuli that, through different mechanisms, can generate structural changes at brain 
level in the elderly. 
Similarly, other works have centered on understanding the changes caused 
by PA on some health predictors, like inflammatory markers in the elderly. However, 
although the results are not completely conclusive, it is considered a promising line 
of research to understand the effects of PA on the systemic inflammatory response, 
which is generated by NCD. Recently, Guohua Zheng et al., (68) performed a meta-
analysis with 11 randomized controlled trials (RCT) in a sample of 1,250 participants. 
The experimental group engaged in aerobic exercise during four weeks, with three 
or more exercise sessions per week. The results showed that aerobic exercise 
reduces significantly the inflammatory markers (C– Reactive Protein (CRP): 
Standard Mean Difference, SMD = 0.53, 95%CI 0.26–0.11, p = 0.0002; Tumoral 
Necrosis Factor Alpha (TNF-α): SMD = 0.75, 95%CI 0.31–1.19, p = 0.0007; 
interleukin 6 (IL-6): SMD = 0.75, 95%CI 0.31–1.19, p = 0.0007), which is why aerobic 
exercise has a positive effect on reducing CRP, TNF-α, and IL-6 in the elderly.  
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These findings coincide with another meta-analysis proposed by Sardelli et 
al., (69) who analyzed the effects of endurance training on inflammatory markers of 
the elderly in 13 RCTs, where endurance training reduced CRP in the elderly [DME] 
= - 0.61; 95%CI = -0.83; -0.31, p <0,001), tended to reduce IL-6 (SMD = -0.19, 95%CI 
= -0.42; 0.02, p = 0.07), and reported no changes in TNF-α. Other analyses in the 
subgroups showed a possible association between muscle mass for changes in CRP 
and in TNF-α. Reductions in CRP and TNF-α only occurred in the RCTs that carried 
out a greater number of exercise (> 8), greater weekly frequency (three times/week), 
and durations over 12 weeks. These results demonstrate the anti-inflammatory effect 
of aerobic and endurance physical exercise, which depends on the muscle mass 
and CFR in the elderly. 
All these works on the benefits of PA in the elderly reveal its importance within 
the active aging approach, with multi-component interventions with physical exercise 
being fundamental to diminish morbidity and delay disability processes in the elderly 
(70,71). 
5. Intrinsic and functional capacity in the elderly 
 
Intrinsic Capacity (IC) is a term proposed recently by the WHO (2). It is 
conceived as a multi-dimensional indicator of the functional state of people, which is 
quantifiable throughout life (72). The IC is defined as the sum of all the individual’s 
physical and mental capacities (59). This capacity becomes the base for the 
Functional Ability (FA). A higher relation between individuals and their environment 
indicates higher FA degree and independence (58,60).  
 
The IC focuses on the function and not on the deficiencies or losses resulting 
from disease. It is believed that IC is a holistic approach, proposed to better 
comprehend the aging process (2). It may be said that IC is a theoretical construct 
that originates from the International Classification of Functioning, Disability, and 
Health (ICF) (75), also derives from the results of the English Longitudinal Study of 
Aging (ELSA) and the Hertfordshire Aging Study (HAS) in the United Kingdom (76). 
  
Figure 1 represents IC as the inner part of a cube, center of FA, determined 
by the individual’s personal and phenotypic characteristics. Likewise, it is 
conditioned by trends related with age, health habits, traits and abilities, gradual 
accumulation of biological changes, risk factors, presence of diseases and lesions, 
and geriatric syndromes.  
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Figure 1. Conceptual model of healthy aging. Modified from reference (2). 
Reprinted courtesy of the Copyright Holder under a Creative Commons License 
CC BY 2.0 (https://creativecommons.org/licenses/by/2.0/) 
 
The IC is a dynamic construct that changes throughout life. The Healthy Aging 
model by the WHO proposes that IC reaches its maximum point during adult age 
and tends to decline as of middle age. This decline is different in each person, among 
individuals, and within each IC domain (74). These differences may be observable 
through continuous evaluations of the IC domains, which permit estimating a course 
or trajectory of IC over time, independent of the biological aging (2), Figure 2. 
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Figure 2. Trajectories of FA and IC. Modified from reference (2). Reprinted 
courtesy of the Copyright Holder under a Creative Commons License CC BY 2.0 
(https://creativecommons.org/licenses/by/2.0/) 
 
Cesari et al., (77) refer to five IC domains, which are necessary for its proper 
screening. These domains are: cognition, psychological aspects, sensory (vision 
and audition), locomotion, and vitality. It is important, to consider these domains as 
a cluster of information, which must be studied together from an integrative 
approach. Measurement and follow up of these domains become important 
biomarkers to predict health, functionality, quality of life, and dependence in the 
elderly (78). The following describes each of these aspects. 
 
 Regarding the cognitive domain, the decline of the cognitive function is a 
frequent problem during aging. In recent decades, research has focused on 
demonstrating the relationship between the decline in the cognitive function as a 
stage prior to dementia (79), Alzheimer’s disease (80), and Parkinson (81). Among 
the possible mechanisms showing this relationship are changes in the cerebral 
vascular function during aging (82). The cognitive function is an important indicator 
of risk of mortality, disability, and of poor quality of life in the elderly (83). Due to this, 
its measurement is primordial as an indicator of the cognitive domain within the IC. 
For this, different neuro-psychological tests have been used to measure memory, 
intelligence, and capacity to solve problems (84). The test used in screening 
cognitive function is the Mini Mental State Examination (MMSE)(85–87). 
 
 In addition, psychological disorders and affective diseases are highly 
prevalent in the elderly (86). These disorders represent risk of mortality, principally 
due to cardiovascular disease (88). Similarly, these psychological disorders are 
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related significantly with the presence of mental diseases, like: depression, 
schizophrenia, bipolar disease, and anxiety disorders (89). Due to the 
aforementioned, psychological aspects become an essential domain of IC, which 
seeks to evaluate the social interactions of the elderly, as well as the emotional 
vitality and mood state (77). Monitoring the psychosocial aspects permits early 
detection of mental disease in the elderly. The Geriatric Depression Scale (GDS-15) 
(90,91) is among the instruments used to identify and distinguish symptoms of 
depression and dementia. 
Sensory deficits are among the principal causes of falls in the elderly (92). 
Globally, 285-million people have visual impairment. Of these people, the elderly 
represent from 65% to 82% of these figures (93). Visual impairment affects the 
cognitive domain and the mobility domain within IC (94), generating a higher risk of 
hospitalization (95), disability (96), co-morbidities, like psychiatric diseases (97) and 
mortality (98). The Peek Acuity test (99) is suggested to assess visual acuity in the 
elderly; it is used in the clinical practice and in the community environment. 
Other frequent sensory deficiencies are hearing loss caused by impairment 
of the vestibular system in the elderly. It is estimated that from 50% to 80% of the 
population over 80 years of age has between moderate and severe hearing disability 
(100). Hearing disability is associated with degenerative diseases, like Alzheimer's. 
It is also associated with poor quality of life (96), depression (101), low mobility (102), 
and risk of all-cause mortality (103). The instrument to evaluate auditory sensory is 
the Whispered Voice Test (WVT) (104,105) in adults. These sensory deficiencies 
are considered another domain to bear in mind within the IC. 
The following IC domain is that of locomotion. This domain is fundamental to 
estimate functionality in the elderly. It is so important that, according to the theory of 
continuous movement, the existence of life on the planet is strongly tied to movement 
from the molecular to the macro (106). Locomotion is associated with different states 
of health (74). Balance, strength, and gait rate are indicators of FA and locomotion 
in the elderly. Neuromuscular changes affect balance, strength, and gait in the 
elderly, which is why they are associated with a higher risk of falls (107,108). Hence, 
low muscle mass and strength is associated with all-cause mortality (109) and 
physical disability (110) in the elderly. Other associations have been identified, like 
the association between obesity and decline in gait rate (111). 
Regarding gait rate, it is a valid and reliable measure to predict reduction in 
dependence, mortality due to cancer, and cardiovascular disease (112). The Short 
Physical Performance Battery (SPPB) tests (113) are used to adequately evaluate 
the locomotion domain. 
Finally, the last domain is that of vitality. This term gathers those functions 
that guarantee adequate body homeostasis (74), mainly that having to do with 
energy expenditure, metabolism, nutritional state, and hormone activity. With aging, 
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changes take place in all these aspects of energy regulation. The capacity of the 
elderly to maintain adequate nutrient absorption processes, as well as reduction in 
taste, smell, and changes in hormonal and metabolic mediators are changes related 
with aging. Energy expenditure and basal metabolic rate are also compromised with 
aging (114,115). To assess part of these changes in the nutritional and metabolic 
state in the elderly, the Mini-Nutritional Assessment Scale Short Form (MNA-
SF)(116) should be used. This scale provides information on the nutritional state, 
symptoms of acute disease, psychological stress, weight loss, and food intake. It 
also provides information on prior conditions of frailty and to the Frailty Syndrome, 
as well as information on the cognitive function and possible depression states (117).  
 
 
Figure 3.  Schematic diagram of the five IC domains. Modified from 
reference (77). Reprinted courtesy of the Copyright Holder under a Creative 
Commons License CC BY 2.0 (https://creativecommons.org/licenses/by/2.0/) 
 
As noted, clinical and epidemiological evidence exists that describes the 
behavior of the five IC domains of cognition, psychological aspects, sensory (vision 
and audition), locomotion, and vitality. The set of six instruments suggested to 
measure IC have demonstrated adequate accuracy and sufficient predictive capacity 
(74). Nevertheless, it is still necessary to advance in understanding the relationships 
among domains and their indicators with other clinical and subclinical methods to 
measure health and functionality.  
One of the principal barriers confronted by the IC concept is its insertion within 
health systems and policies, which are centered on identifying and treating the 
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disease deficits, then on the organism’s residual wellbeing. The IC is a theoretical 
construct in processes of consolidation. 
6. Multi-morbidities associated to aging 
 
Aging can be understood as a physiological process of determined change 
occurring at different levels, from the molecular to the multi-systemic. This process 
has a plausible explanation from biology as a phenomenon of slow impairment and 
programmed death at long-term cell level, which is known as "Slow Phenoptosis" 
(SP) related with age (118,119).  
Among the manifestations of SP, we must consider the shortening of 
chromosome telomeres resulting from the cell division (120), cell apoptosis (121), 
variations in cell duplicity rates, and epigenetic alterations in the DNA structure (122), 
or in mRNA intracellular signaling pathways (123). All these changes lead to chronic 
systemic inflammation, alterations in the energy metabolism, and modifications of 
the neuromuscular function (124). The prior systemic changes become co-
morbidities or multi-morbidities of aging, which are conceived as a condition or 
grouping of chronic circumstances that predispose to functional and cognitive 
impairment, frailty, disability, and even mortality in the short term in the elderly. 
The most frequent co-morbidities are high blood pressure (HBP); venous 
insufficiency; metabolic conditions, like diabetes, dyslipidemia; musculoskeletal 
conditions, like arthritis, osteoarthritis, chronic pain (125); cardiovascular disease; 
pulmonary disease; and sensory and mental diseases, like schizophrenia(126). 
These co-morbidities are determining factors in the health and quality of life of the 
elderly. This is why chronic multi-morbidity has become an important theme in caring 
for the elderly, so much so that the National Institute for Health and Care Excellence 
(NICE) in the United Kingdom proposed in 2016 the first recommendation and 
prioritizing guide of multi-morbidity, its measurement, and clinical management for 
health professionals (127). 
The prevalence of co-morbidities in the elderly population has been well 
studied, which is why their prevalence in general is between 55% and 98% in 
individuals over 60 years of age. These co-morbidities increase with age, occur more 
in women and in low-income individuals. Several combinations can be produced of 
pathological processes that coexist and make complex the condition of health (128).  
Various studies have analyzed in depth multi-morbidities in the elderly; such 
is the case of the work proposed by Sakib et al., (129), which conducted an analysis 
of the national base of the Canadian longitudinal study, which extracted data from 
81,179 participants between 45 and 85 years of age. Through self-report, 27 different 
morbidities were identified. A multiple regression was performed to determine the 
association between sociodemographic and lifestyle factors. Of all the participants, 
39.6% (99%CI 38.4-40.7) had 3+ chronic morbidities. Prevalence of 4+ to 5+ 
morbidities was at 14.2% in individuals over 60 years of age; 52% of the elderly had 
3+ co-morbidities. Likewise, (ELSA Study) in Brazil, 19 different types of co-
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morbidities were identified, classifying the multi-morbidity between ≥ 2 and ≥ 3. From 
the total of 9,412 individuals, 67.8% (95%CI 65.6-69.9) and 47.1% (95%CI 44.8-
49.4) showed ≥ 2 and ≥ 3 diseases, respectively. The most frequent morbidities 
included back problems and systemic high blood pressure; co-morbidities ≥ 2 were 
between 11.6% and 23.2%; and morbidities ≥ 3 were between 4.9% and 9.5% (130). 
The appearance of multi-morbidity in the elderly is high even since middle age. 
Multi-morbidity is a fundamental element in the intervention of the elderly, 
given that with a higher number of morbidities coexisting in the individual, the clinical, 
therapeutic, and pharmacological management becomes complicated, which 
increases the demand for more specialized health services, an increase in the risk 
of frailty and functional and cognitive impairment (131).  
Figure 4 presents a schematic diagram of the relation between increased 
demands on health care resulting from the severity and the complexity of the co-
morbidities. 
 
 
Figure 3. Multi-morbidity model in the elderly. Modified from reference (131). 
Reprinted courtesy of the Copyright Holder under a Creative Commons License 
CC BY 2.0 (https://creativecommons.org/licenses/by/2.0/) 
 
In recent years, the spectrum of multi-morbidities has increased, if we bear in 
mind distinct psycho-social aspects, like depression and complex conditions with 
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frailty (22,72,126) and sarcopenia (20,110,132). Thereby, multi-morbidities become 
a growing challenge for the health sector, which requires greater evidence-based 
knowledge and an effective clinical practice for their control and management (133).  
A practical way of predicting the severity in the health condition of individuals 
in relation with the morbidities is by applying distinct multi-morbidity prediction 
indices. Among the instruments most commonly used, there is the multi-morbidity 
index (MMI) (134), which conducts a prognosis of the patients from their clinical 
chart. Taking each diagnosis as an independent variable and using the International 
Classification of Disease, the Cumulative Illness Rating Scale for Geriatrics (CIRS-
G), which uses a scoring system that includes 14 domains, one for each body system 
and a severity scale for each domain (40). Additionally, the Charlson Co-morbidity 
Index (CCI), which helps to predict the risk of mortality due to diabetic neuropathy 
(136); the Kaplan-Feinstein Index (KFI) evaluates the prognosis of patients with 
diabetes in relation with their co-morbidities (137); and the Index of Coexistent 
Diseases (ICD) as strong prediction factor of mortality in kidney patients on dialysis 
(138)(139). Presence of multi-morbidities is associated with a higher degree of 
functional loss and disability (140). Profound knowledge of the evolution of multi-
morbidities is an essential element to bear in mind when implementing plans and 
programs of physical activity and physical exercise in the elderly. 
Finally, this chapter provides a general view of the principal categories of this 
PhD thesis work. Initially, it displayed global and regional epidemiological data of 
aging, and contextualized on the situation of aging, health, and wellbeing of the 
elderly in Colombia. This was followed by the presentation of the concept of healthy 
aging, the benefits of physical activity in the elderly, IC and FA, and the multi-
morbidities associated with aging. The presentation of these concepts is 
fundamental for the study and comprehension of IC as multidimensional indicator of 
functionality and its possible relation with the prevalence of metabolic syndrome, its 
associated factors, definition of cohort points of handgrip strength, and the mediating 
role of gait rate in the relationship between sarcopenia and dependence in the elderly 
in Colombia. 
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1. Introduction 
 The number of elderly people worldwide is expected to double over the next 
50 years [1,2]. Older (> 60 years old) in Latin America and the Caribbean will reach 
~101 million (15% of the population) [3]. For Colombia, the mean life expectancy will 
rise to 77.6 years for women and 69.8 years for men in 2025. Due to this, the Pan 
American Health Organization (PAHO) and the Merck Institute of Aging and Health 
called for greater surveillance over the causes of morbidity and mortality in older 
adults [4]. 
 
 The Metabolic Syndrome (MS) is a complex cluster of cardiovascular risk 
factors that are associated with a sedentary lifestyle, poor nutrition, and consequent 
obesity, and is strongly associated with cardiovascular diseases, include glucose 
intolerance (type 2 diabetes, impaired glucose tolerance, or impaired fasting 
glycemia), insulin resistance, abdominal obesity, dyslipidemia, and hypertension 
[5,6]. Accordingly, MS increases the risk of developing diseases of cardiovascular 
origin such as acute myocardial infarction [7], ischemic stroke or coronary heart 
disease [8,9]. Indeed, the prevalence of cardiovascular disease attributable to MS is 
around 12–17% [10].  
 
Several studies have deepened in the analysis of the presence of MS in Latin 
America reporting its associated factors such as increasing age, Hispanic or 
indigenous heritage, physical inactivity, high alcohol intake, smoking, history of 
hypertension or type 2 diabetes (first-degree family members), and belonging to a 
low socioeconomic status [11]. Likewise, the general prevalence of MS in Latin-
American countries has been established in 24.9% (range: 18.8–43.3%) and is 
slightly more frequent in women (25.3%) than in men (23.2%). On the other hand, 
several risk factors for MS have been suggested, such as alcohol/cigarette smoking 
intake, residence (urban/rural) and inflammatory markers [12], dietary factors, such 
as intake of total fat or saturated fat [13], physical inactivity, and poor physical fitness 
[14]. We previously demonstrated in Colombian collegiate students aged 18–30 
years that those with the sex (male), age (over 23 years old), weight status 
(overweight or obese) and having an unhealthy waist to height ratio were more likely 
to have a prevalence of MS [15]. Additionally, other studies that included diverse 
Hispanic/Latino populations suggested a marked heterogeneity in risk factor 
prevalence within this population [16].  
 
 Latin America has undergone a well-documented epidemiologic transition 
fueling a non-communicable disease epidemic [17] and makeable changes in 
people´s lifestyles that may contribute to greatly increased burden on cluster of 
cardio-metabolic disease as MS [11]. However, only a few studies have analyzed 
MS prevalence specifically in older adults, in whom important changes could still be 
made to their lifestyles to improve independence and quality of life, as well as 
preventing other lethal diseases. Therefore, the aim of this study were to analyze the 
prevalence of MS and its influencing factors in Colombian older people from a 
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sample of the SABE Colombia study. Understanding the MS prevalence in the 
national level is important to develop the effective programs and strategies to prevent 
and control MS.   
 
2. Materials and Methods  
 
2.1. Study Design and Sample Population 
 
 This study is part of the 2015 SABE study Survey on Health, Well-Being, and 
Aging in Latin America and the Caribbean, which is a multicenter project conducted 
by the Pan-American Health Organization (PAHO) and supported by the 
Epidemiological Office of the National Health Ministry in Bogotá, Colombia 
(https://www.minsalud.gov.co/). Details of the survey have been published 
elsewhere [18]. The instrument used was derived from the original SABE study 
conducted in 5 Latin America capital cities [19]. The estimated sample size was 
24,553 individuals, and assuming an 80% response of the target sample was 30,691 
individuals [18]. The final sample size achieved, (including 244 municipalities) was 
23,694 elderly Colombians. Institutional review boards involved in developing the 
SABE-Colombia study (University of Caldas, ID protocol CBCS-021-14, and 
University of Valle, ID protocol 09-014 and O11-015) reviewed and approved the 
study protocol. Written informed consent was obtained from each individual before 
inclusion and completion of the first examination. Permission and details available in 
https://www.minsalud.gov.co/. The study protocol to the secondary analysis was 
approved by the Human Subjects Committee at the Pontificia Universidad Javeriana 
(ACTA ID 20/2017-2017/180, FM-CIE-0459-17). 
 
 The survey included elderly Colombians (≥60 years) using purposive, 
randomized sampling (urban and rural areas). In this sub-sample, 86 municipalities 
were defined for blood sampling, and two out of every five people were called to 
participate. A total of 1637 were included in the present analysis. 
 
2.2. Measurements 
 
 Data collection staff was trained by the research teams of the coordinating 
centers (Universities of Caldas and Valle) for face-to-face interviews and physical 
measurements. Body mass index (BMI) was estimated in kg/m2 from the measured 
weight and height. Sarcopenia was defined according to calf circumference (CC) as 
a "proxy" measure for assessing early identification of sarcopenia in clinical practice, 
due to the low cost and ease of obtaining [20]. As described by Rolland et al., [20] a 
CC smaller than 31 cm is considered to be indicative of sarcopenia. This cut-off has 
been recommended for use in older individuals by the WHO Expert Committee [21].  
 
Handgrip strength was assessed on a Takey dynamometer (Grip Strength 
Dynamometer Model T.K.K. 5001®, Takei Scientific Instruments Co., Ltd, Niigata, 
Japan) including the highest value (kg) from two attempts (both hands). Handgrip 
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strength was categorized into 3 levels by sex (low, moderate and high) according to 
the KORA-age study [22]. 
 
Blood samples were taken by puncturing the capillary vein under 
standardized conditions, with the participant having fasted at least 10–12 hours 
beforehand. The biochemical profile included: (i) HDL-cholesterol (HDL-c); (ii) 
triglycerides; (iii) low-density lipoprotein cholesterol (LDL-c); (iv) total cholesterol; 
and (v) glucose fasting. Samples were analyzed by standard enzymatic colorimetric 
methods. Blood Pressure, Diastolic (DBP) and systolic (SBP), was measured with 
subjects in rest (5-min) with an automated procedure using the OMRON HEM – 705 
monitor (Omron® Healthcare Europe BV, Hoofddorp, The Netherlands).   
 
 For the lifestyle, personal habits regarding alcohol intake (participants were 
categorized as those who do not drink and those who drink less than one day per 
week, two to six days a week, or everyday) and smoking status (participants were 
categorized as those who do not smoke and those who have never-smoked, those 
who currently smoke, or those who previously smoked) were recorded. A “proxy 
physical activity” report was conducted by the following questions: (i) "Have you 
regularly exercised, such as jogging or dancing, or performed rigorous physical 
activity at least three times a week for the past year?" (ii) "Do you walk at least three 
times a week between 9 and 20 blocks (1.6-km) without resting?" and (iii) "Do you 
walk at least three times a week 8 blocks (0.5-km) without resting?" Participants 
were considered physically active if they responded affirmatively two of the three 
questions. Self-reported comorbidities were assessed by asking the participants if 
they had a diagnosis made by a physician. 
 
2.3. Definitions of MS 
 
 MS was defined according to the most recent Joint Interim Statement of the 
International Diabetes Federation Task Force on Epidemiology and Prevention [23] 
by adopting the Ethnic Central and South American criteria for waist circumference. 
Participants were classified as having MS if they had at least 3 of following metabolic 
risk factors or components (MS-components): abdominal obesity (waist 
circumference ≥90 cm for Latin-American men and ≥80 cm for Latin-American 
women; elevated triglycerides (fasting serum triglycerides  ≥150 mg/dL or taking 
medication for abnormal lipid levels); reduced HDL-c (fasting serum HDL-c <40 
mg/dL in males; <50 mg/dL in females or specific treatment for this lipid abnormality); 
elevated blood pressure (SBP ≥130 mmHg or DBP ≥85 mmHg or taking 
hypertension medication); elevated fasting glucose (serum glucose level ≥100 
mg/dL or taking diabetes medication). 
 
2.4. Definitions of potential influencing factors 
 
 Potential influencing factors included sex (male/female), sarcopenia status 
(≤31 cm with sarcopenia or >31 cm without sarcopenia), handgrip strength 
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categorized into 3 score by sex (low, moderate and high levels), alcohol intake 
(never or no/current or yes), smoking status now (never or no/current or yes), and 
physical activity “proxy” levels (physically active/non physically active). 
 
2.5. Statistical Analysis 
 
 General characteristics from the study sample are presented as frequency 
and percentage or as the mean and standard deviation (SD). Two-way analysis of 
variance or the χ2 test to compare sex and age differences were used. Descriptive 
analysis of the prevalence of the MS by sex an age stages, as well as, a descriptive 
analysis of the MS-components have been presented in figures using percentages. 
Relationships between influencing factors of MS and MS (categorical variables) have 
been performed by Pearson Chi-square.  
 
 Simple logistic regressions were performed individually for each independent 
variables to analyze the association with MS. MS was included in each simple 
logistic regression as the dependent variable (reference: to have MS). Sex with 
males as an indicator, age, BMI, to have sarcopenia, handgrip strength with the high 
level of strength as an indicator, be a smoker, have alcoholic intake, and be 
physically inactive, were included as fixed factors.  
 
Then, a multiple logistic regression was used to identify the main predictor or 
influencing factors associated (clinical characteristic) of MS including at the same 
model: sex (indicator: male), sarcopenia (indicator: to have sarcopenia), handgrip 
strength (indicator: high level of handgrip strength) smoking habit (indicator: be 
smoker), alcoholic habit (indicator: to have alcoholic habit) and physical activity 
levels (indicator: be physically inactive) as independent variables. Both, simple 
logistic regression and multiple logistic regression (model) used the intro method. 
Multiple logistic regression was adjusted by the following confounders: age, 
ethnicity, socioeconomic status, urbanicity, BMI, medication use, and medical 
conditions (presence or absence of hypertension, diabetes, respiratory diseases, 
cardiovascular diseases, stroke, osteoporosis or cancer). The analysis of the data 
was performed with the SPSS statistical software package, version 24.0 (IBM, 
Chicago, IL, USA) for Windows. 
 
3. Results 
 
3.1. Characteristics of the study population 
 
 The general characteristics of the participants are presented according to the 
overall sample, sex and aging stages in Table 1. Most of the participants 
(males=213, females=312) belonged to aging stage III (70–80 years). Social status 
in level 2 (42.6%), urban area context (83.3%), and other ethnic groups (54.1%) 
were the most prevalent sociodemographic characteristics. The waist circumference 
and BMI means in the overall sample were 92.5 cm and 27.3 kg/m2, respectively. 
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Most of the sample had abdominal obesity (78.6%), and an overweight status 
(41.3%), but an healthy sarcopenia status (86%). Risky blood parameters for the 
overall sample were SBP (132.64±23.5 mmHg), Fasting Serum Triglycerides 
(160.94±83.3 mg/dL), and LDL-c (126.85 ± 35.3 mg/dL). The handgrip strength 
mean for the overall sample was 32.4 kg, with prevalence at high category (59.4%).  
 
Several statistical differences were observed according to the sex (Table 1). 
Females showed several highest values compared with males (i.e.: abdominal 
obesity, BMI, overweight, total cholesterol, HDL-c, LDL-c), whereas males presented 
higher values regarding waist circumference, blood pressure, and handgrip strength. 
Additionally, numerous statistical differences were observed between aging stages 
within the sex groups (Table 1). 
 
Table 1. Characteristic of the sample study according to age group (stage) and sex 
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3.2. Clinical characteristics and prevalence of MS 
 
 The incidence of alcohol consumption (9.2%) and smoking (12.1%) was low 
but significantly higher in men than in women (smoking: 12.6% vs 6.9%; alcohol: 
21.3% vs 6.1%), and mainly were presented at first aging stages. Most of the sample 
(mainly women at the first aging stages) were not physically active (82.9%). 
Hypertension was the most common chronic comorbidity (44.2%), following of 
diabetes (16.4%). Females presented the highest prevalence compared with males 
(60.8% vs 48%, p<0.001, and 18.3% 13.4%, p=0.009, respectively) at aging stage 
III and IV, respectively. Finally, cardiovascular diseases and stroke with no 
differences between sex and aging stages, Table 2. 
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Table 2. Clinical characteristics and distribution by stage aged group  
 
 
3.3. Prevalence of MS and its distribution by MS-components 
 
 The overall prevalence of MS in the study sample was 54.9% (95% 
confidence interval [CI] 52.4–57.3. The prevalence of MS according to sex, and the 
aging stages is presented in Figure 1. A. MS was more prevalent in females than in 
males (59.8% versus 47.3%) irrespective of the aging stage. For females, the 
prevalence of MS was highest in aging stage III (64.6%), whereas for males it was 
highest in the aging stage I (49.4%). The most prevalent MS-components were 
abdominal obesity (78.5%), low levels of HDL-c (57.3%), elevated arterial blood 
pressure (EABP) (53.1%), and high levels of fasting blood triglycerides (HLFBTg) 
(45.5%). Elevated fasting blood glucose was the least common components of MS 
(31.1%). Related to the MS-components by sex (Figure 1.B), the greatest differences 
were observed for high waist circumference (HWC), and low levels of HDL-c 
(LLHDL), with a higher prevalence in females than in males (HWC: females=88% vs 
males 64 %, p<0.001 and LLHDL: females=60.7% vs males=51.7%, p<0.001). The 
prevalence of HLFBTg was also significantly higher in females than in males 
(females=48.8% vs males=40.8 %, p=0.001). However, males presented a higher 
prevalence of EABP than females (57.2% vs 50.8 %, p=0.001). The prevalence of 
MS according to the MS-components was presented in figure 1.C.  
 
  
Table 2. Clinical characteristics and distribution by stage aged group  
 
   Males (n= 642) Females (n=995) 
P value 
Males 
vs 
females 
Clinical characteristics 
All       
(n=1637) 
 
Overall 
males 
STAGE  
I 
STAGE 
II 
STAGE 
III 
STAGE 
IV 
P value 
(betwee
n stages) 
Overall 
Females 
STAGE  
I 
STAGE  
II 
STAGE  
III 
STAGE 
IV 
P  
value 
(between 
stages) 
 (n=166) (n=150) (n=213) (n=113) (n=303) (n=245) (n=312) (n=135) 
Smoking habits                
No smoke 1486 (90.8)  561 (87.4) 
138 
(83.1) 
121 
(74.7) 
194 
(91.1) 
108 
(95.6) <0.001 
925 (93.1) 
276 
(91.1) 
231 
(94.3) 
293 (94.2) 125 (92.6) 
0.380 <0.001 
Smokes 150 (9.2)  81 (12.6) 28 (16.9) 38 (25.3) 19 (8.9) 5 (4.4) 69 (6.9) 27 (8.9) 14 (5.7) 18 (5.8) 10 (7.4) 
Alcohol consumption                
Non alcoholic 1438 (87.9)  505 (78.7) 
109 
(65.7) 
112 
(74.7) 
182 
(85.4) 
102 
(90.3) <0.001 
933 (93.9) 
278 
(91.7) 
227 
(93.0) 
299 (95.8) 
129 
(95.6) 0.144 <0.001 
Alcoholic 198 (12.1)  137 (21.3) 57 (34.3) 38 (25.4) 31 (14.6) 11 (9.7) 61 (6.1) 25 (8.3) 17 (7.0) 13 (4.2) 6 (4.4) 
Physical Activity “proxy”                
Physically active 280 (17.1)  144 (22.4) 53 (31.9) 45 (30.0) 37 (17.4) 9 (8.0) 
<0.001 
136 (13.7) 45 (14.9) 40 (16.4) 41 (13.2) 10 (7.4) 
0.093 <0.001 
Non-Physically active 1354 (82.9)  498 (77.6) 
113 
(68.1) 
105 
(70.0) 
176 
(82.6) 
104 
(92.0) 
856 (86.3) 
258 
(85.1) 
244 
(83.6) 
269 (86.8) 
125 
(92.6) 
 
Comorbid chronic diseases                
Hypertension 
911 (44.2)  307 (48.0) 63 (38.2) 59 (39.9) 
116 
(54.5) 
69 (61.1) <0.001 604 (60.8) 
151 
(50.0) 
141 
(57.6) 
215 (69.1) 97 (71.9) <0.001 
<.001 
Diabetes  268 (16.4)  86 (13.4) 25 (15.2) 24 (16.1) 30 (14.1) 7 (6.2) 0.090 182 (18.3) 45 (14.9) 47 (19.2) 62 (19.9) 28 (20.7) 0.314 0.009 
Respiratory diseases 183 (11.2)  64 (10.0) 11 (6.6) 11 (7.3) 22 (10.3) 20 (17.7) 0.013 119 (12.0) 25 (8.3) 27 (11.0) 47 (15.1) 20 (14.8) 0.043 0.209 
Cardiovascular diseases 233 (14.3)  80 (12.5) 12 (7.2) 18 (12) 30 (14.2) 20 (19.9) 0.052 153 (15.4) 37 (12.2) 33 (13.5) 55 (17.6) 28 (20.7) 0.065 0.104 
Stroke  85 (5.2)  39 (6.1) 5 (3.0) 10 (6.7) 18 (8.5) 6 (5.3) 0.169 46 (4.6) 11 (3.6) 11 (4.5) 13 (4.2) 11 (8.1) 0.330 0.316 
Osteoporosis 207 (12.7)  33 (5.1) 3 (1.8) 6 (4.0) 15 (7.1) 9 (8.0) 0.054 174 (17.5) 38 (12.6) 37 (15.2) 72 (23.3) 27 (20.0) 0.004 <0.001 
Cancer  90 (5.5)  37 (5.8) 8 (4.8) 6 (4.0) 13 (6.1) 10 (8.8) 0.367 53 (5.3) 15 (5.0) 14 (5.7) 18 (5.8) 6 (4.5) 0.925 0.710 
Data have been expressed as frequency and percentage. P in bold = significant differences  
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Figure 1. The prevalence of MS according to the MS-components. A: Distribution 
of the prevalence of metabolic syndrome according to aging stage and sex. B: 
Prevalence of the MS-components according to sex. (HWC = High Waist 
Circumference; EABP =Elevated Arterial Blood Pressure; HLFG = High Levels of 
Fasting Glucose; HLFBTg= High Levels of Fasting Blood Triglycerides; LLHDL = 
Low Levels of High Density Lipoprotein; C: Prevalence of MS according to 
metabolic abnormalities. **p<0.001; *p=0.001. 
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Additionally, we explore the MS prevalence according to the studied comorbid 
chronic diseases. Participants with MS presented the hypertension as the main 
comorbid chronic disease with a prevalence of 60.9% of the sample. The rest of 
participants with MS presented the following prevalence of the comorbid chronic 
diseases: diabetes (23.1%), cardiovascular disease (16.2%), osteoporosis (14.1%), 
respiratory diseases (11.1%), stroke (5.1%), and cancer (4.8%), Table 2. 
 
3.4. Relationship between MS status and clinical characteristics 
 Relationship between MS status and clinical characteristics were presented 
in table 3. Clinical characteristics such as sex, sarcopenia status and handgrip 
strength were significantly associated (p<0.05).  
 
Table 3. Relationship between MS status and clinical characteristics 
Clinical characteristics Have MS Not Have MS 
Pearson Chi- square  
P value 
Sex    
Men 336 301 
<0.001 
Women 395 588 
Sarcopenia status     
Yes  804 577 
<0.001 
No  78 143 
Handgrip strength    
Low 476 435 
0.025 Medium 201 151 
High 163 104 
Smoking status     
Yes 76 72 
0.108 
No 654 817 
Alcohol intake    
Yes  789 633 
0.212 
No 100 97 
Physical Activity “proxy”    
Physically active 139 139 
0.078 
Non-Physically active 747 592 
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3.5. Influencing factors associated with MS 
 
 Table 4 shows the ORs for the influencing factors associated with MS among 
the Colombian older adults (univariate analysis) were male gender (OR= 1.662, 
95%CI= 1.359–2.032; p<0.001), to have a sarcopenia status (OR= 2.55, 
95%CI=1.900–3.434; p<0.001), and a low handgrip strength (OR=1.432, 95%CI= 
1.084–1.892; p=0.011). Sarcopenia status was the main variable associated with 
MS, with more than two times the approximate risk of occurrence of MS. 
 
Table 4. Univariate association analysis between MS and clinical 
characteristics  
Clinical characteristics OR 95% CI P value 
Sex (reference males) 1.662 1.359 2.032 <0.001 
Sarcopenia status     
Yes (reference No) 2.550 1.901 3.434 <0.001 
Handgrip Strength (reference Hight)     
Low 1.432 1.084 1.892 0.011 
Medium 1.216 0.949 1.559 0.121 
Smoking status     
Yes (reference No) 1.319 0.940 1.850 0.109 
Alcohol intake     
Yes (reference No) 1.209 0.897 1.629 0.212 
Physical Activity “proxy”     
Non-Physically active (reference active) 0.793 0.612 1.026 0.078 
BMI: Body Mass Index; WHO= World Health Organization. p value in bold = significant association 
 After the adjustment by the main confounders in the multiple regression model 
(Figure 2), male gender (OR= 1.388; 95%CI= 1.054–1.828; p=0.020) and a 
sarcopenia status (OR= 1.637; 95%CI= 1.061–0.525; p=0.026) were again 
significantly associated with MS. In addition, being a smoker was positively 
associated with MS (OR= 1.591; 95%CI= 1.036–2.443; p=0.034). Thus, in general, 
to have a sarcopenia status and smoking were the main risk factors associated with 
MS in this sample of Colombian older adults, with more than 1.5 times the 
approximate risk of occurrence of MS. 
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Figure 2. Multiple logistic regression model of the influencing factors associated 
with MS among Colombian older adults. Multiple logistic regression adjusted for 
age, ethnicity, socioeconomic status, urbanicity, BMI, medication use, and medical 
conditions (presence or absence of hypertension, diabetes, respiratory diseases, 
cardiovascular diseases, stroke, osteoporosis or cancer). 
4. Discussion 
 
 The main finding of the present study was the considerably high prevalence 
of MS in the sample (54.9%). The prevalence of MS was more prevalent in females 
than in males irrespective of the aging stage (females highest prevalence in aging 
stage III (70–80 years) and in aging stage I (60–65 years for males). The most 
prevalent MS-components for the overall sample were abdominal obesity (78.5%), 
low levels of HDL-c (57.3%), EABP (53.1%) and high levels of fasting blood 
triglycerides (45.5%). Female gender, a poor sarcopenia status, and be smoking 
were found to be significantly associated with probability of MS (after adjustment).  
 
 It should be noted that while the prevalence of MS in the present sample is 
high (54.9%), it is similar to other Latin American studies in older people, such as 
Ecuador 59.9% [24], Brazil with 51.5.% [16], Southern Cone of Latin America with 
53% [25], in Ecuador elders (≥65 years) with 40% [26],Colombia with 52.2%, [27] 
and in the CARMELA study with 35.5% [28]. A reasonable explanation for the high 
prevalence of MS in the present study could be that most of the sample belonged to 
an urban area (83.3%), where people have a higher risk of MS [29,30]. This might 
be due to several lifestyle aspects, such as dietary patterns or low physical activity 
levels, as was found in our study where most of the sample (82.9%) was insufficiently 
active.  
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According to our results regarding sex, in the six Latin American studies 
previously mentioned [16,24–28], females also had a higher prevalence of MS than 
males in general, and particularly in the older adult groups (when it applied). As 
previously reported, MS is more common in females in an older North American 
population of Mexican origin [31]. Many of the typical aspects of MS, such as 
increased abdominal adiposity and dyslipidemia, hyperglycemia, and 
hyperinsulinism, are experienced in females along the menopausal transition [31]. 
The cessation of estrogen secretion at the beginning of menopause accentuates 
these aspects, decreasing the quality of life [32]. Additionally, it seems that the onset 
of menopause begins earlier in Latin American countries than in Europe and USA, 
what may be associated with higher altitude residency and lower educational-
economical income [33,34]. In the present study, the overall sample belonged to 
social status 1-2 (72.7%), and with a residency at high altitude (Bogota, 2680 m), 
but without significant differences between genders.  
Consequently, scientific investigations on Latin American postmenopausal 
women related to the MS prevalence and its associated factors have increased [35], 
although little is known about older adult populations. In addition, males presented 
the highest MS prevalence (49.4%) in aging stage I (60–65 years), but not in the 
later ones. In agreement with our results, in a cross-sectional analysis of 4289 
Taiwanese individuals [36], the male:female MS ratio reversed after the age of 60 
(men 30.4% vs women 40.3%). Similarly, in a large population-based project 
enrolling 36 cohorts from 10 European countries [37], there was an increase in the 
prevalence of MS from age groups 19–39 years to 60–78 years was nearly two-fold 
in males, and five-fold in females, resulting in a higher prevalence of MS in women 
after the age of 50. Again, the typical changes in the hormonal status during and 
after menopause could explain the significant influence of sex in the age-related 
increase of MS [38,39]. Other explanation could be due to fluctuations in individual 
and social behavior, such as modifications in socio-economic status or adoption of 
an unhealthy lifestyle [40]. 
Overall, the most prevalent MS-components were abdominal obesity (78.5%), 
low levels of HDL-c (57.3%), EABP, and high levels of fasting blood triglycerides 
(45.5%). Likewise, in the study of Davila et al.[27], where 312 (34.7% of the whole 
sample) older adults (55–64 years) from Medellin (Colombia) were evaluated, the 
major MS-metabolic risk factor was abdominal obesity with a prevalence of 87.4%, 
followed by low levels of HDL-c (59.1%), HLFBTg (52.0%) and EABP (44.8%). 
Concerning MS-components analyzed by sex in the whole sample, several 
statistical differences were observed. For instance, females presented a higher 
prevalence of HWC and LLHDL than males. Moreover, females displayed 
significantly higher HLFBTg than males, but males presented a higher prevalence of 
EABP. Accordingly, in a French study conducted in 3508 participants, females 
presented a higher prevalence of HWC, and low HDL-cholesterol, whereas EABP 
was the most commonly found metabolic disorder in males; however, the age range 
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only covered 35–64 years [41]. Alike, a Taiwanese study found a high prevalence of 
BP and TG in males below 60 years, although without differences in MS-components 
between genders in the age group above 60 years [42]. Additionally, a large Korean 
study including 103,763 participants aged 66 years or older revealed that females 
had a significantly higher percentage of abdominal obesity (+12%) and lower HDL-
c levels (−47%) than men, whereas men presented higher rates of EABP (+6%). 
However, contrary to our results, the Korean study indicated that men had usually 
high levels of triglycerides (+5%), compared with woman [43]. Unfortunately, gender-
related differences are sensitive to social and cultural conducts, dietary behaviors 
and psychosocial aspects [38].  
 
 Finally, the multivariate regression model indicated that the clinical 
characteristics that were associated with MS were male gender, to have a 
sarcopenia status, and smoking (after adjustment). In accordance with our results of 
univariate regression analysis, numerous studies have shown the high prevalence 
of MS and associated risk in people with a nutritional status of normal weight near 
the upper range or slightly overweight [44]. Moreover, sarcopenia has been linked 
to several metabolic disorders, and a recent meta-analysis revealed that it is 
positively associated with MS in middle-aged and older non-obese people [45]. In 
our study, sarcopenia status was high (14% for the overall sample) compared with 
a previous study carried out in the same region [46], where 6.96% of the participants 
(≥60 years old) presented sarcopenia. Also, our sarcopenia prevalence is higher 
than most of the studies conducted in older adults in other countries, going from 
Belgium with 12% to the United States with 5%, but not Japan (24.2%) [45]. 
However, stratification cut-off values for community-dwelling populations could vary 
between studies, as well as age range included.  
 
 Lastly, regarding the significant association between MS and smoking status, 
a previous Chinese study showed that active smoking in men was strongly 
associated with increased CVD risk [47], independent of the presence of MS. 
Moreover, tobacco smoke exposure (including active and passive smoking) 
increased the prevalence of coronary heart disease, stroke, and CVD in both 
genders with or without MS. In the same line, smoking habits could also explain in 
part the association between MS and male gender, since in the present sample, 
significantly more smokers were males than females for the whole sample (males = 
12.6% vs females = 6.9) and for most of the age stages. 
 
 In conclusion, the prevalence of MS is 54.9% among Colombian older adults 
and females presented the highest prevalence of MS irrespective of the aging stage. 
High abdominal obesity was the main prevalent MS-components (78.5%). Male 
gender, sarcopenia status, and being a smoker were found to be significantly 
associated with the probability of MS. New health policies and prevention strategies 
focused on the elderly Latin American population should be implemented based on 
these findings. 
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1. Introduction 
Colombia is a country with approximately 48 million inhabitants, with some 
5.2 million inhabitants aged 60 years and older 1. Currently, the life expectancy in 
Colombia is 72.3 years, and by 2025, life expectancy is expected to be 77.6 years 
for women and 69.8 years for men. In this context, the World Health Organization 
(WHO) has published the World Report on Aging and Health 2, which describes 
healthy aging as the result of the interaction between the physical and mental 
capacity of an individual (the intrinsic capacity) and the context of each individual’s 
life (the environment) 3. Accordingly, healthy aging depends upon intrinsic capacity, 
socioeconomic status and physical environment, and the interactions between these 
factors 4. In this vein, the WHO has proposed five domains –locomotion, vitality, 
cognition, psychological, and sensory –that can be used to evaluate an individual’s 
intrinsic capacity. 
Muscular strength as evaluated by handgrip strength has predictive value for 
assessing declines in physical and mental capacities in older adults 5, which are both 
components of the intrinsic capacity construct. Recent studies have shown that 
greater handgrip muscular strength is associated with lower all-cause 6 and cancer 
mortality 7.  
The world’s population is rapidly getting older 8; thus, the preservation of 
muscle strength and power with advancing age is of considerable clinical 
significance. Against this background, the development of clinically-viable screening 
tools for detecting individuals at heightened risk for functional limitations is warranted 
7. Indeed, it has been reported that handgrip strength reference values and muscular 
weakness cut-off points for older adults are needed 9, but no data have yet been 
described for the Colombian elderly population. Additionally, several cross-sectional 
studies have presented different handgrip strength cut-off points in Italian 10, Finnish 
11, Chinese 12, and American 13 14 older adults, thus suggesting that different 
ethnicities may have different muscle weakness cut-off points for identifying clinically 
relevant health outcomes. 
The results of the Survey on Health, Well-Being, and Aging in Latin America 
and the Caribbean, (SABE, from the initials in Spanish SAlud, Bienestar & 
Envejecimiento) have increased our understanding of the aging process and have 
helped to create public policies aimed at improving the well-being of the Latin 
American and Caribbean populations. They have also provided a framework for 
performing a second set of studies in the region.  
The purposes of this study were three-fold: (1) to describe handgrip strength 
in older individuals aged ≥ 60 years in Colombia; (2) to identify sex- and age-specific 
muscle weakness cut-off points in older adults; and (3) to determine the odds of 
adverse events for each of the intrinsic capacity domains for individuals with 
handgrip strength greater than the muscle weakness cut-off points, as compared 
with their weaker counterparts. 
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2. Materials and methods 
 
2.1. Study design 
 
This study is part of the 2015 SABE study Survey on Health, Well-Being, and 
Aging in Latin America and the Caribbean. Of the initial 23,694 elderly Colombians 
who took part in SABE–Colombia, a total of 5,237 were included in the present 
analysis after excluding participants without handgrip strength results (n = 18,457). 
There were no differences in the study key characteristics (i.e., age, body mass, 
height, body-mass index [BMI], and sex distribution) between the current study 
sample and the original SABE study sample (all p>0.05). The 5,237 elderly 
Colombians constituted the final analytical sample of the non-institutionalized 
population. Institutional review boards at the two universities involved in developing 
the SABE–Colombia study (University of Caldas, ID protocol CBCS-021-14 and 
University of Valle, ID protocol 09-014 and O11-015) reviewed and approved the 
study protocol, and written informed consent was obtained from each individual 
before inclusion and completion of the first examination (including permission to use 
secondary data and blood samples). 
 
Details of background and design methods (i.e., characteristics of 
participants, sample calculation, outcomes, and analysis plan) of the SABE Study 
have been previously published elsewhere 1; nevertheless, the most relevant 
information is briefly described below. All information collected was obtained through 
face-to-face interviews conducted at each site on mobile capture devices (e.g., 
tablets) or with printed versions of the questionnaire. During the personal interviews, 
direct physical measurements were taken, including handgrip strength (absolute and 
relative; i.e., handgrip strength [kg] /body mass [kg]), measured with a Takei 
dynanometer (Takei Scientific Instruments Co. Tokyo, Japan), height (standing and 
sitting) and weight. Five domains of the intrinsic capacity (locomotion, vitality, 
cognition, psychological, and sensory) were assessed as follows: (i) the cognition 
domain was assessed by the modified version of the mini-mental state examination 
(MMSE) 15 16; (ii) the locomotion domain was defined according to five definitions –
sarcopenia 17, prevalence of falls, functional impairments assessed with an activities 
of daily living (ADL) scale 18, mobility /disability 19, and physical performance 
assessed by the validated Spanish version of the short physical performance battery 
(SPPB) 20; (iii) the psychological domain was assessed by the Yesavage geriatric 
depression scale (YGDS) and mental problems; (iv) the sensory domain was 
assessed as hearing and vision problems 21; and (v) the vitality domain was 
assessed as loss of appetite 22 and weight loss.  
 
The self -reported comorbidities or medical conditions category was assessed 
by asking the participants if they had been diagnosed by a physician with 
hypertension, diabetes, respiratory diseases, cardiovascular diseases, cancer, or 
osteoporosis. Drug use was evaluated with the following question: "Do you currently 
take or use any prescription medication"? For the lifestyle domain, personal habits 
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regarding alcohol consumption and cigarette smoking were recorded. A “proxy 
physical activity” was also evaluated. Finally, hospitalization > 24 h in the last year 
was recorded.  
 
2.2. Data analysis 
 
We used SPSS v24.0 software for Windows (SPSS, Chicago, IL, USA), 
except for the LMS method calculations (see below). The optimal power to obtain 
normality was calculated for each of a series of age groups and the trend 
summarized by a smooth (L) curve. Trends in the mean (M) and coefficient of 
variation (S) were similarly smoothed. The resulting L, M and S curves contain the 
information to produce any centile curve, and to convert measurements (even 
extreme values) into exact standard deviation (SD) scores 23. Anthropometric and 
handgrip characteristics from the study sample are presented as the mean and SD. 
Normality for the selected variables was verified using histograms and Q-Q plots. 
Differences were analyzed by two-way analysis of variance or the Chi-square test 
(χ2) to compare sex and age differences. 
 
The LMS method assumes that the outcome variable has a normal distribution 
after a Box-Cox power transformation is applied, according to the LMS method 
implemented in the LMS Chart Maker Pro Version 2.54 (Medical Research Council, 
London, UK). Smoothed and specific curves for each age were obtained via a 
penalized maximum likelihood with the following abbreviations: M (median), L (Box-
Cox transformation) and S (coefficient of variation) 24. The appropriate number of 
degrees of freedom was selected on the basis of the deviance, Q-tests and worm 
plots, following the suggestions of Royston & Wright 25. The 3rd, 10th, 25th, 50th, 75th, 
90th, and 97th smoothing centiles were chosen as age- and sex-specific reference 
values. Statistical significance was assessed with a two-tailed α level of 0.05. 
 
 Finally, logistic regression models were used to compare the prevalence of 
adverse events in the five domains of the intrinsic capacity according to the cut-off 
for handgrip strength. The analysis was adjusted for age, ethnicity, socioeconomic 
status, urbanicity, BMI, smoking status, alcohol intake, drug use, physical activity, 
and medical conditions (presence or absence of osteoporosis, cardiovascular 
diseases, hypertension, diabetes, cancer, or respiratory diseases). 
3. Results 
The characteristics of the sample are summarized in Table 1. Age ranged 
from 60 to 85 years, with a mean of 70.5 ± 7.8 years. Absolute and relative handgrip 
strength was higher among men than among women (p<0.001). In the total sample, 
self-reported comorbidities were presented in the following proportions of cases: 
osteoporosis (12.3%), cardiovascular diseases (14.3%), hypertension (55.9%), 
diabetes (16.6%), cancer (4.9%), and respiratory diseases (10.8%). According to the 
intrinsic capacity domains, overall, women had more problems with locomotion, 
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sensory, and psychological parameters than men (p<0.01), except in terms of 
hearing problems. 
Table 1. Characteristics of the study participants (n=5.237) 
Characteristics 
Men  
(n=2,172) 
Women  
(n=3,065) 
Overall  
(n=5,237) P for group 
Mean ± SD Mean ± SD Mean ± SD 
Anthropometric and handgrip strength    
Age (years) 70.8 ± 8.0 70.2 ± 7.7 70.5 ± 7.8 0.004 
Height (cm) 162.9 ± 6.9 150.9 ± 6.3 156.0 ± 8.8 <0.001 
Weight (kg) 67.8 ± 12.5 62.7 ± 13.2 64.8 ± 13.1 <0.001 
BMI (kg/m2) 25.6 ± 4.0 27.7 ± 5.3 26.8 ± 4.9 <0.001 
Handgrip strength (kg)  26.7 ± 8.5 16.7 ± 5.7 20.9 ± 8.6 <0.001 
Handgrip (kg)/weight (kg) 0.40 ± 0.12 0.27 ± 0.10 0.33 ± 0.12 <0.001 
Sociodemographic outcomes n (%) n (%) n (%)  
Socioeconomic status       
Level I  807 (37.2) 986 (32.2) 1,793 (34.2) 0.088 
Level II  897 (41.3) 1,295 (42.3) 2,192 (41.9) 0.397 
Level III  417 (19.2) 662 (21.6) 1,079 (20.6) 0.709 
Level IV  38 (1.7) 90 (2.9) 128 (2.4) <0.001 
Level V-VI  13 (0.6) 32 (1.0) 45 (0.9) 0.763 
Urbanicity      
Urban  1,602 (73.8) 2,453 (80.0) 4,055 (77.4) 0.589 
Rural  570 (26.2) 612 (20.0) 1,182 (22.6) 0.016 
Ethnic group     
Indigenous  171 (7.9) 142 (4.6) 313 (6.0) <0.001 
Black “mulato” or Afro-
Colombian 202 (9.3) 226 (7.4) 428 (8.2) 
0.016 
White  540 (24.9) 848 (27.7) 1,388 (26.5) 0.671 
Others*  955 (44.0) 1,351 (44.1) 2,306 (44.0) 0.342 
Cognition outcome        
Cognitive impairment 304 (14.0) 498 (16.2) 802 (15.3) 0.014 
Locomotion outcomes        
Sarcopenia 445 (20.5) 796 (26.0) 1,241 (23.7) <0.001 
Falls 324 (14.9) 560 (18.3) 884 (16.9) <0.001 
Functional impairment 322 (14.8) 677 (22.1) 999 (19.1) <0.001 
Difficulty walking 400 meters 274 (12.6) 423 (13.8) 697 (13.3) <0.001 
SPPB < 6 points 455 (20.9) 1015 (33.1) 1,470 (28.1) <0.001 
Psychological outcomes        
Depression 1,073 (49.4) 1,605 (52.4) 2,678 (51.1) <0.001 
Mental problems 123 (5.7) 342 (11.2) 465 (8.9) <0.001 
Sensory outcomes        
Visual problems 1,187 (54.7) 1,715 (56.0) 2,902 (55.4) <0.001 
Hearing problems 618 (28.5) 682 (22.3) 1,300 (24.8) <0.001 
Vitality        
Weight loss 335 (15.4) 582 (19.0) 582 (11.1) <0.001 
Appetite loss 403 (18.6) 868 (28.3) 1,271 (24.3) <0.001 
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Comorbid chronic diseases        
Hypertension 1,040 (47.9) 1,889 (61.6) 2,929 (55.9) <0.001 
Diabetes  306 (14.1) 562 (18.3) 868 (16.6) <0.001 
Respiratory diseases 217 (10.0) 351 (11.5) 568 (10.8) 0.050 
Cardiovascular disease 297 (13.7) 452 (14.7) 749 (14.3) 0.145 
Osteoporosis  101 (4.7) 543 (17.7) 644 (12.3) <0.001 
Cancer  98 (4.5) 161 (5.3) 259 (4.9) 0.122 
Clinical outcomes      
Hospitalized > 24 h last year 249 (11.5) 378 (12.3) 627 (12.0) 0.187 
Drug use  1,360 (62.6) 2,424 (79.1) 3,784 (72.3) <0.001 
Lifestyle outcomes        
Alcohol 494 (22.7) 151 (4.9) 645 (12.3) <0.001 
Smoking  329 (15.1) 219 (7.1) 548 (10.5) <0.001 
Meeting PA recommendations 1,683 (77.5) 2,630 (85.8) 4,313 (82.4) <0.001 
Data are presented as mean ± SD or No. (percentage) of participants. SD, standard deviation; BMI, Body mass index; PA, 
physical activity. * Others (mestizo,gitano/ROM, etc). Significant difference between men and women group were analyzed by 
t-student or chi-square test. 
 
Table 2 and Figure 1 show smoothed age- and sex-specific percentiles of 
handgrip strength in men and women. The data showed that men performed better 
in the test at all ages than women. In men, the 50th centile of handgrip strength 
ranged from 17.6 kg to 30.5 kg, and in women from 12.4 kg to 18.5 kg. There was a 
decrease in muscle strength across the age range in both sexes. 
 
Table 2. Smoothed age-and sex-specific percentile of handgrip strength 
Sex/age group n L S P3 P10 P25 P50(M) P75 P90 P97 
Men (n=2,172)           
60–64 562 1.07 0.26 14.0 19.6 25.1 30.5 35.9 41.2 46.4 
65–69 535 1.04 0.28 12.6 18.0 23.3 28.6 33.9 39.1 44.3 
70–74 423 0.95 0.30 11.0 16.0 21.2 26.3 31.6 36.8 42.1 
75–79 304 0.81 0.33 9.4 13.9 18.7 23.8 29.1 34.6 40.3 
80–84 201 0.69 0.36 7.5 11.4 15.7 20.4 25.5 30.9 36.6 
85 + 147 0.60 0.40 6.0 9.3 13.2 17.6 22.5 27.8 33.6 
Women 
(n=3,065) 
          
60–64 873 1.00 0.32 6.8 10.7 14.6 18.5 22.4 26.3 30.1 
65–69 774 1.10 0.32 6.1 9.8 13.6 17.3 21.1 24.8 28.6 
70–74 563 1.02 0.35 5.0 8.7 12.4 16.1 19.8 23.5 27.2 
75–79 427 0.99 0.36 4.0 7.6 11.1 14.7 18.3 21.8 25.4 
80–84 271 1.14 0.43 1.9 5.8 9.6 13.4 17.2 21.0 24.8 
85 + 157 0.98 0.44 1.4 5.1 8.8 12.4 16.1 19.8 23.5 
L, power in the Box-Cox transformation for “correcting” the skewness, M, median, S, coefficient of variation; P, 
percentile. 
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Figure 1. Absolute strength smoothed centile curves for men (A) and women (B) for 
Colombian aged 60 + years. The analysis was adjusted for age, ethnicity, socioeconomic 
status, urbanicity, BMI, smoking status, alcohol intake, drug use, physical activity, and 
medical conditions (presence or absence of osteoporosis, cardiovascular diseases, 
hypertension, diabetes, cancer, or respiratory diseases).* Pooled intrinsic capacity was 
calculated without hospitalization outcome values. 
 
Weak handgrip cut-off values using <1 SD by sex and age group are shown 
in Table 3. These cut-off points ranged from 17.4 to 8.6 and 10.1 to 4.9 in men and 
women, respectively. 
 
Table 3. 1 Weak handgrip cut point values using<1 SD by sex and age group 
Sex/age group  Cut point (kg) 
Men Mean  
60–64 17.4 
65–69 15.7 
70–74 14.3 
75–79 12.3 
80–84 10.1 
85 + 8.6 
Women  
60–64 10.1 
65–69 8.9 
70–74 8.2 
75–79 6.7 
80–84 5.3 
85 + 4.9 
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Finally, Figure 2 shows the association between optimal handgrip strength 
(kg) with the domains of intrinsic capacity. Overall, participants with optimal handgrip 
strength had better intrinsic capacity than weak older adults, including both men 
(odds ratio [OR]=0.62, 95%CI 0.53 to 0.71; p<0.001) and women (OR=0.79, 95%CI 
0.68 to 0.92; p=0.002). Regarding the intrinsic capacity domains, older men with 
optimal handgrip strength had lower odds of having cognition (OR=0.50, 95%CI 0.29 
to 0.85; p=0.010), locomotion (OR=0.47, 95%CI 0.37 to 0.59; p<0.001), and vitality 
(OR=0.68, 95%CI 0.47 to 0.98; p=0.040) than their weaker counterparts. Older 
women with optimal handgrip strength also had lower odds of having cognition 
(OR=0.44, 95%CI 0.24 to 0.80; p=0.007), locomotion (OR=0.66, 95%CI 0.51 to 0.85; 
p=0.001), and psychological (OR=0.57, 95%CI 0.40 to 0.82; p=0.002) problems than 
their weaker counterparts (Figure 2). Additionally, older men with handgrip strength 
greater than the muscle weakness cut-off points had lower odds of hospitalization 
than their weaker counterparts (OR=0.47, 95%CI 0.29 to 0.78; p=0.004). 
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Figure 2. Association between health handgrip strength (Kg) with the components 
of the intrinsic capacity and hospitalization 
4. Discussion 
Using a nationally representative sample of older Colombian adults, this study 
presents normative data for handgrip strength, identifies sex- and age-specific 
muscle weakness cut-off points, and determines the odds of adverse events for each 
Group by
Subgroup within study
Adverse event Outcome Statistics for each study Odds ratio and 95% CI
Odds Lower Upper 
ratio limit limit Z-Value p-Value
Cognition Cognitive impairtment Cognition 0.50 0.29 0.85 -2.58 0.010
Cognition 0.50 0.29 0.85 -2.58 0.010
Hospitalization Hospitalized > 24h last year Hospitalization 0.47 0.29 0.78 -2.91 0.004
Hospitalization 0.47 0.29 0.78 -2.91 0.004
Locomotion Sarcopenia Locomotion 0.85 0.49 1.49 -0.56 0.578
Locomotion Falls Locomotion 0.65 0.40 1.04 -1.78 0.075
Locomotion Functional impairtment Locomotion 0.42 0.25 0.69 -3.41 0.001
Locomotion Difficulty walking 400 meters Locomotion 0.24 0.15 0.39 -5.80 0.000
Locomotion SPPB < 6 points Locomotion 0.47 0.28 0.81 -2.74 0.006
Locomotion 0.47 0.37 0.59 -6.51 0.000
Psychological Depression Psychological 1.19 0.80 1.77 0.85 0.396
Psychological Mental problems Psychological 0.41 0.22 0.75 -2.88 0.004
Psychological 0.86 0.62 1.21 -0.87 0.386
Sensory Visual problems Sensory 0.82 0.51 1.31 -0.83 0.409
Sensory Hearing problems Sensory 0.73 0.47 1.11 -1.49 0.136
Sensory 0.77 0.56 1.05 -1.66 0.097
Vitality Weight loss Vitality 0.97 0.54 1.73 -0.12 0.905
Vitality Appetite loss Vitality 0.54 0.34 0.87 -2.55 0.011
Vitality 0.68 0.47 0.98 -2.05 0.040
0.1 0.2 0.5 1 2 5 10
Favours A Favours B
M eta Analysis
M eta Analysis
A. Men 
B. Women 
Pooled intrinsic capacity*        0.62    0.53    0.71    -6.68  < 0.001 
Group by
Subgroup within study
Adverse event Outcome Statistics for each study Odds ratio and 95% CI
Odds Lower Upper 
ratio limit limit Z-Value p-Value
Cognition Cognitive impairtment Cognition 0.44 0.24 0.80 -2.72 0.007
Cognition 0.44 0.24 0.80 -2.72 0.007
Hospitalization Hospitalized > 24h last year Hospitalization 0.72 0.39 1.31 -1.07 0.283
Hospitalization 0.72 0.39 1.31 -1.07 0.283
Locomotion Sarcopenia Locomotion 0.83 0.47 1.47 -0.65 0.515
Locomotion Falls Locomotion 0.95 0.55 1.65 -0.17 0.866
Locomotion Functional impairtment Locomotion 0.53 0.30 0.91 -2.29 0.022
Locomotion Difficulty walking 400 meters Locomotion 0.86 0.38 1.93 -0.37 0.713
Locomotion SPPB < 6 points Locomotion 0.43 0.26 0.72 -3.21 0.001
Locomotion 0.66 0.51 0.85 -3.18 0.001
Psychological Depression Psychological 0.50 0.32 0.79 -2.97 0.003
Psychological Mental problems Psychological 0.71 0.39 1.32 -1.08 0.280
Psychological 0.57 0.40 0.82 -3.03 0.002
Sensory Visual problems Sensory 0.98 0.59 1.61 -0.08 0.934
Sensory Hearing problems Sensory 1.30 0.72 2.34 0.86 0.391
Sensory 1.10 0.75 1.61 0.49 0.624
Vitality Weight loss Vitality 1.63 0.86 3.07 1.50 0.134
Vitality Appetite loss Vitality 1.08 0.78 1.48 0.45 0.650
Vitality 1.17 0.88 1.56 1.08 0.281
0.1 0.2 0.5 1 2 5 10
Favours A Favours B
M eta Analysis
M eta Analysis
Pooled intrinsic capacity*       0.79    0.68    0.92    -3.03   0.002 
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intrinsic capacity domain for individuals with handgrip strength greater than the 
muscle weakness cut-off points. Overall, older adults with handgrip strength greater 
than the muscle weakness cut-off points had lower odds of adverse events in most 
of the intrinsic capacity domains (especially in cognition and locomotion domains) 
and hospitalization (only in men) than their weaker peers. Our results may inform 
intervention strategies aiming to increase muscle strength and promote healthy 
aging. 
Several handgrip strength normative ranges for older adults from populations 
with different nationalities and ethnicities have been published in the last several 
years 26-30, however, to our knowledge, normal handgrip strength values have never 
been described for the Colombian population. We found that, overall, older 
Colombian adults have lower handgrip strength values than their peers in other 
populations 26-29. Our results showing that gender and age affect handgrip strength 
are in accordance with the findings of previous studies 26-29. Thus, the results of this 
study contribute to the current body of literature by presenting sex- and age-specific 
weakness cut-off points among the Colombian elderly.  
Different handgrip strength mean values have been observed in different 
countries, as reported previously 20, but the nature of these differences is not known. 
Differences in handgrip strength mean values between Colombian older individuals 
from a less-developed country (this study) and individuals in developed countries 
may be due to a number of factors, although it is uncertain which of the three factors, 
genetic, environment or biological, are more decisive for handgrip strength results 
31. For instance, biological or environment factors such as health status, lifestyle, 
and demographic and socioeconomic characteristics vary greatly between countries 
with different handgrip strength levels. Along this line, education and socioeconomic 
status are factors that might explain differences in handgrip strength ranges among 
countries 32. Also, beyond ethnic differences in height and in skeletal muscle mass 
and function 33, there are well-recognized differences in dietary protein intake 
between different countries, and this variation might also explain differences in 
muscle strength 34. Absolute strength has also been related to nutrition status and is 
reported to have positive influence on individuals’ grip strength. Another possible 
reason for the divergence between studies might be methodological differences (i.e., 
variability in the equipment used and the protocol for measuring handgrip strength) 
35. 
Several studies have determined absolute 11, 14, 10 and relative handgrip 
strength cut-off points 12, 13, which are overall higher than our cut-off points. For 
example, Duchowny et al. 14 determined cut-off points for weakness associated with 
gait speed (<0.8 m/second) in older American adults, with values of <40 kg and <31 
kg in men and women, respectively. Similarly, Cruz-Jentoft et al. 10 found that among 
community-dwelling older adults in Italy, a handgrip strength <30 kg in men and <20 
kg in women was associated with slow gait speed and an inability to walk 1 km 
without difficulty. Therefore, different cut-off points are observed in different 
countries; however, while the nature of these differences is unclear 31, as mentioned, 
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heterogeneous designs, genetic, and environmental factors may explain some of the 
differences among the studies. 
The handgrip strength cut-off points reported in the present study are useful 
for determining who among older adults may benefit from lifestyle modifications to 
preserve muscle strength and reduce the odds of physical and mental limitations. In 
this context, our results reveal that older men with handgrip strength greater than the 
muscle weakness cut-off points had a lower odds of hospitalization for >24 hours 
than their weaker counterparts. However, the cross-sectional design of the present 
study did not allow us to determine whether the measured handgrip strength differed 
from habitual strength, or if the handgrip was impaired as a result of the presenting 
condition (see limitations, below). Our results partially confirm those of previous 
studies that analyzed the prospective association between customary handgrip 
strength and hospital admission, which showed varying results 9 36. The 
Hertfordshire Cohort Study 9 provided evidence that handgrip strength among 
community-dwelling men and women in the UK was associated with risk of hospital 
admission over the following decade. By contrast, a prospective study of 279 older 
adults aged ≥70 years from Germany who were followed-up for 18 months found no 
association between handgrip strength and the risk of hospital admission 36. The 
differences between these studies may be explained by the thresholds for 
admission, which likely differ between healthcare systems, and their cross-sectional 
design.  
A recent narrative review reported that weak handgrip strength was 
associated with reduced cognitive performance over time; therefore, greater 
handgrip strength may be protective against cognitive decline in older adults 37. 
Indeed, recent evidence has shown that weak handgrip strength is associated with 
an increased risk of psychological problems such as depression 38 39. These findings 
were confirmed by the results of our analysis, which suggested that older adults with 
handgrip strength greater than the muscle weakness cut-off points had lower odds 
of cognitive impairment and depression than their weaker peers. Overall, weak 
handgrip strength, cognition and depression share some risk and pathogenic factors 
(particularly an increased rate of oxidative stress 40 and inflammation 41, decreased 
sex hormone levels 42 and maximal voluntary contraction 43) that may influence the 
onset of depression and cognitive impairment 44. Given the strength of the evidence 
in this area, handgrip strength and our cut-off points are easy to utilize and are 
clinically useful biomarkers of cognitive decline and mental health across the lifespan 
of individuals from the Colombian population. 
Physical decline, in terms of decreasing muscle weakness and poor mobility, 
has been repeatedly included as an additional vital sign 45 and a key instrument for 
the functional assessment of older patients 46. The present results are also in 
agreement with those of previous research and suggest that handgrip weakness is 
associated with measures of functional limitations in older adults 47. For example, 
Ishizakiet et al. 48 determined that older adults with weak handgrip strength had 
difficulty performing many tasks, such as shopping for groceries, preparing meals 
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and performing housework. Our lower cut-off points appear to have the ability to 
identify older adults of both sexes with locomotion problems. Therefore, it seems 
that it is especially important for older adults to preserve muscle strength to avoid 
functional limitations, such as by participating in muscle strengthening activities to 
preserve function. Additionally, our results suggest that optimal handgrip strength is 
associated with a lower odds of experiencing weight loss in older men, and so 
muscle strength could favor the maintenance of optimal homeostasis 7. 
Finally, the only intrinsic capacity domain that did not appear to be related to 
handgrip strength was hearing impairment. Hearing loss in the elderly is of 
increasing importance as the global population ages. Disabling hearing negatively 
affects communication and social engagement and can lead to reduced quality of 
life in adults 49, and may also underlie cardiovascular risk and diseases (i.e. diabetes, 
hypertension and history of cerebrovascular accident) 50. These associations are 
mainly related to the compromised blood supply to the cochlea under vascular 
disease conditions 51, as well as other sensor neural, nutritional status and medical 
comorbidity factors that may accumulate with age and are not a result of normal 
aging 51. Peripheral age-related hearing loss is also a possible biomarker and 
modifiable risk factor for cognitive decline, cognitive impairment, and dementia 50 52.  
Our results, however, revealed that an individual with low levels of handgrip strength 
might not necessarily have a worse hearing status, and suggest that different age-
related mechanisms could be underlying this. 
The strengths of this study include the large sample size of older adults with 
a nationally representative proportion of persons aged ≥60 and the objective 
assessment of muscle strength. This study does, however, have some limitations. 
First, the cross-sectional design did not allow a definitive conclusion that weak 
muscle strength precedes adverse events. Second, several measures, such as falls, 
history of chronic disease, and drug use, were self-reported by participants; 
therefore, different types of response biases may have been introduced.  
5. Conclusion 
This study provides reference values for handgrip strength in Colombian 
individuals 60 years and older. After categorizing participants as weak or not weak 
based on the handgrip cut-off points, non-weakness was associated with a 
decreased odds of intrinsic capacity impairments, especially in the cognition and 
locomotion domains, and of hospitalization (only in men). Therefore, a simple 
handgrip strength test with the appropriate cut-off points may be a good candidate 
for clinical assessment of risks to physical and mental health in older Colombian 
adults.  
Funding: This study is part of a larger project that has been funded by a 
Colciencias y Ministerio de Salud y la Protección Social de Colombia (The SABE 
Study ID 2013, no. 764).  
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CHAPTER 4  
GAIT SPEED AS A MEDIATOR OF THE EFFECT OF SARCOPENIA 
ON DEPENDENCY IN ACTIVITIES OF DAILY LIVING. 
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1. Introduction 
 Sarcopenia is an age-related loss of muscle mass and function in older 
adults and may favor the appearance of cardiovascular complications or 
neurodegenerative disorders (1,2). While its prevalence is variable depending on 
its localization and the method of evaluation, it is estimated that 29% of older 
persons in community-dwelling populations and 14–33% in long-term care 
populations are affected by sarcopenia (3). In Colombia, recent results from 
SABE Bogota study estimated that sarcopenia affects 11.5% of the older 
population (4). Sarcopenia is related to several functional comorbidities including 
mobility disorders, risk of falls and fractures, and a loss of physical independence 
in activities of daily living (ADL) (5,6). It seems that sarcopenia depends on 
several coadjuvant factors such as inflammatory processes related to aging, 
nutritional status, intramuscular fat, and genetics, in addition to the reduction of 
physical activity, which is a crucial precursor of sarcopenia (2,7). In the context 
of the aforementioned factors, there is evidence to indicate that both aerobic and 
resistance training, promotes a healthy anti-inflammatory milieu (largely through 
the release of muscle-derived myokines (8) mitigate mitochondria-related 
dysfunction (8) (and ameliorates age-related loss of muscle mass, strength (9) 
as well as functional capacity and physical performance (10). 
 As a locomotor capacity, gait speed is representative of neuromuscular 
quality (morphological and neuronal) (1) and a critical determining factor for 
healthy ageing. Indeed, the European Working Group on Sarcopenia in Older 
People (EWGSOP) has developed an algorithm including gait speed 
measurement as the easiest and most reliable way to determine sarcopenia in 
clinical practice (11), and also this has been used to diagnose functional disability 
and dependence in older adults (11–13). Correspondingly, the loss of muscle 
mass and consequently the declining of gait speed are age-associated; for 
example in a four-year follow-up of older Chinese, the percentage decline in gait 
speed was −8.2% and −9.0% in men and women, respectively (14).  
 On the other hand, sarcopenia, resulting from reduced skeletal muscle 
mass, is associated with aging (15). Based on the need for a simpler method of 
assessing muscle mass in community-based, and large-scale epidemiological 
contexts, several regions (Europe, USA, and Asia) and organizations 
incorporated the use of calf circumference (CC), as a marker of muscle mass in 
elderly people in primary care setting (11,16–18) (REF). In a Japanese study 
including 526 participants, CC was positively correlated with appendicular 
skeletal muscle and as a surrogate marker of muscle mass for diagnosing 
sarcopenia (19). 
 In addition, the sarcopenia and the impairment of gait speed are strongly 
associated to loss of independence in ADL (20–22). Therefore, have three factors 
related Sarcopenia, declining of gait speed, loss of independency in ADL; and 
between them a vicious circle is forms. Consequently and taking into account the 
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bibliography (23, 24), the gait speed seems to be the key factor that can worsen 
this vicious circle or on the contrary improve it. This possible role of gait speed is 
known as a mediator role and can be explore through mediation analysis. 
Statistical mediation analysis allows us to understand how an independent 
variable “X” affects a dependent variable “Y” through the indirect effect of the 
mediating variable “M” (15). For instance, mediation analysis could identify if gait 
speed do and do not mediate these adverse effect of sarcopenia on dependency. 
This knowledge could help to adjust physical activity program in older adults, 
emphasizing the improvement of gait speed. Accordingly, the mediator variable 
“M” (gait speed) may play a role as the mediator of the relationship between the 
antecedent variable “X” (sarcopenia) and the outcome variable “Y” (loss of 
independence), (25) Figure 1.   
 
Figure 1.  Statistical mediation simple diagram 
 While it is known that the level of physical fitness affects independence, 
and that exercise can counteract the detrimental effects of sarcopenia, to our 
knowledge no studies have addressed the role of the gait speed in the 
relationship between sarcopenia and loss of functional independence. Here, we 
hypothesized that gait speed could have an attenuating effect on the relationship 
between sarcopenia and loss of independence.  
2. Method 
2.1 Study Design and Sample Population 
  The present study is part of the 2015 SABE study Survey on Health, Well-
Being, and Aging in Latin America and the Caribbean. SABE is a multicenter 
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project originally conducted by the Pan-American Health Organization (PAHO) 
and supported by the Epidemiological Office of the National Health Ministry in 
Bogotá, Colombia (https://www.minsalud.gov.co/). Details of the survey have 
been published elsewhere (26).  
 In brief, data collection took place between April and September 2015, and 
the response proportion ranged from ~62% in urban areas to 77% in rural sites 
(26). The estimated sample size was 24,553 individuals, and assuming an 80% 
response the target sample was 30,691 individuals (26). The estimated sample 
size was 24,553 individuals, and assuming an 80% response the target sample 
was 30,691 individuals. However, at fieldwork after implementing several 
strategies to achieve the overall sample and prevent nonparticipation, response 
proportion was about 70% and varied by region and urban/rural distributions. The 
final sample size achieved, including 244 municipalities (n=23,694 older adults) 
across all departments (i.e., states) of the country. Of the 23,694 participants who 
took part in SABE Survey, a total of 19,705 remained in the present analysis after 
excluding participants without a BMI (n = 1,684), ADL (n = 1,281) and CC (n = 
1,024) values.  
 Institutional review boards at the two universities involved in developing 
the SABE Colombia study (University of Caldas [ID protocol CBCS-021-14] and 
University of Valle [ID protocol 09-014 and O11-015]) reviewed and approved the 
study protocol, and written informed consent was obtained from each individual 
before inclusion and completion of the first examination (including permission to 
use secondary data and blood samples). Permission was obtained from the 
National Health Ministry in Bogotá, Colombia, to use the publicly available data 
for research and teaching purposes (Pontificia Universidad Javeriana). The study 
protocol to the secondary analysis was approved by The Human Subjects 
Committee at the Pontificia Universidad Javeriana (ACTA ID 20/2017-2017/180, 
FM-CIE-0459-17). Further details can be obtained from the website of the 
National Health Ministry in Bogotá, Colombia-SABE 
(https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/VS/ED/GCFI/
doc-metodologia-sabe.pdf). 
2.2 Data Collection 
 Body measurement assessments were collected by investigators trained 
in standardized measurement methods, previously trained by research staff from 
the coordinating centers (Universities of Caldas and Valle). All information 
collected was obtained through face-to-face interviews conducted at each site on 
mobile capture devices (tablets) or with printed versions of the questionnaire.  
 Body mass was measured using weighing scales to the nearest 0.1 kg; 
height was measured using a stadiometer to the nearest 0.1 cm; with the body 
mass index (BMI, kg/m2) was subsequently derived. We defined sarcopenia 
according to CC, as proposed by Rolland et al. (27), as a "proxy" measure for 
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assessing muscle mass and early identification of sarcopenia in clinical practice, 
due to the low cost and ease of application. As described (27), a CC <31 cm is 
considered to be indicative of low muscle mass. This cut-off has been 
recommended for use in older individuals by the WHO Expert Committee (28) 
Thus, CC measures are practical have acceptable accuracy for estimating 
sarcopenia when compared with dual-energy x-ray absorptiometry, the gold 
standard for body composition assessment (27). CC was measured at a plane 
perpendicular to the long axis of the calf while the participant was sitting on chair 
with foot flat on the floor using an inelastic tape measure. Thus, the CC values 
presented here combine the results of left- and right-foot subjects, without 
consideration for lower-body dominance. Gait speed over a distance of 3 m was 
measured three times and the analysis used the shortest time of the three 
attempts.   
 Functional impairment was assessed with an ADL evaluation using a 
Spanish-adapted version of the physical level ADL (Barthel Index) (29). The items 
are weighted: a maximum score of 100 indicates independence, 91–99 minimal 
dependence, 75–90 mild dependence, 50–74 moderate dependence, 25–49 
severe dependence, and 0–24 total dependence (30). The socioeconomic level 
(I to VI), ethnic group (indigenous, black ‘mulato’ or afro-colombian, white, and 
others, mestizo, gitano, etc.), and tobacco smoking (patients were categorized 
as those who do not smoke, those who have never-smoked, those who currently 
smoke, or those who previously smoked) were recorded. Finally, a “proxy 
physical activity” was evaluated by the following questions: (i) “Have you regularly 
exercised, such as jogging or dancing, or performed rigorous physical activity at 
least three times a week for the past year?” (ii) “Do you walk at least three times 
a week between 9 and 20 blocks (1.6 km) without resting? “ And (iii) “Do you walk 
at least three times a week 8 blocks (0.5 km) without resting?” Those participants 
who responded affirmatively to two of the three questions were considered 
physically active. 
2.4 Statistical Analysis 
 Before statistical analysis was performed, the normality of variables was 
tested using the Kolmogorov -Smirnov test. The variables that presented non-
uniformity were transformed via natural logarithm or reciprocal transformation 
(1/x) depending on positive or negative skew (31). For the descriptive analysis of 
the sample, we used percentages and frequency distributions for categorical 
variables, and mean with standard deviation (SD) for continuous quantitative 
variables. The characteristics of the participants with and without sarcopenia 
were compared with the Chi-squared test for categorical variables and Student’s 
t-test for continues variables. The association between sarcopenia condition and 
gait speed and dependency level, were analysed by linear regression using three 
separate models. We entered sarcopenia as predictor variable and gait speed 
and dependency categories as outcome variables and three separate model: 
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Model 1 adjusted by sex, gender and BMI; Model 2 adjusted by model 1 + 
nutritional status; Model 3 adjusted by model 2 and problems to walk 400-m. 
To examine whether gait speed mediated the association between sarcopenia 
and dependence components of physical function, a simple mediation models 
were generated using ordinary least squares with the macro PROCESS version 
3.2, adjusted for age, sex and body mass index (BMI). Mediation hypotheses 
were tested using the bias-corrected bootstrap method with 5,000 samples to 
calculate confidence intervals (CI95%). An indirect effect was considered 
significant when the confidence interval did not include zero (25).  
3. Results 
 The descriptive characteristics and differences between the sarcopenia 
and non-sarcopenia groups are shown in Table 1. The classification of 
sarcopenia according to the CC criterion categorized 16.1% of older adults with 
sarcopenia, with a higher prevalence of sarcopenia in females than in males. 
Regarding sociodemographic covariates, the results indicated a higher 
prevalence of sarcopenia with advanced age and with low socioeconomic level. 
In total, 80.7% of the participants with sarcopenia did not achieve the minimum 
level of recommended physical activity proxy. Finally, BMI was significantly 
higher in the non-sarcopenia group whereas dependency was significantly higher 
in the sarcopenia group (19.6% versus 13.8%).  
Table 1. Sample characteristics stratified by sarcopenia status 
Sample 
characteristics 
Sarcopenia (N = 
3,168) 
Non-sarcopenia (N = 
16,537) 
Total (N = 
19,705) p-value 
Female, n (%) 2,021 (18.4) 8,943 (81.6) 10,964 (55.6) <0.001 
  Male, n (%)  1,147 (13.1) 7,594 (86.9) 8,741 (44.4) 
Age group, n (%)     
60–64 621 (10.3) 5,393 (89.7) 6,014 (30.5) 
<0.001 
65–69 640 (12.8) 4,360 (87.2) 5,000 (25.4) 
70–74 644 (17.3) 3,076 (82.7) 3,720 18.9) 
75–79 585 (21.7) 2,107 (78.3) 2,692 (13.7) 
80–84 392 (26.5) 1,086 (73.5) 1,478 (7.5) 
85 + 286 (35.7) 515 (64.3) 801 (4.1) 
Socioeconomic level, 
n (%) 
    
1 1,714 (54.1) 6,971 (42.2) 8,685 (44.1) 
<0.001 
2 1,073 (33.9) 6,420 (38.8) 7,493 (38.0) 
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3 309 (9.8) 2,654 (89.6) 2,963 (15.0) 
4 57 (1.8) 383 (2.3) 440 (2.2) 
>5 15 (0.5) 109 (0.7) 124 (0.6) 
Ethnic group, n (%)        
Indigenous 236 (10.3) 1,124 (7.8) 1,360 (8.1) 
 <0.001 
Black 288 (12.6) 1,701 (11.8) 1,989 (11.9) 
White 546 (23.9) 4,002 (27.7) 4,548 (27.1) 
Others 1,212 (53.1)  7,646 (52.8) 8,858 (52.9) 
Smoking status, n (%)     
 Yes  526 (16.6) 1,695 (10.3) 2,221 (11.3) 
<0.001 
No 2,642 (83.4) 14,840 (89.7) 17,482 (88.7) 
Physical Activity “proxy”, n (%)      
Yes  3,190 (19.3) 375 (11.8) 3,565 (18.1) 
<0.001 
No 13,327 (80.7) 2,790 (88.2) 16,117 (81.9) 
Problems to walk 400-
m, n (%) 
 
 
  
 No  2,120 (66.9) 11,810 (71.4) 13,930 (70.7) 
<0.001 
Barely 502 (15.8) 2,505 (15.1) 3,007 (15.3) 
Some problems 275 (8.7) 1,138 (6.9) 1,413 (7.2) 
A lot of problems 249 (7.9) 1,008 (6.1) 1,257 (6.4) 
Can not walk 400-m 17 (0.5) 63 (0.4) 92 (0.4) 
BMI, mean (SD) 22.4 (3.7) 27.9 (4.6) 27.0 (4.9) <0.001 
Nutritional status, n 
(%) 
    
Malnutrition 282 (8.9) 413 (2.5) 650 (3.3) 
<0.001 
Risk of malnutrition 1,603 (50.6) 5,325 (32.3) 6,838 (34.7) 
Normal nutritional 
status 
1,283 (40.5) 10,782 (65.2) 12,217 (62.0) 
Missing data   4090  
Dependency levels, n 
(%) 
    
 Dependency  1 (0.0) 0 (0.0) 1 (0.0) 
<0.001 
Severe 13 (0.4) 6 (0.1) 19 (0.1) 
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Moderate 250 (7.9) 836 (5.1) 1,086 (5.5) 
Mild 357 (11.3) 1,433 (8.7) 1,790 (9.1) 
Non dependency 2,547 (80.4) 14,262 (86.2) 16,809 (85.3) 
Table 2 shows the associations between sarcopenia and gait speed and 
dependency level. The results from regression analysis indicate a significant 
association between sarcopenia and gait speed independently of age, gender, 
BMI, nutritional status and problems to walk 400-m. Likewise, the association 
between sarcopenia and dependency level is significant when adjusted the 
regression by age, gender, BMI and nutritional status; however, this association 
is not significant when included in the model the problems to walk 400-m.   
Table 2. Associations between sarcopenia and gait speed and dependency in 
older adults 
Outcome variable β P-value 95 % CI 
Gait speed 
Model 1 −0.040 <0.001 (−0.038 to −0.017) 
Model 2 −0.021 0.001 (−0.033 to −0.009) 
Model 3 −0.017 0.006 (−0.029 to −0.005) 
Dependency 
Model 1 −0.066 <0.001 (−0.088 to −0.044) 
Model 2 −0.017 0.007 (−0.055 to −0.009) 
Model 3 −0.019 0.101 (−0.041 to 0.004) 
Model 1 = adjusted by sex, age and BMI     
Model 2 = adjusted by model 1 + nutritional status     
Model 3 = adjusted by model 2 + difficulties to walk 400-m 
Figure 2, shows the mediation models used to determine whether the 
performance in physical function could mediate the adverse effect of sarcopenia 
on dependency. In Figure 2, the regression a (β = −0.02; P=0.001) indicated that 
sarcopenia leads to lower gait speed, and b (β = 0.25; P<0.001) shows a 
significant direct relationship between higher gait speed and less functional 
dependence. Also, a direct effect (β = −0.05; P<0.001) was observed for the 
adverse outcome of sarcopenia on functional dependence. Our mediational 
hypothesis was confirmed since the confidence intervals did not include zero 
(−0.009 to −0.004); therefore, gait speed has a mediation effect on the 
relationship between sarcopenia and functional dependence.  
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Figure 2. Gait speed as mediator of the effect of sarcopenia on dependency in 
activities daily living. 
4. Discussion 
 The major findings of our analysis were that sarcopenia may negatively 
influence the independence in ADL in older adults, but this adverse association 
could be counteracted if physical function performance does not decline. 
Therefore, gait speed may positively influence the detrimental effect of 
sarcopenia for dependency, after adjusting for age, gender and BMI. Older adults 
who present characteristics of sarcopenia but have a better gait speed than their 
fewer fit peers will show better functional dependency in ADL, since the 
association between sarcopenia and dependence was mediated for this physical 
fitness component. Our results thus contribute to the current knowledge by 
providing evidence that presenting a better profile in gait speed may ameliorate 
the negative impact of sarcopenia on dependency.  
 CC is an anthropometric parameter that is closely related to whole body 
muscle mass and is known to be associated with the nutrition status of the elderly 
population (22). Our findings indicate that lower CC, a valid predictor of 
sarcopenia (18,19), might increase the risk of dependency in older adults. This 
result is similar to previous cross-sectional studies in which lower CC was 
associated with poor functioning in basic ADL, indicating the high dependency of 
these patients and a high necessity of care (20,32). Our results also suggest that 
sarcopenia induces a lower gait speed. Indeed, it is well documented that the 
deterioration of gait speed related to sarcopenia during aging is due to 
quantitative and qualitative changes in muscle structure and function (1). We also 
found that the lower the gait speed the greater dependency, which is in accord 
with the literature on this topic (6,33), in which a lower gait speed is related to 
more problems in ADL. Accordingly, physical activity focused on counteracting 
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the decline in gait speed could prevent functional dependency. Overall, our 
findings are consistent with previous studies presenting strong evidence on the 
preventive role of gait speed on all-cause mortality (24). Consequently, the 
mediator role of gait speed between sarcopenia and dependence has 
robustness. 
 Our results clearly show the differences between older adults with 
sarcopenia and non-sarcopenia in the performance in gait speed and the level of 
dependence. As shown previous studies, our findings confirm that sarcopenia 
results in lower gait speed (18,34) and independence in daily living (6,35). 
Consequently, the promotion of physical activity in older adults is key to maintain 
the muscle mass to prevent the deterioration of gait speed. In this line, it seems 
that preventing the deterioration of gait speed is crucial, since it has been shown 
to be the physical function component more related to sarcopenia, functional 
independence, vitality and frailty (22,35–37) and is used as a significant predictor 
of frailty and all-cause mortality (22,38). Furthermore, recent studies have related 
a decline in gait speed, sarcopenia, pro-inflammatory biomarkers and functional 
dependence (39,40), fostering a vicious cycle that may be broken with physical 
exercise (9).  
 There are several plausible explanations for our finding. First, there was a 
close relationship between sarcopenia, physical performance (gait speed) and 
dependency. Muscle mass is a metabolic tissue and endocrine organ, and the 
construction of muscle mass releases several endocrines called myokines 
produced, expressed and released by muscle fibers under contraction and exert 
both local and pleiotropic effects (39). In this line, reports of a previous cross-
sectional study show a greater proportion of low muscle density in older people 
with a lower CC scores; moreover, an association was found between high BMI 
and increased functional disability and the presence of comorbidities and 
coexisting factors of disability. In addition, reduced muscular strength is known to 
be significantly and independently associated with functional impairment, walking 
speed, mobility tasks, physical performance, and all-cause mortality in the elderly 
population (39,40). Accordingly, gait speed performance, which is related to 
muscle mass quality, may be one mechanism for the mediator role between 
sarcopenia and dependence. 
 Our study has several limitations that warrant consideration. First, the 
cross-sectional design of the study limits the causality of the findings and only 
associations can be drawn, providing hypotheses that can be verified in future 
studies. A second limitation is the criteria used to establish sarcopenia and non-
sarcopenia groups, since the EWGSOP proposes an algorithm for sarcopenia 
case-finding and not only CC; however, it seems that CC is a valid and reliable 
method to diagnoses sarcopenia (18,19). Another limitation that could affect the 
results of this study is the level of functional dependence, since this was assessed 
through a self-reported questionnaire (41).    
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 To the best of our knowledge, this is the first study aimed at investigating 
the possible role of gait speed performance in the relationship between 
sarcopenia and functional dependence. As previously discussed, there is an 
adverse effect of sarcopenia on functional dependence in older adults, and 
depending on the level of gait speed, this adverse effect could be aggravated or 
improved. Thus, gait speed plays a mediator role between sarcopenia and 
dependence in ADL. 
5. Conclusions and implications 
 The relationship between sarcopenia and functional dependence is 
mediated by gait speed, which can attenuate this negative impact.  Accordingly, 
promoting physical exercise in older adults with sarcopenia focused on improving 
gait speed should counteract the loss of functional independence associated with 
sarcopenia. 
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General discussion 
 
The most relevant finding of this doctoral thesis work are the interactions 
between health conditions and the IC domains in a sample of older adults of the 
2015 SABE Colombia Survey. Regarding metabolic syndrome (MS)as an 
abnormal metabolic condition, its prevalence was established along with the 
associated risk factors in the elderly. Likewise, a description of the values of 
handgrip strength was made, determining for the first time, the cut-off points of 
strength by sex and age for this population, and their association with decreased 
probability of impairment of the IC. Finally, the mediating role of gait rate was 
explored as an indicator of the locomotion domain between sarcopenia and 
dependence on activities of daily living. 
In this sense, evidence is provided on health conditions associated with 
losses of IC, responsible for much of the decline in functionality and dependency 
in the elderly (1). Thus, it can be deducted that if we know how to enhance the 
IC domains with adequate health conditions, better functionality, healthy aging, 
and wellbeing in the elderly can be achieved, as proposed by the WHO (2,3). 
Likewise, variations in health conditions contribute to the diversity found in FA in 
the elderly in older age with younger groups(4).  
Different interactions between health conditions and IC losses can be 
established, for example, increased metabolic cardio risk determined by the 
presence of MS, which leads to losses in the vitality domain within the IC. This 
metabolic alteration is associated with both loss of strength and muscle mass in 
the locomotion domain and this, in turn, leads to changes in nutritional status. 
The analysis of IC, as a multi-dimensional indicator, is complex, but useful 
for understanding and comparing functional capacity among individuals and 
population groups, independent of chronological age and multimorbidity (1). That 
is why, recently, the WHO presented a guide on comprehensive care, focused 
on measurement and on ways for primary care and care of the elderly, which 
seeks to provide guidance on the measurement protocols of the elderly, 
associated with losses in IC: loss of mobility, malnutrition, visual impairment, 
hearing loss, cognitive decline, symptoms of depression. 
Prevalence of MS and associated factors (study 1) 
The main finding herein was the considerably high prevalence of MS in 
the sample (54.9%). The occurrence of MS was more prevalent in females than 
in males; irrespective of the aging stage (females had the highest prevalence in 
aging stage III (70–80 years) and in aging stage I (60–65 years for males). The 
most prevalent MS-components for the overall sample were abdominal obesity 
(78.5%), low levels of HDL-c (57.3%), EABP (53.1%), and high levels of fasting 
blood triglycerides (45.5%). 
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A relationship exists between MS and all-cause mortality and CVD 
mortality. Recently, Sang-Yhun et al., (5) performed a meta-analysis with 20 
prospective studies, finding that MS is associated with all-cause mortality and 
CVD mortality [relative risk (RR), 1.23; 95%CI, 1.15–1.32; I2 = 55.9%] and CVD 
mortality (RR, 1.24; 95%CI, 1.11–1.39; I2 = 58.1%). Risk estimates of all-cause 
mortality for single components of metabolic syndrome were significant for higher 
values of waist circumference or body mass index (RR, 0.94; 95% CI, 0.88–1.00), 
higher values of blood glucose (RR, 1.19; 95% CI, 1.05–1.34), and lower values 
of high-density lipoprotein (HDL) cholesterol (RR, 1.11; 95% CI, 1.02–1.21). In 
the elderly population, metabolic syndrome was associated with increased risk of 
all-cause and CVD mortality. Therefore, having a 54.9% prevalence of MS in 
older adults in Colombia, presents an increased risk of all-cause and CVD 
mortality. 
It should be noted that while the prevalence of MS in the present sample 
is high (54.9%), it is similar to that of other Latin American studies in the elderly 
with 53% (6) and Mexico (7). In relation to gender, the higher prevalence of MS 
in women is explained by hormonal changes in menopause (8). This higher 
prevalence in women is associated with a higher risk of knee osteoarthritis (odds 
ratio (OR) = 1,644, p <0.001; and OR = 1,608, p <0.001) (9). Thereby, MS is 
associated with displacement of locomotion in adult women. 
Similarly, MS, as a health condition, was associated with losses in 
cognitive functions, dietary patterns, and metabolic health in older adults in New 
Zealand (10). The foregoing was also demonstrated by Kassam et al., in a cross-
sectional study in which the prevalence of metabolic syndrome in the elderly with 
schizophrenia, in individuals 55 years or older (n = 353), almost half of them (n = 
77; 51.7%) tested positive, according to the NCEP ATPIII criteria for MS. These 
findings support that the prevalence of MS among the elderly with morbidities is 
high, and their diagnosis and prior intervention is essential to improve the 
wellbeing of the elderly (11). 
Finally, MS is a health condition that plays an important role in the 
inflammatory profile of the elderly, mainly due to increased levels of IL-6 and CRP 
(12), which entails even greater cardiometabolic risk in the elderly. 
Handgrip strength values and their association with IC. 
 Handgrip strength is a considerably reliable measure, to evaluate muscle 
strength due to its reproducibility, reliability, and validity (13). Muscular strength, 
as evaluated by handgrip strength, has predictive value to assess declines in 
physical and mental capacities in the elderly (14); these are both components of 
the intrinsic capacity construct. Recent studies have shown that greater handgrip 
muscular strength is associated with lower all-cause and cancer mortality (15). 
Other authors have associated low handgrip values with increased waist 
circumference and body mass index (16), which is why it is considered a predictor 
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of nutritional status (17) and the presence of chronic diseases, hypertension (HT), 
diabetes mellitus (DM), coronary heart disease (CHD), and chronic obstructive 
pulmonary disease (COPD) (18). 
The aging process is related to changes in muscle mass and, in its 
neurophysiological component, to changes that generate loss in the contractile 
capacity of muscle fiber, so that 57% muscle strength losses in type-II muscle 
fiber have been reported, as well as 25% decrease in type-I muscle fiber (19). 
Loss of muscle mass and strength affects physical performance, functional 
status, and mobility and favors the presence of sarcopenia, understood as a 
progressive loss of muscle mass and strength that increases the risk of disability 
and death in the elderly (20.21). 
Overall, older adults with handgrip strength greater than the muscle 
weakness cut-off points had lower odds of adverse events in most of the intrinsic 
capacity domains (especially in cognition and locomotion domains) and 
hospitalization (only in men) than their weaker peers. Our results may inform 
intervention strategies aiming to increase muscle strength and promote healthy 
aging. 
Several papers have published normative reference values of handgrip 
strength in older people in different populations (22,23,24); however, in Colombia, 
it is the first time that reference values are reported for this population. 
In conclusion, our findings demonstrated the association between an 
optimal prehensile force with each of the IC domains, mainly with the cognitive, 
locomotion, and vitality domains. No associations with the auditory sensitivity 
domain will be established. Low strength values are associated with cognitive 
change and depression than their weakest peers with reduced cognitive 
performance (26-28). Given the results obtained, our prehensile force cohort 
points are useful to predict cognitive risk and mental health in the elderly in 
Colombia. 
Gait rate as a mediator of the effect of sarcopenia on dependency in 
activities of daily living. 
Sarcopenia is the loss of muscle mass and age-dependent function. It is a 
common condition among the elderly and is associated with several adverse 
health outcomes (29). Sarcopenia is associated with falls, frailty, malnutrition, 
disability, and mortality (30-32) and it is a highly prevalent in the elderly (33). 
Sarcopenia brings costs to health and social systems; therefore, it is necessary 
to study its interactions with the IC domains. 
Slow walking speed has been used to predict adverse health outcomes, 
such as hospital admissions, falls, and mortality (34,35). Our findings 
demonstrated the positive mediating effect of gait rate to decrease the negative 
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impact that sarcopenia has on ADLs. Older adults with sarcopenia, but who have 
a better walking speed have a better functional dependence on ADL. 
 Decreased walking speed has been related to cognitive deficits in the 
elderly (36). This reflects decreased information processing to respond to orders, 
standing, and moving the body; it is a complex activity that requires important 
cognitive processes. In addition, our findings demonstrate how the presence of 
sarcopenia is associated with low speed in gait and, consequently, in the loss of 
functionality and independence (37). Gait rate can positively affect the negative 
effects of sarcopenia on functional dependence. 
 What is evident is a close relationship between the cognitive domains of 
vitality and cognition, given that strength, muscle mass, cognitive processes, and 
functional dependence are related. What is relevant is that for the first time these 
interrelations with epidemiological evidence are demonstrated, so the 
compression between the interactions between the biomarkers of each domain 
is a field of work that must be developed towards the future. 
References 
1. De Carvalho I, Martin F, Cesari M, Sumi Y, Thiyagarajan J, Beard J. 
Operationalising the concept of intrinsic capacity in clinical settings. WHO 
Working Group on Metrics and Research Standards for Healthy Ageing, 
Clinical Consortium on Healthy Ageing; 2017.Nov. background paper No 
1 
 
2. Resolution WHA69.3. The global strategy and action plan on ageing and 
health 2016–2020: towards a world in which everyone can live a long and 
healthy life. In: Sixty-ninth World Health Assembly, Geneva, 23–28 May 
2016. Resolutions and decisions, annexes. Geneva: World Health 
Organization; 2016. Available from: 
http://apps.who.int/gb/ebwha/pdf_files/WHA69-REC1/A69_2016_REC1-
en.pdf#page=27  [cited 2019 Mar 7]. 
 
3. World Health Organization. World report on ageing and health 2015. 2015. 
Available from: https://www.who.int/ageing/events/world-report-2015-
launch/en/. 
4. World Health Organization; Integrated care for older people (ICOPE): 
Guidance for person-centred assessment and pathways in primary care. 
Geneva. (WHO/FWC/ALC/19.1). Licence: CC BY-NC-SA 3.0 IGO. 
5. Ju S, Lee J, Kim D. Association of metabolic syndrome and its components 
with all-cause and cardiovascular mortality in the elderly: A meta-analysis 
of prospective cohort studies. Medicine (Baltimore). 2017 Nov; 
96(45):e8491. 
100 
 
 
6. Rubinstein A, Irazola V, Calandrelli M, Elorriaga N, Gutierrez L, Lanas F, 
Manfredi J, Mores N, Olivera H, Poggio R. Multiple cardiometabolic risk 
factors in the Southern Cone of Latin America: A population-based study 
in Argentina, Chile, and Uruguay. Int. J. Cardiol. 2015, 183, 82–88. 
 
7. Aleman-Mateo H, López-Teros MJ, Urquidez-Romero R, Huesca L. 
Prevalence of metabolic syndrome and its determinants in older Mexican 
non-diabetic adults. Nutricion hospitalaria.2018; 35(2), 294-304. 
 
8. Dallongeville J, Cottel D; Arveiler D, Tauber, J.-P.; Bingham, A.; Wagner, 
A.; Fauvel J, Ferrieres J, Ducimetiere P, Amouyel P. The association of 
metabolic disorders with the metabolic syndrome is different in men and 
women. Ann. Nutr. Metab. 2004; 48(1): 43–50. 
 
9. Lee BJ, Yang S, Kwon S, Choi KH, Kim W. Association Between Metabolic 
Syndrome and Knee Osteoarthritis: A Cross-Sectional Nationwide Survey 
Study. Journal of rehabilitation medicine. 2019; 51(6): 464-470. 
 
10. Mumme KD, Von Hurst PR, Conlon CA, Jones B, Haskell-Ramsay CF, 
Stonehouse W, Beck KL. Study protocol: associations between dietary 
patterns, cognitive function and metabolic syndrome in older adults–a 
cross-sectional study. BMC public health.2019; 19(1), 535. 
 
11. Kassm SA, Hoertel N, Naja W, McMahon K, Barrière S, Blumenstock, 
Guerin-Langlois C. Metabolic syndrome among older adults with 
schizophrenia spectrum disorder: Prevalence and associated factors in a 
multicenter study. Psychiatry research.2019; 275:238-246. 
 
12. Neves C, Mambrini, J, Torres K, Teixeira-Carvalho A, Martins-Filho O, 
Lima-Costa, M, Peixoto S. Association of metabolic syndrome with 
inflammatory markers in a sample of community-dwelling older 
adults.Cadernos de saude publica.2019 ; 35(3). 
 
13. Bohannon RW. Muscle strength: clinical and prognostic value of hand-grip 
dynamometry. Curr Opin Clin Nutr Metab Care. 2015 Sep; 18(5):465-70. 
 
14. Rijk JM, Roos PR, Deckx L, Van den Akker M, Buntinx  F. Prognostic value 
of handgrip strength in people aged 60 years and older: a systematic 
review and meta‐analysis. Geriatr Gerontol int 2016; 16 (1):5-20. 
 
15. Celis-Morales CA, Welsh P, Lyall DM, Steell L, Petermann F, Anderson J, 
et al. Associations of grip strength with cardiovascular, respiratory and 
101 
 
cancer outcomes, and all-cause mortality: prospective cohort study of half 
a million UK Biobank participants. BMJ 2018;361 :k1651. 
 
16. Silva N, Mezanes T, Melo R, Pedraza D. Handgrip strength and flexibility 
and their association with anthropometric variables in elderly. Rev Assoc 
Med Bras. 2013; 59(2):128-35. 
 
17. Gale C, Martyn C, Cooper C, Sayer A. Grip strength, body composition, 
and mortality. Int J Epidemiol. 2007; 36:228-35  
 
18. Rantanen T, Masaki K, Foley D, Izmirlian G, White L, Guralnik JM. Grip 
strength changes over 27 yr in Japanese- American men. J Appl 
Physiol.1998; 85(6): 2047-2053. 
 
19. Artigas S, Rolland Y, Zamboni M, Leheudre A. How to assess functional 
status: a new muscle quality index. J Nutr Health Aging. 2012; 16(1):67-
77. 
 
20. Cruz–Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, 
et al. Sarcopenia: European Working Group on Sarcopenia in Older 
People: Sarcopenia: European consensus on definition and diagnosis - 
report of the European Working Group on Sarcopenia in Older People. 
Age Ageing. 2010; 39: 412-23. 
 
21. Clark CB, Manini MT. What is dynapenia? Nutrition. 2012; 28:495-503 
 
22. Mendes J, Amaral TF, Borges N, Santos A, Padrão P, Moreira P, et al. 
Handgrip strength values of Portuguese older adults: a population based 
study. BMC Geriatr 2017; 17: 191. 
23. Pedrero-Chamizo R, Gomez-Cabello A, Delgado S, Rodríguez-Llarena S, 
Rodríguez-Marroyo JA, Cabanillas E, Meléndez A, et al. Physical fitness 
levels among independent non-institutionalized Spanish elderly: the 
elderly EXERNET multi-center study. Arch gerontol geriatr. 2012; 
55(2):406-16. 
 
24. Kenny RA, Coen RF, Frewen J, Donoghue OA, Cronin H, Savva GM. 
Normative values of cognitive and physical function in older adults: 
findings from the Irish Longitudinal Study on Ageing. J Am Geriatr Soc. 
2013 may;61(s2):S279-90 
 
25. Wang YC, Bohannon RW, Li X, Yen SC, Sindhu B, Kapellusch J.e. 
Summary of grip strength measurements obtained in the 2011-2012 and 
2013-2014 National Health and Nutrition Examination Surveys. J  Hand 
Ther. 2018 Apr; S0894-1130(17)30389-7. 
102 
 
 
26. Fritz NE, McCarthy CJ, Adamo DE. Handgrip strength as a means of 
monitoring progression of cognitive decline–A scoping review. Ageing Res 
Rev. 2017 May; 35:112-123. 
 
27. Chang KV, Hsu TH, Wu WT, Huang KC, Han DS. Is sarcopenia associated 
with depression? A systematic review and meta-analysis of observational 
studies. Age Ageing. 2017 Sep 1; 46(5):738-746. 
 
28. Veronese N, Stubbs B, Trevisan C, Bolzetta F, De Rui M, Solmi M, et al. 
Poor Physical Performance Predicts Future Onset of Depression in Elderly 
People: Progetto Veneto Anziani Longitudinal Study. Phy ther. 2017 Jun 
1; 97(6):659-668 
 
29. Marzetti E, Calvani R, Tosato M, Cesari M, Di Bari M, Cherubini A, et al. 
Sarcopenia: an overview. Aging Clin Exp Res. 2017 Feb; 29(1):11-17.  
 
30. Landi F, Cruz-Jentoft AJ, Liperoti R, Russo A, Giovannini S, Tosato M, et 
al. Sarcopenia and mortality risk in frail older persons aged 80 years and 
older: results from IlSIRENTE study. Age Ageing.2013; 42:203–209. 
 
31. Cerri AP, Bellelli G, Mazzone A, Pittella F, Landi F, Zambon A, Annoni G 
Sarcopenia and malnutrition in acutely ill hospitalized elderly: prevalence 
and outcomes. Clin Nutr .2015; 34:745–751. 
 
32. Vetrano DL, Landi F, Volpato S, Corsonello A, Meloni E, Bernabei R, 
Onder G. Association of sarcopenia with short- and long-term mortality in 
older adults admitted to acute care wards: results from the CRIME study. 
J Gerontol  Biol Sci Med Sci.2014; 69:1154–1161. 
 
33. Reginster JY, Cooper C, Rizzoli R, Kanis JA, Appelboom G, Bautmans I, 
et al. Recommendations for the conduct of clinical trials for drugs to treat 
or prevent sarcopenia. Aging Clin Exp Res.2016; 28:47–58.  
 
34. Sanders, JB., Bremmer, MA., Comijs, HC., Van De Ven, PM., Deeg, DJ, 
Beekman AT. Gait speed and processing speed as clinical markers for 
geriatric health outcomes. Am J Geriatr Psychiatry.2017; Apr; 25(4):374-
385 
 
35. Studenski S, Perera S, Patel K, Rosano C, Faulkner K, Inzitari M, et al: 
Gait speed and survival in older adults. JAMA 2011; Jun 305:50–58. 
 
103 
 
36. Finkel D, Reynolds CA, McArdle JJ, Pedersen NL. Age changes in 
processing speed as a leading indicator of cognitive aging. Psychol Aging. 
2007 Sep; 22(3):558-68. 22:558–568. 
 
37. Studenski S, Perera S, Wallace D, Chandler JM, Duncan PW, Rooney E, 
et al. Physical performance measures in the clinical setting. J Am Geriatr 
Soc. 2003 Mar; 51(3):314–22.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
104 
 
CHAPTER 6  
CONCLUSIONS, AND FUTURE PERSPECTIVES 
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Study 1 (Chapter 2)  
Conclusion 
 
The prevalence of MS is 54.9% among the Colombian elderly and females 
had the highest prevalence of MS, irrespective of the aging stage. High 
abdominal obesity was the main prevalent MS component (78.5%). Male gender, 
sarcopenia status, and being a smoker were found significantly associated with 
the probability of MS. New health policies and prevention strategies focused on 
the elderly Latin American population should be implemented based on these 
findings. 
 
Future perspective 1: 
 
When observing a prevalence of MS in the Colombian elderly, due to the 
characteristics of the population from each region of the country, the need is clear 
to conduct regional studies to evaluate the factors associated with the prevalence 
of MS in the elderly and, therefore, improve the diagnosis and treatment of the 
disease with cardiovascular risk reduction. 
 
It is important to conduct clinical trials with multicomponent trials to see 
their effects on each of the components of MS in the Colombian elderly. 
 
The SABE study can be continued in five years to identify patterns of 
epidemiological trend in long-term MS prevalence. 
 
Research should continue on the interactions of MS with other 
components of the IC domains. 
 
 
Study 2 (Chapter 3)  
Conclusion 
 
A simple measure, such as prehensile strength, and cohort point 
deficiency can be good biomarkers for the clinical assessment of physical and 
mental health risks in the Colombian elderly. 
 
Future perspective 2: 
 
With strength reference values for the elderly population in Colombia, it is 
necessary to carry out additional studies on the effects of enhancing physical 
exercise programs in this population to assess the improvements in strength and 
its effects on the elderly population. 
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Further research is required on the role of strength as an indicator of the 
locomotion domain and its interactions with other biomarkers from other domains, 
such as cognition vitality, visual and auditory impairments, and psychological 
aspects. 
 
Study 3 (Chapter 4)  
Conclusion 
 
The relationship between sarcopenia and functional dependence is 
mediated by gait rate, which can attenuate this negative impact. Accordingly, 
promoting physical exercise in older adults with sarcopenia focused on improving 
gait rate should take into account the loss of functional independence associated 
with sarcopenia. Gait rate is a clinical marker and an important measure of 
functional capacity among the elderly. 
 
Future perspective 2: 
 
With respect to gait rate in the relationship between sarcopenia and 
functional dependence, it is necessary to study this mediation in the elderly with 
underlying pathological conditions, like COPD and brain diseases, with the 
proposed identification of possible changes within rehabilitation programs so that 
they focus on the priority rehabilitation objective 
 
It is suggested to continue studying other possible mediations of gait rate 
with other health conditions, such as frailty. 
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Abstract
Background: Understanding the metabolic syndrome prevalence in the national 
level is important to develop the effective programs and strategies to prevent and 
control metabolic syndrome. This study aimed to analyze the prevalence of 
metabolic syndrome and its influencing factors in older individuals aged ≥60 years 
in Colombia. 
Methods: The data for this study came from a secondary cross-sectional, nationally 
representative SABE study Survey on Health, Well-Being, and Aging in Colombia, 
2015. A total of 1637 participants (60.7% women, 70.5±7.9 years) from 86 
Colombian municipalities participated. A structured questionnaire was used to 
collect data on socio-demography, lifestyle, and medical conditions. Measurements 
included anthropometric variables, handgrip strength, high-density lipoprotein 
cholesterol, triglycerides, fasting glucose, and blood pressure. Univariate and 
multiple regression models were established as part of the main analysis. 
Results: Using the harmonized Joint Scientific Statement criteria, metabolic 
syndrome was present in 54.9% of the study population, with a higher prevalence 
among females than males (59.8% vs. 47.3%). Individuals who were cigarette 
smoking (odds ratio [OR] = 1.59; 95% confidence interval [CI] = 1.03–2.44; 
p=0.034), male gender (OR = 1.38; 95%CI = 1.05–1.82; p=0.020) and sarcopenia 
(OR = 1.63; 95%CI = 1.06–2.52; p=0.026) were more likely to have a higher 
prevalence estimate of metabolic syndrome.
Conclusions: Overall prevalence of metabolic syndrome among older adults in 
Colombia is high. Smoking, male gender, and sarcopenia status are associated 
with metabolic syndrome. These results suggested that metabolic syndrome is still 
a serious public burden in Colombia, and screening for promotion of healthy lifestyle 
and nutrition counselling should be offered routinely in old age.
Keywords: Older adults, Metabolic risk, Cardiovascular diseases, Prevalence
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1. Introduction
The number of elderly people worldwide is expected to double over the next 50 
years [1,2]. Older (> 60 years old) in Latin America and the Caribbean will reach 
~101 million (15% of the population)[3]. For Colombia, the mean life expectancy will 
rise to 77.6 years for women and 69.8 years for men in 2025. Due to this, the Pan 
American Health Organization (PAHO) and the Merck Institute of Aging and Health 
called for greater surveillance over the causes of morbidity and mortality in older 
adults [4].
The Metabolic Syndrome (MS) is a complex cluster of cardiovascular risk factors 
that are associated with a sedentary lifestyle, poor nutrition, and consequent obesity, 
and is strongly associated with cardiovascular diseases, include glucose intolerance 
(type 2 diabetes, impaired glucose tolerance, or impaired fasting glycemia), insulin 
resistance, abdominal obesity, dyslipidemia, and hypertension [5,6]. Accordingly, 
MS increases the risk of developing diseases of cardiovascular origin such as acute 
myocardial infarction [7], ischemic stroke or coronary heart disease [8,9]. Indeed, the 
prevalence of cardiovascular disease attributable to MS is around 12–17% [10]. 
Several studies have deepened in the analysis of the presence of MS in Latin 
America reporting its associated factors such as increasing age, Hispanic or 
indigenous heritage, physical inactivity, high alcohol intake, smoking, history of 
hypertension or type 2 diabetes (first-degree family members), and belonging to a 
low socioeconomic status [11]. Likewise, the general prevalence of MS in Latin-
American countries has been established in 24.9% (range: 18.8–43.3%) and is 
slightly more frequent in women (25.3%) than in men (23.2%). On the other hand, 
several risk factors for MS have been suggested, such as alcohol/cigarette smoking 
intake, residence (urban/rural) and inflammatory markers [12], dietary factors, such 
as intake of total fat or saturated fat [13], physical inactivity, and poor physical fitness 
[14]. We previously demonstrated in Colombian collegiate students aged 18–30 
years that those with the sex (male), age (over 23 years old), weight status 
(overweight or obese) and having an unhealthy waist to height ratio were more likely 
to have a prevalence of MS [15]. Additionally, another studies that included diverse 
Hispanic/Latino populations suggested a marked heterogeneity in risk factor 
prevalence within this population [16]. 
Latin America has undergone a well-documented epidemiologic transition 
fuelling a non-communicable disease epidemic [17] and makeable changes in 
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people´s lifestyles that may contribute to greatly increased burden on cluster of 
cardio-metabolic disease as MS [11]. However, only a few studies have analyzed 
MS prevalence specifically in older adults, in whom important changes could still be 
made to their lifestyles to improve independence and quality of life, as well as 
preventing other lethal diseases. Therefore, the aim of this study were to analyze the 
prevalence of MS and its influencing factors in Colombian older people from a 
sample of the SABE Colombia study. Understanding the MS prevalence in the 
national level is important to develop the effective programs and strategies to prevent 
and control MS.  
2. Materials and Methods
2.1. Study Design and Sample Population
This study is part of the 2015 SABE study Survey on Health, Well-Being, and 
Aging in Latin America and the Caribbean, which is a multicenter project conducted 
by the Pan-American Health Organization (PAHO) and supported by the 
Epidemiological Office of the National Health Ministry in Bogotá, Colombia 
(https://www.minsalud.gov.co/). Details of the survey have been published 
elsewhere [18]. The instrument used was derived from the original SABE study 
conducted in 5 Latin America capital cities [19]. The estimated sample size was 
24,553 individuals, and assuming an 80% response of the target sample was 30,691 
individuals [18]. The final sample size achieved, (including 244 municipalities) was 
23,694 elderly Colombians. 
Institutional review boards involved in developing the SABE-Colombia study 
(University of Caldas, ID protocol CBCS-021-14, and University of Valle, ID protocol 
09-014 and O11-015) reviewed and approved the study protocol. Written informed 
consent was obtained from each individual before inclusion and completion of the 
first examination. Permission and details available in https://www.minsalud.gov.co/. 
The study protocol to the secondary analysis was approved by the Human Subjects 
Committee at the Pontificia Universidad Javeriana (ACTA ID 20/2017-2017/180, FM-
CIE-0459-17).
The survey included elderly Colombians (≥60 years) using purposive, 
randomized sampling (urban and rural areas). In this sub-sample, 86 municipalities 
were defined for blood sampling, and two out of every five people were called to 
participate. A total of 1637 were included in the present analysis.
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2.2. Measurements
Data collection staff was trained by the research teams of the coordinating 
centers (Universities of Caldas and Valle) for face-to-face interviews and physical 
measurements. Body mass index (BMI) was estimated in kg/m2 from the measured 
weight and height. Sarcopenia was defined according to calf circumference (CC) as 
a "proxy" measure for assessing early identification of sarcopenia in clinical practice, 
due to the low cost and ease of obtaining [20]. As described by Rolland et al., [20] a 
CC smaller than 31 cm is considered to be indicative of sarcopenia. This cut-off has 
been recommended for use in older individuals by the WHO Expert Committee [21].
Handgrip strength was assessed on a Takey dynamometer (Grip Strength 
Dynamometer Model T.K.K. 5001®, Takei Scientific Instruments Co., Ltd, Niigata, 
Japan) including the highest value (kg) from two attempts (both hands). Handgrip 
strength was categorized into 3 levels by sex (low, moderate and high) according to 
the KORA-age study [22].
Blood samples were taken by puncturing the capillary vein under standardized 
conditions, with the participant having fasted at least 10–12 hours beforehand. The 
biochemical profile included: (i) HDL-cholesterol (HDL-c); (ii) triglycerides; (iii) low-
density lipoprotein cholesterol (LDL-c); (iv) total cholesterol; and (v) glucose fasting. 
Samples were analyzed by standard enzymatic colorimetric methods. 
Blood Pressure, Diastolic (DBP) and systolic (SBP), was measured with subjects 
in rest (5-min) with an automated procedure using the OMRON HEM – 705 monitor 
(Omron® Healthcare Europe BV, Hoofddorp, The Netherlands).  
For the lifestyle, personal habits regarding alcohol intake (participants were 
categorized as those who do not drink and those who drink less than one day per 
week, two to six days a week, or everyday) and smoking status (participants were 
categorized as those who do not smoke and those who have never-smoked, those 
who currently smoke, or those who previously smoked) were recorded. A “proxy 
physical activity” report was conducted by the following questions: (i) "Have you 
regularly exercised, such as jogging or dancing, or performed rigorous physical 
activity at least three times a week for the past year?" (ii) "Do you walk at least three 
times a week between 9 and 20 blocks (1.6-km) without resting?" and (iii) "Do you 
walk at least three times a week 8 blocks (0.5-km) without resting?" Participants were 
considered physically active if they responded affirmatively two of the three 
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questions. Self-reported comorbidities were assessed by asking the participants if 
they had a diagnosis made by a physician.
2.3. Definitions of MS
MS was defined according to the most recent Joint Interim Statement of the 
International Diabetes Federation Task Force on Epidemiology and Prevention [23] 
by adopting the Ethnic Central and South American criteria for waist circumference. 
Participants were classified as having MS if they had at least 3 of following metabolic 
risk factors or components (MS-components): abdominal obesity (waist 
circumference ≥90 cm for Latin-American men and ≥80 cm for Latin-American 
women; elevated triglycerides (fasting serum triglycerides  ≥150 mg/dL or taking 
medication for abnormal lipid levels); reduced HDL-c (fasting serum HDL-c <40 
mg/dL in males; <50 mg/dL in females or specific treatment for this lipid abnormality); 
elevated blood pressure (SBP ≥130 mmHg or DBP ≥85 mmHg or taking 
hypertension medication); elevated fasting glucose (serum glucose level ≥100 mg/dL 
or taking diabetes medication).
2.4. Definitions of potential influencing factors
Potential influencing factors included sex (male/female), sarcopenia status (≤31 
cm with sarcopenia or >31 cm without sarcopenia), handgrip strength categorized 
into 3 score by sex (low, moderate and high levels), alcohol intake (never or 
no/current or yes), smoking status now (never or no/current or yes), and physical 
activity “proxy” levels (physically active/non physically active).
2.5. Statistical Analysis
General characteristics from the study sample are presented as frequency and 
percentage or as the mean and standard deviation (SD). Two-way analysis of 
variance or the χ2 test to compare sex and age differences were used. Descriptive 
analysis of the prevalence of the MS by sex an age stages, as well as, a descriptive 
analysis of the MS-components have been presented in figures using percentages. 
Relationships between influencing factors of MS and MS (categorical variables) have 
been performed by Pearson Chi-square. 
Simple logistic regressions were performed individually for each independent 
variables to analyze the association with MS. MS was included in each simple logistic 
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regression as the dependent variable (reference: to have MS). Sex with males as an 
indicator, age, BMI, to have sarcopenia, handgrip strength with the high level of 
strength as an indicator, be a smoker, have alcoholic intake, and be physically 
inactive, were included as fixed factors. 
Then, a multiple logistic regression was used to identify the main predictor or 
influencing factors associated (clinical characteristic) of MS including at the same 
model: sex (indicator: male), sarcopenia (indicator: to have sarcopenia), handgrip 
strength (indicator: high level of handgrip strength) smoking habit (indicator: be 
smoker), alcoholic habit (indicator: to have alcoholic habit) and physical activity 
levels (indicator: be physically inactive) as independent variables. Both, simple 
logistic regression and multiple logistic regression (model) used the intro method. 
Multiple logistic regression was adjusted by the following confounders: age, ethnicity, 
socioeconomic status, urbanicity, BMI, medication use, and medical conditions 
(presence or absence of hypertension, diabetes, respiratory diseases, 
cardiovascular diseases, stroke, osteoporosis or cancer). 
The analysis of the data was performed with the SPSS statistical software 
package, version 24.0 (IBM, Chicago, IL, USA) for Windows.
3. Results
3.1. Characteristics of the study population
The general characteristics of the participants are presented according to the 
overall sample, sex and aging stages in Table 1. Most of the participants 
(males=213, females=312) belonged to aging stage III (70–80 years). Social status 
in level 2 (42.6%), urban area context (83.3%), and other ethnic groups (54.1%) were 
the most prevalent sociodemographic characteristics. The waist circumference and 
BMI means in the overall sample were 92.5 cm and 27.3 kg/m2, respectively. Most 
of the sample had abdominal obesity (78.6%), and an overweight status (41.3%), 
but an healthy sarcopenia status (86%). Risky blood parameters for the overall 
sample were SBP (132.64±23.5 mmHg), Fasting Serum Triglycerides (160.94±83.3 
mg/dL), and LDL-c (126.85 ± 35.3 mg/dL). The handgrip strength mean for the 
overall sample was 32.4 kg, with prevalence at high category (59.4%). 
Several statistical differences were observed according to the sex (Table 1). 
Females showed several highest values compared with males (i.e.: abdominal 
obesity, BMI, overweight, total cholesterol, HDL-c, LDL-c), whereas males presented 
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higher values regarding waist circumference, blood pressure, and handgrip strength. 
Additionally, numerous statistical differences were observed between aging stages 
within the sex groups (Table 1).
** Table 1 here **
3.2. Clinical characteristics and prevalence of MS
The incidence of alcohol consumption (9.2%) and smoking (12.1%) was low but 
significantly higher in men than in women (smoking: 12.6% vs 6.9%; alcohol: 21.3% 
vs 6.1%), and mainly were presented at first aging stages. Most of the sample 
(mainly women at the first aging stages) were not physically active (82.9%). 
Hypertension was the most common chronic comorbidity (44.2%), following of 
diabetes (16.4%). Females presented the highest prevalence compared with males 
(60.8% vs 48%, p<0.001, and 18.3% 13.4%, p=0.009, respectively) at aging stage 
III and IV, respectively. Finally, cardiovascular diseases and stroke with no 
differences between sex and aging stages, Table 2.
** Table 2 here **
3.3. Prevalence of MS and its distribution by MS-componets
The overall prevalence of MS in the study sample was 54.9% (95% confidence 
interval [CI] 52.4–57.3. The prevalence of MS according to sex, and the aging stages 
is presented in Figure 1. A. MS was more prevalent in females than in males (59.8% 
versus 47.3%) irrespective of the aging stage. For females, the prevalence of MS 
was highest in aging stage III (64.6%), whereas for males it was highest in the aging 
stage I (49.4%). The most prevalent MS-components were abdominal obesity 
(78.5%), low levels of HDL-c (57.3%), elevated arterial blood pressure (EABP) 
(53.1%), and high levels of fasting blood triglycerides (HLFBTg) (45.5%). Elevated 
fasting blood glucose was the least common components of MS (31.1%). Related to 
the MS-components by sex (Figure 1.B), the greatest differences were observed for 
high waist circumference (HWC), and low levels of HDL-c (LLHDL), with a higher 
prevalence in females than in males (HWC: females=88% vs males 64 %, p<0.001 
and LLHDL: females=60.7% vs males=51.7%, p<0.001). The prevalence of HLFBTg 
was also significantly higher in females than in males (females=48.8% vs 
males=40.8 %, p=0.001). However, males presented a higher prevalence of EABP 
than females (57.2% vs 50.8 %, p=0.001). The prevalence of MS according to the 
MS-components was presented in figure 1.C. 
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Additionally, we explore the MS prevalence according to the studied comorbid 
chronic diseases. Participants with MS presented the hypertension as the main 
comorbid chronic disease with a prevalence of 60.9% of the sample. The rest of 
participants with MS presented the following prevalence of the comorbid chronic 
diseases: diabetes (23.1%), cardiovascular disease (16.2%), osteoporosis (14.1%), 
respiratory diseases (11.1%), stroke (5.1%), and cancer (4.8%), Table 2. 
** Figure 1 here **
3.4. Relationship between MS status and clinical characteristics
Relationship between MS status and clinical characteristics were presented in 
table 3. Clinical characteristics such as sex, sarcopenia status and handgrip strength 
were significantly associated (p<0.05). 
** Table 3 here **
3.5. Influencing factors associated with MS
Table 4 shows the ORs for the influencing factors associated with MS among 
the Colombian older adults (univariate analysis) were male gender (OR= 1.662, 
95%CI= 1.359–2.032; p<0.001), to have a sarcopenia status (OR= 2.55, 
95%CI=1.900–3.434; p<0.001), and a low handgrip strength (OR=1.432, 95%CI= 
1.084–1.892; p=0.011). Sarcopenia status was the main variable associated with 
MS, with more than two times the approximate risk of occurrence of MS.
** Table 4 here **
After the adjustment by the main confounders in the multiple regression model 
(Figure 2), male gender (OR= 1.388; 95%CI= 1.054–1.828; p=0.020) and a 
sarcopenia status (OR= 1.637; 95%CI= 1.061–0.525; p=0.026) were again 
significantly associated with MS. In addition, being a smoker was positively 
associated with MS (OR= 1.591; 95%CI= 1.036–2.443; p=0.034). Thus, in general, 
to have a sarcopenia status and smoking were the main risk factors associated with 
MS in this sample of Colombian older adults, with more than 1.5 times the 
approximate risk of occurrence of MS.
** Figure 2 here **
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4. Discussion
The main finding of the present study was the considerably high prevalence of 
MS in the sample (54.9%). The prevalence of MS was more prevalent in females 
than in males irrespective of the aging stage (females highest prevalence in aging 
stage III (70–80 years) and in aging stage I (60–65 years for males). The most 
prevalent MS-components for the overall sample were abdominal obesity (78.5%), 
low levels of HDL-c (57.3%), EABP (53.1%) and high levels of fasting blood 
triglycerides (45.5%). Female gender, a poor sarcopenia status, and be smoking 
were found to b  significantly associated with probability of MS (after adjustment). 
It should be noted that while the prevalence of MS in the present sample is high 
(54.9%), it is similar to other Latin American studies in older people, such as Ecuador 
59.9% [24], Brazil with 51.5.% [16], Southern Cone of Latin America with 53% [25], 
in Ecuador elders (≥65 years) with 40% [26],Colombia with 52.2%, [27] and in the 
CARMELA study with 35.5% [28]. A reasonable explanation for the high prevalence 
of MS in the present study could be that most of the sample belonged to an urban 
area (83.3%), where people have a higher risk of MS [29,30]. This might be due to 
several lifestyle aspects, such as dietary patterns or low physical activity levels, as 
was found in our study where most of the sample (82.9%) was insufficiently active. 
According to our results regarding sex, in the six Latin American studies 
previously mentioned [16,24–28], females also had a higher prevalence of MS than 
males in general, and particularly in the older adult groups (when it applied). As 
previously reported, MS is more common in females in an older North American 
population of Mexican origin [31]. Many of the typical aspects of MS, such as 
increased abdominal adiposity and dyslipidemia, hyperglycemia, and 
hyperinsulinism, are experienced in females along the menopausal transition [31]. 
The cessation of estrogen secretion at the beginning of menopause accentuates 
these aspects, decreasing the quality of life[32]. Additionally, it seems that the onset 
of menopause begins earlier in Latin American countries than in Europe and USA, 
what may be associated with higher altitude residency and lower educational-
economical income [33,34]. In the present study, the overall sample belonged to 
social status 1-2 (72.7%), and with a residency at high altitude (Bogota, 2680 m), but 
without significant differences between genders. 
Consequently, scientific investigations on Latin American postmenopausal 
women related to the MS prevalence and its associated factors have increased [35], 
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although little is known about older adult populations. In addition, males presented 
the highest MS prevalence (49.4%) in aging stage I (60–65 years), but not in the 
later ones. In agreement with our results, in a cross-sectional analysis of 4289 
Taiwanese individuals [36], the male:female MS ratio reversed after the age of 60 
(men 30.4% vs women 40.3%). Similarly, in a large population-based project 
enrolling 36 cohorts from 10 European countries [37], there was an increase in the 
prevalence of MS from age groups 19–39 years to 60–78 years was nearly two-fold 
in males, and five-fold in females, resulting in a higher prevalence of MS in women 
after the age of 50. Again, the typical changes in the hormonal status during and 
after menopause could explain the significant influence of sex in the age-related 
increase of MS [38,39]. Other explanation could be due to fluctuations in individual 
and social behavior, such as modifications in socio-economic status or adoption of 
an unhealthy lifestyle [40].
Overall, the most prevalent MS-components were abdominal obesity (78.5%), 
low levels of HDL-c (57.3%), EABP, and high levels of fasting blood triglycerides 
(45.5%). Likewise, in the study of Davila et al.[27], where 312 (34.7% of the whole 
sample) older adults (55–64 years) from Medellin (Colombia) were evaluated, the 
major MS-metabolic risk factor was abdominal obesity with a prevalence of 87.4%, 
followed by low levels of HDL-c (59.1%), HLFBTg (52.0%) and EABP (44.8%).
Concerning MS-components analyzed by sex in the whole sample, several 
statistical differences were observed. For instance, females presented a higher 
prevalence of HWC and LLHDL than males. Moreover, females displayed 
significantly higher HLFBTg than males, but males presented a higher prevalence of 
EABP. Accordingly, in a French study conducted in 3508 participants, females 
presented a higher prevalence of HWC, and low HDL-cholesterol, whereas EABP 
was the most commonly found metabolic disorder in males; however, the age range 
only covered 35–64 years [41]. Alike, a Taiwanese study found a high prevalence of 
BP and TG in males below 60 years, although without differences in MS-components 
between genders in the age group above 60 years [42]. Additionally, a large Korean 
study including 103,763 participants aged 66 years or older revealed that females 
had a significantly higher percentage of abdominal obesity (+12%) and lower HDL-c 
levels (−47%) than men, whereas men presented higher rates of EABP (+6%). 
However, contrary to our results, the Korean study indicated that men had usually 
high levels of triglycerides (+5%), compared with woman [43]. Unfortunately, gender-
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related differences are sensitive to social and cultural conducts, dietary behaviors 
and psychosocial aspects [38]. 
Finally, the multivariate regression model indicated that the clinical 
characteristics that were associated with MS were male gender, to have a 
sarcopenia status, and smoking (after adjustment). In accordance with our results of 
univariate regression analysis, numerous studies have shown the high prevalence 
of MS and associated risk in people with a nutritional status of normal weight near 
the upper range or slightly overweight [44]. Moreover, sarcopenia has been linked 
to several metabolic disorders, and a recent meta-analysis revealed that it is 
positively associated with MS in middle-aged and older non-obese people [45]. In 
our study, sarcopenia status was high (14% for the overall sample) compared with a 
previous study carried out in the same region [46], where 6.96% of the participants 
(≥60 years old) presented sarcopenia. Also, our sarcopenia prevalence is higher 
than most of the studies conducted in older adults in other countries, going from 
Belgium with 12% to the United States with 5%, but not Japan (24.2%) [45]. 
However, stratification cut-off values for community-dwelling populations could vary 
between studies, as well as age range included. 
Lastly, regarding the significant association between MS and smoking status, a 
previous Chinese study showed that active smoking in men was strongly associated 
with increased CVD risk [47], independent of the presence of MS. Moreover, tobacco 
smoke exposure (including active and passive smoking) increased the prevalence 
of coronary heart disease, stroke, and CVD in both genders with or without MS. In 
the same line, smoking habits could also explain in part the association between MS 
and male gender, since in the present sample, significantly more smokers were 
males than females for the whole sample (males = 12.6% vs females = 6.9) and for 
most of the age stages.
In conclusion, the prevalence of MS is 54.9% among Colombian older adults and 
females presented the highest prevalence of MS irrespective of the aging stage. 
High abdominal obesity was the main prevalent MS-components (78.5%). Male 
gender, sarcopenia status, and being a smoker were found to be significantly 
associated with the probability of MS. New health policies and prevention strategies 
focused on the elderly Latin American population should be implemented based on 
these findings.
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Figure Legend
Figure 1.  A: Distribution of the prevalence of metabolic syndrome according to 
aging stage and sex. B: Prevalence of the MS-components according to sex. (HWC 
= High Waist Circumference; EABP =Elevated Arterial Blood Pressure; HLFG = High 
Levels of Fasting Glucose; HLFBTg= High Levels of Fasting Blood Triglycerides; 
LLHDL = Low Levels of High Density Lipoprotein; C: Prevalence of MS according to 
metabolic abnormalities. **p<0.001; *p=0.001. 
Figure 2. Multiple logistic regression model of the influencing factors associated with 
MS among Colombian older adults. Multiple logistic regression adjusted for age, 
ethnicity, socioeconomic status, urbanicity, BMI, medication use, and medical 
conditions (presence or absence of hypertension, diabetes, respiratory diseases, 
cardiovascular diseases, stroke, osteoporosis or cancer).
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Table 1. Characteristic of the sample study according to age group (stage) and sex.
Males (n=642) Females (n=995)
P 
value
Males
vs
femal
es
STAGE
I
STAGE
II
STAGE
III
STAGE
IV
STAGE
I
STAGE
II
STAGE
III
STAGE
IV
All       
(n=1637)
Overall 
males
(n=166 ) (n=150) (n=213) (n=113)
P 
value
(bet
ween 
stage
s)
Overall 
females
(n=303) (n=245) (n=312) (n=135)
P 
value
(betw
een 
stages
Sociodemographic characteristics
Age* 70.5 (7.9) 71.1 (8.1) 62.0 (1.38) 66.98 (1.5) 74.1 (2.8) 84.3 (3.6)
70.5 
(7.9) 62.0 (1.42) 66.8 (1.4) 74.1 (2.8) 84.7 (4.1)
Social Stratus
Level 1 492 (30.1) 205 (31.9) 50 (30.1) 48 (32.0) 68 (31.9) 39 (34.5)
287 
(28.8) 90 (29.7) 73 (29.8) 91 (29.2) 33 (24.4)
Level 2 697 (42.6) 266 (41.4) 75 (45.2) 58 (38.7) 92 (43.2) 41 (36.3)
431 
(43.3) 129 (42.6) 108 (44.1) 132 (42.3) 62 (45.9)
Level 3 410 (25.0) 158 (24.6) 35 (21.1) 41 (27.3) 51 (23.9) 31 (27.4)
252 
(25.3) 73 (24.1) 62 (25.3) 81 (26.0) 36 (26.7)
Level 4 30 (1.8) 10 (1.6) 3 (1.8) 3 (2.0) 2 (0.9) 0 (0.0) 20 (2.0) 10 (3.3) 1 (0.4) 6 (1.9) 3 (2.2)
Level >5 8 (0.5) 3 (0.5) 3 (1.8) 0 (0.0) 0 (0.0) 0 (0.0)
0.352
5 (0.5) 1 (0.3) 1 (0.4) 2 (0.6) 1 (0.7)
0.719
Urbanicity
Urban 1363 (83.3) 514 (80.1) 138 (83.1) 119 (79.3) 169 (79.3) 88 (77.9)
849 
(85.3) 258 (85.1) 212 (86.5) 263 (84.3) 116 (85.9
Rural 274 (16.7) 128 (19.9) 28 (16.9) 31 (20.7) 44 (20.7) 25 (22.1)
0.697 146 
(14.7) 45 (14.9) 33 (13.5) 49 (15.7) 19 (14.1)
0.897
Ethnic group
Indigenous 85 (6.1) 50 (9.2) 14 (8.8) 11 (8.0) 22 (12.2) 3 (4.6) 35 (4.1) 12 (4.2) 14 (6.1) 7 (2.7) 2 (2.7)
Black “mulato” or Afro-Colombian 130 (9.4) 57 (10.5) 16 (10.1) 15 (10.9) 15 (8.3) 11 (16.9) 73 (8.6) 31 (11.0) 16 (7.0) 21 (8.1) 5 (6.7)
White 422 (30.4) 154 (28.5) 52 (32.7) 39 (28.30) 48 (26.7) 15 (23.1)
268 
(31.7) 87 (30.7) 70 (30.7) 83 (32.0) 28 (37.3)
Others* 750 (54.1) 281(51.8) 77 (48.4) 138 (52.9) 95 (52.8) 36 (55.4)
0.404
469 
(55.5) 153 (54.1) 128 (56.1) 148 (57.1) 40 (53.3)
0.535 <.001
Anthropometric Characteristics
Waist Circumference* 92.5 (11.0) 93.4 (10.9) 93.3 (10.8) 92.1 (11.5)
93.87 
(10.2)
93.5 (11.8) 
@ 1.000
91.8 
(11.0) 91.7 (11.1) 92.8 (9.8) 92.7 (11.7) 88.4 (10.9)
$*@ <.030 <.001
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Abdominal Obesity 1285 (78.6) 410 (64.0) 108 (65.1) 95 (63.3) 137 (64.6) 70 (61.9)
875 
(88.0) 265 (87.5) 223 (91.0) 279 (89.7) 108 (80.0)
Non-Abdominal Obesity 350 (21.4) 231 (36.0) 58 (34.9) 55 (36.7) 75 (35.4) 43 (38.1)
0.950 119 
(12.0) 38 (12.5) 22 (9.0) 32 (10.3) 27 (20.0)
.010 <.001
BMI* 27.36 (4.6) 26.0 (3.9) 26.5 (3.7)
 @ 25.8 (4.1) @ 26.1 (3.6)
 
@ 25.2 (4.0)
>1.0
00
28.2 
(4.9) 28.3 (4.7)
 @ 28.8 (4.5) 
@ 28.6 (5.2) @ 25.7 (4.3) $* <.001 <.001
Nutritional Status
Underweight (<18.5 kg/m2) 22 (1.5) 12 (2.0) 3 (1.9) 6 (4.1) 1 (0.5) 2 (2.2) 10 (15.0) 1 (0.4) 1 (0.4) 4 (1.4) 4 (3.9)
Normal weight (18.5-24.9 kg/m2) 463 (30.9) 237 (39.8) 44 (28.0) 62 (42.8) 85 (42.1) 46 (50.5)
226 
(25.0) 67 (23.5) 52 (22.4) 61 (21.6) 46 (44.7)
Overweight (25-29.9 kg/m2) 618 (41.3) 255 (42.9) 83 (52.9) 55 (37.9) 87 (43.1) 30 (33.0)
363 
(40.2) 121 (42.5) 85 (36.6) 120 (42.4) 37 (35.9)
Obese (>30 kg/m2) 395 (26.4) 91 (15.3) 27 (17.2) 22 (15.2) 29 (14.4) 13 (14.3)
0.011
304 
(33.7) 96 (33.7) 94 (40.6) 98 (34.6) 16 (15.5)
<.001 <.001
Sarcopenia status
No 1393 (86) 551 (87.0) 149 (90.9) 130 (87.2) 183 (87.1) 89 (80.9)
842 
(85.4) 275 (91.1) 224 (92.2) 261 (84.7) 82 (61.7)
Yes 226 (14.0) 82 (13.0) 15 (9.1) 19 (12.8) 27 (12.9) 21 (19.1)
0.122 144 
(14.6) 27 (8.9) 19 (7.8) 47 (15.3) 51 (38.3)
<.001 0.350
Blood Parameters
ASBP (mmHg)* 132.64 (23.5) 134.0 (23.8)
131.6 
(22.0) $@ 131.4 (24.1)
135.3 
(24.3)
138.5 
(24.4)
>1.0
00
131.7 
(23.3)
126.51 
(21.9)$@
130.8 
(22.3) 135.4 (10.4)
$ 136.7 (26.2) $ <.001 .024
ADBP (mmHg)* 72.66 (11.7) 74.3 (12.3)
76.95 
(12.6) $ @ 74.4 (11.8)
73.4 
(12.0)$@
72.2 
(12.8)$@
<0.0
20
71.6 
(11.1)
72.3 
(10.4)@
73.3 
(11.7) 71.3 (10.3)
@ 67.4 (11.9)$*@ <.001 .045
Fasting Glycemia (mg/dL)* 98.34 (26.5) 97.25 (26.3) 95.6 (23.7) 95.1 (21.3)
100.5 
(33.1) 96.3 (24.0) 1.000
99.1 
(26.3) 99.6 (27.1)
100.2 
(32.1) 99.1 (23.6) 95.5 (17.1) >.050 >.050
Fasting Serum Triglycerides 
(mg/dL)* 160.94 (83.3)
153.7 
(81.6)
175.4 (9.3) 
$ 154.1 (16.6)
145.3 
(75.5)$@
137.8 
(69.8)$
<0.0
04
165.6 
(84.1) 166.1 (85.9)
167.7 
(89.3) 170.9 (83.3)
@ 148.6 (69.9) >.050 .001
HDL-Cholesterol (mg/dL)* 45.63 (12.9) 41.8 (11.3)
41.3 
(11.7)@ 42.1 (11.6)
@ 41.9 
(11.0)@
42.1 
(10.9)@ 1.000
48.1 
(13.3)
47.8 
(12.5)@
47.29 
(12.6)@ 47.46 (13.7)
@ 51.6 (14.5)$* <.020 <.001
LDL-Cholesterol (mg/dL)* 126.85 (35.3) 120.1 (32.7)
122.7 
(12.1)@
125.4 
(33.3)$
117.8 
(32.8) @
113.4 
(31.5)$ @ 0.033
131.2 
(36.2)
137.6 
(33.2)$@
129.10 
(37.1)
129.3 (38.6) 
$@
125.2 (33.6) 
$@ <.030 .010
Total-Cholesterol (mg/dL)* 195.32 (41.4) 183.9 (38.6)
189.8 
(39.4)$ @
189.8 
(39.28)$ @
180.3 
(37.4) @
174.5 
(36.4)$ @
<0.0
15
202.6 
(41.4)
209.0 
(39.4)$@
200.8 
(42.1)@
200.2 
(43.6)$@
197.2 
(38.1)$@ <.040 .010
Physical Fitness Parameters
Handgrip strength (kg) 32.4 (12.3) 40.03 (12.6)
44.8 
(12.1)@ 43.3 (10.9)
@ 38.87 
(11.7)@
30.3 
(11.6)$*@
<0.0
01
27.2 
(9.1) 29.1 (9.0)
$@ 27.9 
(8.7)$@ 25.8 (9.3)
@ 24.7 (8.6)$@ <.040 <.001
Low** 270 (17.5) 131 (21.2) 15 (9.3) 15 (10.1) 45 (22.3) 56 (52.8)
139 
(15.0) 25 (8.7) 32 (13.7 53 (18.3) 29 (25.0)
Moderate** 357 (23.1) 138 (22.3) 29 (18.0) 33 (22.1) 54 (26.7) 22 (20.8)
219 
(23.6) 66 (22.9) 52 (22.2) 73 (25.3) 28 (24.1)
High** 918 (59.4) 349 (56.5) 117 (72.7) 101 (67.8) 103 (51.0) 28 (26.4)
<0.0
01
569 
(61.4) 197 (68.4) 150 (64.1) 163 (56.4) 59 (50.9)
<.001 .007
Data have been expressed as frequency and percentage for qualitative variables and *mean and standard deviation for quantitative variables. MS: metabolic syndrome 
** Low: men, ≤30 (kg); women, ≤18 (kg). Moderate: men, >30 (kg) and ≤38 (kg); women, >18 (kg) and ≤24 (kg). High: men, >38 (kg); women, >24 (kg). ASP: Arterial 
Systolic Blood Pression; ADBP: Arterial Diastolic Blood Pression; HDL: High Density Lipoprotein; LDL: Low Density Lipoprotein; WHO: World Health Organization. 
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Missing DATA: Abdominal obesity = 2; Sarcopenia =18; Handgrip strength = 92; Smoking habits = 1; Fasting Glycemia = 15; Fasting Serum Triglycerides = 5; HDL-
Cholesterol = 8;  
Two-way ANOVA statistical significance symbols: (for pairs comparisons a highest p value was presented) $ statistical differences between aging stage groups
@ statistical differences between sex groups; $* statistical differences regarding the rest of the age subgroups; @* statistical differences regarding the rest of the age 
subgroups
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Table 2. Clinical characteristics and distribution by stage aged group 
Males (n= 642) Females (n=995)
STAGE 
I
STAGE 
II
STAGE 
III
STAGE 
IV
STAGE 
I
STAGE 
II
STAGE 
III
STAGE 
IV
Clinical characteristics
All       
(n=1637)
Overall 
males
(n=166 ) (n=150) (n=213) (n=113)
P value
(betwee
n stages)
Overall
Females
(n=303) (n=245) (n=312) (n=135)
P 
value
(between 
stages)
P value
Males
vs
females
Smoking habits
No smoke 1486 (90.8) 561 (87.4)
138 
(83.1)
121 
(74.7)
194 
(91.1)
108 
(95.6)
925 (93.1)
276 
(91.1)
231 
(94.3)
293 (94.2) 125 (92.6)
Smokes 150 (9.2) 81 (12.6) 28 (16.9) 38 (25.3) 19 (8.9) 5 (4.4)
<0.001
69 (6.9) 27 (8.9) 14 (5.7) 18 (5.8) 10 (7.4)
0.380 <0.001
Alcohol consumption
Non alcoholic 1438 (87.9) 505 (78.7)
109 
(65.7)
112 
(74.7)
182 
(85.4)
102 
(90.3)
933 (93.9)
278 
(91.7)
227 
(93.0)
299 (95.8)
129 
(95.6)
Alcoholic 198 (12.1) 137 (21.3) 57 (34.3) 38 (25.4) 31 (14.6) 11 (9.7)
<0.001
61 (6.1) 25 (8.3) 17 (7.0) 13 (4.2) 6 (4.4)
0.144 <0.001
Physical Activity “proxy”
Physically active 280 (17.1) 144 (22.4) 53 (31.9) 45 (30.0) 37 (17.4) 9 (8.0) 136 (13.7) 45 (14.9) 40 (16.4) 41 (13.2) 10 (7.4)
Non Physically active 1354 (82.9) 498 (77.6)
113 
(68.1)
105 
(70.0)
176 
(82.6)
104 
(92.0)
<0.001
856 (86.3)
258 
(85.1)
244 
(83.6)
269 (86.8)
125 
(92.6)
0.093 <0.001
Comorbid chronic diseases
Hypertension
911 (44.2) 307 (48.0) 63 (38.2) 59 (39.9)
116 
(54.5)
69 (61.1) <0.001 604 (60.8)
151 
(50.0)
141 
(57.6)
215 (69.1) 97 (71.9) <0.001
<.001
Diabetes 268 (16.4) 86 (13.4) 25 (15.2) 24 (16.1) 30 (14.1) 7 (6.2) 0.090 182 (18.3) 45 (14.9) 47 (19.2) 62 (19.9) 28 (20.7) 0.314 0.009
Respiratory diseases 183 (11.2) 64 (10.0) 11 (6.6) 11 (7.3) 22 (10.3) 20 (17.7) 0.013 119 (12.0) 25 (8.3) 27 (11.0) 47 (15.1) 20 (14.8) 0.043 0.209
Cardiovascular diseases 233 (14.3) 80 (12.5) 12 (7.2) 18 (12) 30 (14.2) 20 (19.9) 0.052 153 (15.4) 37 (12.2) 33 (13.5) 55 (17.6) 28 (20.7) 0.065 0.104
Stroke 85 (5.2) 39 (6.1) 5 (3.0) 10 (6.7) 18 (8.5) 6 (5.3) 0.169 46 (4.6) 11 (3.6) 11 (4.5) 13 (4.2) 11 (8.1) 0.330 0.316
Osteoporosis 207 (12.7) 33 (5.1) 3 (1.8) 6 (4.0) 15 (7.1) 9 (8.0) 0.054 174 (17.5) 38 (12.6) 37 (15.2) 72 (23.3) 27 (20.0) 0.004 <0.001
Cancer 90 (5.5) 37 (5.8) 8 (4.8) 6 (4.0) 13 (6.1) 10 (8.8) 0.367 53 (5.3) 15 (5.0) 14 (5.7) 18 (5.8) 6 (4.5) 0.925 0.710
Data have been expressed as frequency and percentage. P in bold = significant differences 
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Table 3. Relationship between MS status and clinical characteristics
Clinical characteristics Have MS Not Have MS
Pearson Chi- square 
P value
Sex
    Men 336 301
    Women 395 588
<0.001
Sarcopenia status 
    Yes 804 577
    No 78 143
<0.001
Handgrip strength
Low 476 435
Medium 201 151
High 163 104
0.025
Smoking status 
    Yes 76 72
       No 654 817
0.108
Alcohol intake
Yes 789 633
No 100 97
0.212
Physical Activity “proxy”
Physically active 139 139
Non Physically active 747 592
0.078
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Table 4. Univariate association analysis between MS and clinical characteristics 
Clinical characteristics OR 95% CI P value
Sex (reference males) 1.662 1.359 2.032 <0.001
Sarcopenia status
Yes (reference No) 2.550 1.901 3.434 <0.001
Handgrip Strength (reference Hight)
Low 1.432 1.084 1.892 0.011
Medium 1.216 0.949 1.559 0.121
Smoking status
Yes (reference No) 1.319 0.940 1.850 0.109
Alcohol intake
Yes (reference No) 1.209 0.897 1.629 0.212
Physical Activity “proxy”
Non Physically active (reference active) 0.793 0.612 1.026 0.078
BMI: Body Mass Index; WHO= World Health Organization. p value in bold = significant association
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Reference values for handgrip strength and their
association with intrinsic capacity domains among
older adults
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Abstract
Objective The purposes of this study were three-fold: (i) to describe handgrip strength in older individuals aged ≥60 years in
Colombia; (ii) to identify sex-speciﬁc and age-speciﬁc muscle weakness cut-off points in older adults; and (iii) to determine the
odds of adverse events for each of the intrinsic capacity domains for individuals with handgrip strength greater than the
muscle weakness cut-off points, as compared with their weaker counterparts.
Methods A cross-sectional study was conducted in Colombia, among 5237 older adults aged ≥60 years old (58.5% women,
70.5 ± 7.8 years), according to ‘SABE Survey 2015’. Handgrip strength data were obtained with a Takei dynamometer.
Sociodemographic variables, ﬁve domains of intrinsic capacity (i.e. locomotion, vitality, cognition, psychological, and sensory),
and medical conditions were assessed and analyzed. Adjustments variables were age, ethnicity, socio-economic status,
urbanicity, body mass index, smoking status, alcohol intake, drug use, physical activity, and co-morbid chronic diseases.
Sex-stratiﬁed analyses were conducted with logistic regression models.
Results Handgrip strength was greater among men than among women (26.7 ± 8.5 vs. 16.7 ± 5.7 kg, respectively, P< 0.001)
at all ages. Weak handgrip strength cut-off points ranged from 17.4 to 8.6 and from 10.1 to 4.9 in men and women, respec-
tively. Overall, participants with optimal handgrip strength had better intrinsic capacity [in men, odds ratio (OR) = 0.62, 95%
conﬁdence interval (CI) 0.53 to 0.71; P < 0.001; and in women, OR = 0.79, 95% CI 0.68 to 0.92; P = 0.002] than their weaker
counterparts. Also, men with optimal handgrip strength had a lower risk of hospitalization (OR = 0.47, 95% CI 0.29 to 0.78;
P = 0.004) than their weaker counterparts.
Conclusions This study is the ﬁrst to describe handgrip strength values and cut-off points for muscle weakness among a
nationally representative sample of Colombian older adults by age and sex. After categorizing older adults as weak or not weak
based on the handgrip cut-off points, non-weakness was associated with a decreased odds of intrinsic capacity impairments.
These cut-off points may be good candidates for clinical assessment of risks to physical and mental health in older Colombian
adults.
Keywords Skeletal muscle; Handgrip; Older adults; Locomotion; Vitality; Cognition; Mental health
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Introduction
Colombia is a country with approximately 48 million inhabi-
tants, with some 5.2 million inhabitants aged 60 years and
older.1 Currently, the life expectancy in Colombia is
72.3 years, and by 2025, life expectancy is expected to be
77.6 years for women and 69.8 years for men. In this
context, the World Health Organization has published the
World Report on Aging and Health,2 which describes healthy
ageing as the result of the interaction between the physical
and mental capacity of an individual (the intrinsic capacity)
and the context of each individual’s life (the environment).3
Accordingly, healthy ageing depends upon intrinsic capacity,
socio-economic status, and physical environment, and the in-
teractions between these factors.4 In this vein, the World
Health Organization has proposed ﬁve domains—locomotion,
vitality, cognition, psychological, and sensory—that can be
used to evaluate an individual’s intrinsic capacity.
Muscular strength as evaluated by handgrip strength has
predictive value for assessing declines in physical and mental
capacities in older adults,5 which are both components of the
intrinsic capacity construct. Recent studies have shown that
greater handgrip muscular strength is associated with lower
all-cause6 and cancer mortality.7
The world’s population is rapidly getting older8; thus, the
preservation of muscle strength and power with advancing
age is of considerable clinical signiﬁcance. Against this back-
ground, the development of clinically viable screening tools
for detecting individuals at heightened risk for functional lim-
itations is warranted.7 Indeed, it has been reported that hand-
grip strength reference values and muscular weakness cut-off
points for older adults are needed,9 but no data have yet been
described for the Colombian elderly population. Additionally,
several cross-sectional studies have presented different hand-
grip strength cut-off points in Italian,10 Finnish,11 Chinese,12
and American13,14 older adults, thus suggesting that different
ethnicities may have different muscle weakness cut-off points
for identifying clinically relevant health outcomes.
The results of the Survey on Health, Well-Being, and Aging
in Latin America and the Caribbean (SABE, from the initials in
Spanish SAlud, Bienestar, and Envejecimiento) have increased
our understanding of the ageing process and have helped to
create public policies aimed at improving the well-being of
the Latin American and Caribbean populations. They have
also provided a framework for performing a second set of
studies in the region.
The purposes of this study were three-fold: (i) to describe
handgrip strength in older individuals aged ≥60 years in
Colombia; (ii) to identify sex-speciﬁc and age-speciﬁc muscle
weakness cut-off points in older adults; and (iii) to determine
the odds of adverse events for each of the intrinsic capacity
domains for individuals with handgrip strength greater than
the muscle weakness cut-off points, as compared with their
weaker counterparts.
Materials and methods
Study design
This study is part of the 2015 SABE study Survey on Health,
Well-Being, and Aging in Latin America and the Caribbean.
Of the initial 23 694 elderly Colombians who took part in
SABE Colombia, a total of 5237 were included in the present
analysis after excluding participants without handgrip
strength results (n = 18 457). There were no differences in
the study key characteristics (i.e. age groups, body mass,
height, body mass index, and sex distribution) between the
current study sample and the original SABE study sample
(all P > 0.05). The 5237 elderly Colombians constituted the
ﬁnal analytical sample of the non-institutionalized population.
Institutional review boards at the two universities involved in
developing the SABE Colombia study (University of Caldas,
ID protocol CBCS-021-14, and University of Valle, ID protocol
09-014 and O11-015) reviewed and approved the study
protocol, and written informed consent was obtained from
each individual before inclusion and completion of the ﬁrst
examination (including permission to use secondary data
and blood samples). The study protocol to the secondary
analysis was approved by The Human Subjects Committee
at the Pontiﬁcia Universidad Javeriana (ACTA ID 20/2017-
2017/180, FM-CIE-0459-17).
Details of background and design methods (i.e. charac-
teristics of participants, sample calculation, outcomes, and
analysis plan) of the SABE study have been previously pub-
lished elsewhere1; nevertheless, the most relevant informa-
tion is brieﬂy described in the succeeding texts. All
information collected was obtained through face-to-face in-
terviews conducted at each site on mobile capture devices
(e.g. tablets) or with printed versions of the questionnaire.
During the personal interviews, direct physical measure-
ments were taken, including handgrip strength [absolute
and relative; i.e. handgrip strength (kg)/body mass (kg)],
measured with a Takei dynanometer (Takei Scientiﬁc
Instruments Co., Tokyo, Japan), height (standing and
sitting), and weight. Five domains of the intrinsic capacity
(locomotion, vitality, cognition, psychological, and sensory)
were assessed as follows: (i) the cognition domain was
assessed by the modiﬁed version of the mini-mental state
examination15,16; (ii) the locomotion domain was deﬁned
according to ﬁve deﬁnitions—sarcopenia,17 prevalence of
falls, functional impairments assessed with an activities of
daily living scale,18 mobility/disability,19 and physical perfor-
mance assessed by the validated Spanish version of the
short physical performance battery20; (iii) the psychological
domain was assessed by the Yesavage Geriatric Depression
Scale and mental problems; (iv) the sensory domain was
assessed as hearing and vision problems21; and (v) the
vitality domain was assessed as loss of appetite22 and
weight loss.
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The self-reported co-morbidities or medical conditions
category was assessed by asking the participants if they had
been diagnosed by a physician with hypertension, diabetes,
respiratory diseases, cardiovascular diseases, cancer, or osteo-
porosis. Drug use was evaluated with the following question:
‘Do you currently take or use any prescription medication’?
For the lifestyle domain, personal habits regarding alcohol
consumption and cigarette smoking were recorded. A ‘proxy
physical activity’ was also evaluated. Finally, hospitalization
>24 h in the last year was recorded. Details of the methods
are available in the Supporting Information.
Data analysis
We used SPSS v24.0 software for Windows (SPSS, Chicago, IL,
USA), except for the LMS method calculations (see the
succeeding texts). The optimal power to obtain normality
was calculated for each of a series of age groups and the
trend summarized by a smooth (L) curve. Trends in the mean
(M) and coefﬁcient of variation (S) were similarly smoothed.
The resulting L, M, and S curves contain the information to
produce any centile curve and to convert measurements
(even extreme values) into exact standard deviation (SD)
scores.23 Anthropometric and handgrip characteristics from
the study sample are presented as the mean and SD.
Normality for the selected variables was veriﬁed using
histograms and Q–Q plots. Differences were analyzed by
two-way analysis of variance or the χ2 test to compare sex
and age differences.
The LMS method assumes that the outcome variable has a
normal distribution after a Box–Cox power transformation is
applied, according to the LMS method implemented in the
LMS Chart Maker Pro Version 2.54 (Medical Research Council,
London, UK). Smoothed and speciﬁc curves for each age were
obtained via a penalized maximum likelihood with the follow-
ing abbreviations: M (median), L (Box–Cox transformation),
and S (coefﬁcient of variation).24 The appropriate number
of degrees of freedom was selected on the basis of the
deviance, Q-tests, and worm plots, following the suggestions
of Royston and Wright.25 The P3, P10, P25, P50, P75, P90,
and P97 smoothing centiles were chosen as age-speciﬁc and
sex-speciﬁc reference values. Statistical signiﬁcance was
assessed with a two-tailed α level of 0.05.
Finally, logistic regression models were used to compare
the prevalence of adverse events in the ﬁve domains of the
intrinsic capacity according to the cut-off for handgrip
strength. The analysis was adjusted for age, ethnicity,
socio-economic status, urbanicity, body mass index, smoking
status, alcohol intake, drug use, physical activity, and medical
conditions (presence or absence of osteoporosis, cardiovas-
cular diseases, hypertension, diabetes, cancer, or respiratory
diseases).
Results
The characteristics of the sample are summarized in Table 1.
Age ranged from 60 to85 years,with ameanof70.5 ±7.8 years.
Absolute and relative handgrip strength was higher among
men than among women (P < 0.001). In the total sample,
self-reported co-morbidities were presented in the following
proportions of cases: cancer (4.9%), respiratory diseases
(10.8%), osteoporosis (12.3%), cardiovascular diseases
(14.3%), diabetes (16.6%), and hypertension (55.9%). Accord-
ing to the intrinsic capacity domains, overall, women had more
problemswith locomotion, sensory, and psychological parame-
ters than men (P< 0.01), except in terms of hearing problems.
Table 2 and Figure 1 show smoothed age-speciﬁc and
sex-speciﬁc percentiles of handgrip strength in men (panel
A) and women (panel B). The data showed that men per-
formed better in the test at all ages than women. In men,
the 50th centile of handgrip strength ranged from 17.6 to
30.5 kg and in women from 12.4 to 18.5 kg. There was a de-
crease in muscle strength across the age range in both sexes.
Weak handgrip cut-off values using <1 SD by sex and age
group are shown in Table 3. These cut-off points ranged from
17.4 to 8.6 and from 10.1 to 4.9 in men and women,
respectively.
Finally, Figure 2 shows the association between optimal
handgrip strength (kg) with the domains of intrinsic capacity.
Overall, participants with optimal handgrip strength had bet-
ter intrinsic capacity than weak older adults, including both
men [odds ratio (OR) = 0.62, 95% conﬁdence interval (CI)
0.53 to 0.71; P < 0.001] and women (OR = 0.79, 95% CI 0.68
to 0.92; P = 0.002). Regarding the intrinsic capacity domains,
older men with optimal handgrip strength had lower odds of
having cognition (OR = 0.50, 95% CI 0.29 to 0.85; P = 0.010),
locomotion (OR = 0.47, 95% CI 0.37 to 0.59; P < 0.001), and
vitality (OR = 0.68, 95% CI 0.47 to 0.98; P = 0.040) problems
than their weaker counterparts. Older women with optimal
handgrip strength also had lower odds of having cognition
(OR = 0.44, 95% CI 0.24 to 0.80; P = 0.007), locomotion
(OR = 0.66, 95% CI 0.51 to 0.85; P = 0.001), and psychological
(OR = 0.57, 95% CI 0.40 to 0.82; P = 0.002) problems than their
weaker counterparts (Figure 2). Additionally, older men with
handgrip strength greater than the muscle weakness cut-off
points had lower odds of hospitalization than their weaker
counterparts (OR = 0.47, 95% CI 0.29 to 0.78; P = 0.004).
Discussion
Using a nationally representative sample of older Colombian
adults, this study presents normative data for handgrip
strength, identiﬁes sex-speciﬁc and age-speciﬁc muscle weak-
ness cut-off points, and determines the odds of adverse
events for each intrinsic capacity domain for individuals with
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handgrip strength greater than the muscle weakness cut-off
points. Overall, older adults with handgrip strength greater
than the muscle weakness cut-off points had lower odds of
adverse events in most of the intrinsic capacity domains
(especially in cognition and locomotion domains) and hospi-
talization (only in men) than their weaker peers. Our results
may inform intervention strategies aiming to increase muscle
strength and promote healthy ageing.
Table 1 Characteristics of the study participants (n = 5237)
Characteristics
Men (n = 2172) Women (n = 3065) Overall (n = 5237) P for
groupMean ± SD Mean ± SD Mean ± SD
Anthropometric and handgrip strength
Age (years) 70.8 ± 8.0 70.2 ± 7.7 70.5 ± 7.8 0.004
Height (cm) 162.9 ± 6.9 150.9 ± 6.3 156.0 ± 8.8 <0.001
Weight (kg) 67.8 ± 12.5 62.7 ± 13.2 64.8 ± 13.1 <0.001
BMI (kg/m2) 25.6 ± 4.0 27.7 ± 5.3 26.8 ± 4.9 <0.001
Handgrip strength (kg) 26.7 ± 8.5 16.7 ± 5.7 20.9 ± 8.6 <0.001
Handgrip (kg)/weight (kg) 0.40 ± 0.12 0.27 ± 0.10 0.33 ± 0.12 <0.001
n (%) n (%) n (%)
Sociodemographic outcomes
Socio-economic status
Level I 807 (37.2) 986 (32.2) 1793 (34.2) 0.088
Level II 897 (41.3) 1295 (42.3) 2192 (41.9) 0.397
Level III 417 (19.2) 662 (21.6) 1079 (20.6) 0.709
Level IV 38 (1.7) 90 (2.9) 128 (2.4) <0.001
Level V–VI 13 (0.6) 32 (1.0) 45 (0.9) 0.763
Urbanicity
Urban 1602 (73.8) 2453 (80.0) 4055 (77.4) 0.589
Rural 570 (26.2) 612 (20.0) 1182 (22.6) 0.016
Ethnic group
Indigenous 171 (7.9) 142 (4.6) 313 (6.0) <0.001
Black ‘mulato’ or Afro-Colombian 202 (9.3) 226 (7.4) 428 (8.2) 0.016
White 540 (24.9) 848 (27.7) 1388 (26.5) 0.671
Othersa 955 (44.0) 1351 (44.1) 2306 (44.0) 0.342
Cognition outcome
Cognitive impairment 304 (14.0) 498 (16.2) 802 (15.3) 0.014
Locomotion outcomes
Sarcopenia 445 (20.5) 796 (26.0) 1241 (23.7) <0.001
Falls 324 (14.9) 560 (18.3) 884 (16.9) <0.001
Functional impairment < 90 points 126 (5.8) 229 (7.4) 335 (6.3) <0.001
Difﬁculty walking 400 m 274 (12.6) 423 (13.8) 697 (13.3) <0.001
SPPB < 6 points 455 (20.9) 1015 (33.1) 1470 (28.1) <0.001
Psychological outcomes
Depression 1073 (49.4) 1605 (52.4) 2678 (51.1) <0.001
Mental problems 123 (5.7) 342 (11.2) 465 (8.9) <0.001
Sensory outcomes
Visual problems 1187 (54.7) 1715 (56.0) 2902 (55.4) <0.001
Hearing problems 618 (28.5) 682 (22.3) 1300 (24.8) <0.001
Vitality
Weight loss 335 (15.4) 582 (19.0) 582 (11.1) <0.001
Appetite loss 403 (18.6) 868 (28.3) 1271 (24.3) <0.001
Co-morbid chronic diseases
Hypertension 1040 (47.9) 1889 (61.6) 2929 (55.9) <0.001
Diabetes 306 (14.1) 562 (18.3) 868 (16.6) <0.001
Respiratory diseases 217 (10.0) 351 (11.5) 568 (10.8) 0.050
Cardiovascular disease 297 (13.7) 452 (14.7) 749 (14.3) 0.145
Osteoporosis 101 (4.7) 543 (17.7) 644 (12.3) <0.001
Cancer 98 (4.5) 161 (5.3) 259 (4.9) 0.122
Clinical outcomes
Hospitalized >24 h last year 249 (11.5) 378 (12.3) 627 (12.0) 0.187
Drug use 1360 (62.6) 2424 (79.1) 3784 (72.3) <0.001
Lifestyle outcomes
Alcohol 494 (22.7) 151 (4.9) 645 (12.3) <0.001
Smoking 329 (15.1) 219 (7.1) 548 (10.5) <0.001
Meeting PA recommendations 1683 (77.5) 2630 (85.8) 4313 (82.4) <0.001
Data are presented as mean ± SD or no. (percentage) of participants. Signiﬁcant differences between men and women group were
analyzed by Student’s t-test or χ2 test.
BMI, body mass index; PA, physical activity; SD, standard deviation; SPPB, short physical performance battery.
aOthers (mestizo, gitano and gypsy, etc.).
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Several handgrip strength normative ranges for older
adults from populations with different nationalities and eth-
nicities have been published in the last several years26–30;
however, to our knowledge, normal handgrip strength values
have never been described for the Colombian population. We
found that, overall, older Colombian adults have lower
handgrip strength values than their peers in other popula-
tions.26–29 Our results showing that gender and age affect
handgrip strength are in accordance with the ﬁndings of pre-
vious studies.26–29 Thus, the results of this study contribute to
the current body of literature by presenting sex-speciﬁc and
age-speciﬁc weakness cut-off points among the Colombian
elderly.
Different handgrip strength mean values have been ob-
served in different countries, as reported previously,20 but
the nature of these differences is not known. Differences
in handgrip strength mean values between Colombian older
individuals from a less-developed country (this study) and
individuals in developed countries may be due to a number
of factors, although it is uncertain which of the three fac-
tors, genetic, environment, or biological, are more decisive
for handgrip strength results.31 For instance, biological or
environment factors such as health status, lifestyle, and de-
mographic and socio-economic characteristics vary greatly
between countries with different handgrip strength levels.
Along this line, education and socio-economic status are
factors that might explain differences in handgrip strength
Figure 1 Absolute strength smoothed centile curves for men (A) and women (B) for Colombian aged 60+ years.
Table 2 Smoothed age-speciﬁc and sex-speciﬁc percentile of handgrip strength (kg) in men and women
Sex/age group n L S P3 P10 P25 P50 (M) P75 P90 P97
Men (n = 2172)
60–64 562 1.07 0.26 14.0 19.6 25.1 30.5 35.9 41.2 46.4
65–69 535 1.04 0.28 12.6 18.0 23.3 28.6 33.9 39.1 44.3
70–74 423 0.95 0.30 11.0 16.0 21.2 26.3 31.6 36.8 42.1
75–79 304 0.81 0.33 9.4 13.9 18.7 23.8 29.1 34.6 40.3
80–84 201 0.69 0.36 7.5 11.4 15.7 20.4 25.5 30.9 36.6
85+ 147 0.60 0.40 6.0 9.3 13.2 17.6 22.5 27.8 33.6
Women (n = 3065)
60–64 873 1.00 0.32 6.8 10.7 14.6 18.5 22.4 26.3 30.1
65–69 774 1.10 0.32 6.1 9.8 13.6 17.3 21.1 24.8 28.6
70–74 563 1.02 0.35 5.0 8.7 12.4 16.1 19.8 23.5 27.2
75–79 427 0.99 0.36 4.0 7.6 11.1 14.7 18.3 21.8 25.4
80–84 271 1.14 0.43 1.9 5.8 9.6 13.4 17.2 21.0 24.8
85+ 157 0.98 0.44 1.4 5.1 8.8 12.4 16.1 19.8 23.5
L, power in the Box–Cox transformation for ‘correcting’ the skewness; M, median; P, percentile; S, coefﬁcient of variation.
Table 3 Weak handgrip cut point values using <1 SD by sex and age
group
Sex/age group Cut point (kg)
Men Mean
60–64 17.4
65–69 15.7
70–74 14.3
75–79 12.3
80–84 10.1
85+ 8.6
Women
60–64 10.1
65–69 8.9
70–74 8.2
75–79 6.7
80–84 5.3
85+ 4.9
SD, standard deviation.
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ranges among countries.32 Also, beyond ethnic differences
in height and in skeletal muscle mass and function,33 there
are well-recognized differences in dietary protein intake
between different countries, and this variation might also
explain differences in muscle strength.34 Absolute strength
has also been related to nutrition status and is reported
to have positive inﬂuence on individuals’ grip strength.
Another possible reason for the divergence between studies
might be methodological differences (i.e. variability in the
equipment used and the protocol for measuring handgrip
strength).35
Several studies have determined absolute10,11,14 and
relative handgrip strength cut-off points12,13 that are overall
higher than our cut-off points. For example, Duchowny
et al.14 determined cut-off points for weakness associated
with gait speed (<0.8 m/s) in older American adults, with
Figure 2 Association between healthy handgrip strength (kg) with the components of the intrinsic capacity and hospitalization. The analysis was ad-
justed for age, ethnicity, socio-economic status, urbanicity, body mass index, smoking status, alcohol intake, drug use, physical activity, and medical
conditions (presence or absence of osteoporosis, cardiovascular diseases, hypertension, diabetes, cancer, or respiratory diseases). *Pooled intrinsic ca-
pacity was calculated without hospitalization outcome values. CI, conﬁdence interval; SPPB, short physical performance battery.
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values of <40 and <31 kg in men and women, respectively.
Similarly, Cruz-Jentoft et al.10 found that among
community-dwelling older adults in Italy, a handgrip strength
<30 kg in men and <20 kg in women was associated with
slow gait speed and an inability to walk 1 km without
difﬁculty. Therefore, different cut-off points are observed in
different countries; however, while the nature of these
differences is unclear,31 as mentioned, heterogeneous
designs, genetic, and environmental factors may explain
some of the differences among the studies.
The handgrip strength cut-off points reported in the
present study are useful for determining who among older
adults may beneﬁt from lifestyle modiﬁcations to preserve
muscle strength and reduce the odds of physical and
mental limitations. In this context, our results reveal that
older men with handgrip strength greater than the muscle
weakness cut-off points had a lower odds of hospitalization
for >24 h than their weaker counterparts. However, the
cross-sectional design of the present study did not allow
us to determine whether the measured handgrip strength
differed from habitual strength or if the handgrip was
impaired as a result of the presenting condition (see limita-
tions in the succeeding texts). Our results partially conﬁrm
those of previous studies that analyzed the prospective as-
sociation between customary handgrip strength and hospi-
tal admission, which showed varying results9,36 The
Hertfordshire Cohort Study9 provided evidence that hand-
grip strength among community-dwelling men and women
in the UK was associated with risk of hospital admission
over the following decade. In contrast, a prospective study
of 279 older adults aged ≥70 years from Germany who
were followed up for 18 months found no association
between handgrip strength and the risk of hospital
admission.36 The differences between these studies may
be explained by the thresholds for admission, which likely
differ between healthcare systems and their cross-sectional
design.
A recent narrative review reported that weak handgrip
strength was associated with reduced cognitive perfor-
mance over time; therefore, greater handgrip strength
may be protective against cognitive decline in older
adults.37 Indeed, recent evidence has shown that weak
handgrip strength is associated with an increased risk of
psychological problems such as depression.38,39 These ﬁnd-
ings were conﬁrmed by the results of our analysis, which
suggested that older adults with handgrip strength greater
than the muscle weakness cut-off points had lower odds
of cognitive impairment and depression than their weaker
peers. Overall, weak handgrip strength, cognition, and de-
pression share some risk and pathogenic factors (particu-
larly an increased rate of oxidative stress40 and
inﬂammation,41 decreased sex hormone levels,42 and maxi-
mal voluntary contraction43) that may inﬂuence the onset
of depression and cognitive impairment.44 Given the
strength of the evidence in this area, handgrip strength
and our cut-off points are easy to utilize and are clinically
useful biomarkers of cognitive decline and mental health
across the lifespan of individuals from the Colombian
population.
Physical decline, in terms of decreasing muscle weakness
and poor mobility, has been repeatedly included as an ad-
ditional vital sign45 and a key instrument for the functional
assessment of older patients.46 The present results are also
in agreement with those of previous research and suggest
that handgrip weakness is associated with measures of
functional limitations in older adults.47 For example, Ishizaki
et al.48 determined that older adults with weak handgrip
strength had difﬁculty performing many tasks, such as
shopping for groceries, preparing meals, and performing
housework. Our lower cut-off points appear to have the
ability to identify older adults of both sexes with locomo-
tion problems. Therefore, it seems that it is especially
important for older adults to preserve muscle strength to
avoid functional limitations, such as by participating in
muscle strengthening activities to preserve function. Addi-
tionally, our results suggest that optimal handgrip strength
is associated with a lower odds of experiencing weight loss
in older men, and so muscle strength could favour the
maintenance of optimal homeostasis.7
Finally, the only intrinsic capacity domain that did not ap-
pear to be related to handgrip strength was hearing impair-
ment. Hearing loss in the elderly is of increasing importance
as the global population ages. Disabling hearing negatively
affects communication and social engagement and can lead
to reduced quality of life in adults49 and may also underlie
cardiovascular risk and diseases (i.e. diabetes, hypertension,
and history of cerebrovascular accident).50 These associations
are mainly related to the compromised blood supply to the
cochlea under vascular disease conditions,51 as well as other
sensor neural, nutritional status, and medical co-morbidity
factors that may accumulate with age and are not a result
of normal ageing.51 Peripheral age-related hearing loss is also
a possible biomarker and modiﬁable risk factor for cognitive
decline, cognitive impairment, and dementia.50–52 Our
results, however, revealed that an individual with low levels
of handgrip strength might not necessarily have a worse
hearing status and suggest that different age-related mecha-
nisms could be underlying this.
The strengths of this study include the large sample size of
older adults with a nationally representative proportion of
persons aged ≥60 and the objective assessment of muscle
strength. This study does, however, have some limitations.
First, the cross-sectional design did not allow a deﬁnitive
conclusion that weak muscle strength precedes adverse
events. Second, several measures, such as falls, history of
chronic disease, and drug use, were self-reported by partici-
pants; therefore, different types of response biases may have
been introduced.
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Conclusions
This study provides reference values for handgrip strength in
Colombian individuals 60 years and older. After categorizing
participants as weak or not weak based on the handgrip
cut-off points, non-weakness was associated with a de-
creased odds of intrinsic capacity impairments, especially in
the cognition and locomotion domains, and of hospitalization
(only in men). Therefore, a simple handgrip strength test with
the appropriate cut-off points may be a good candidate for
clinical assessment of risks to physical and mental health in
older Colombian adults.
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Gait speed as a mediator of the effect of sarcopenia on
dependency in activities of daily living
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Abstract
Background Sarcopenia in older adults is strongly associated with an increase in dependency in activities of daily living (ADL)
and with a decline in gait speed. Interestingly, gait speed has been shown to independently predict mortality. In this context,
our study aimed to explore the mediator role of gait speed on the relationship between sarcopenia and dependency in ADL.
Methods A cross-sectional study was conducted in Colombia, 19 705 older adults with a mean age of 70 years, 55.6%
women, 16.1% with sarcopenia, and 14.7% mild, moderate, or severe dependency in ADL, according to ‘SABE Survey 2015’.
Sarcopenia was assessed by calf circumference and ADL dependence through the Barthel Index. Gait speed was measured over
a distance of 3 m. The association between sarcopenia condition and gait speed and dependency level was analysed by linear
regression adjusted by covariates. To examine whether gait speed mediated the association between sarcopenia and depen-
dence components of physical function, simple mediation models were generated using ordinary least squares with the macro
PROCESS version 3.2, adjusted for age, sex, and body mass index (BMI).
Results Signiﬁcant differences (P< 0.05) were found in gait speed and dependency in ADL between the sarcopenia and non-
sarcopenia groups after adjusting for age, sex, and BMI. BMI was signiﬁcantly higher in the non-sarcopenia group whereas de-
pendency was signiﬁcantly higher in the sarcopenia group (19.6% vs. 13.8%). Results from mediation model regression analysis
indicated a signiﬁcant and direct detrimental effect of sarcopenia on dependency in ADL (β = 0.05; P < 0.001), and a signif-
icant indirect effect of gait speed on the direct effect (0.009 to 0.004).
Conclusions The negative effect of sarcopenia on functional dependence was mediated by the gait speed. Therefore, gait
speed may positively inﬂuence the detrimental effect of sarcopenia for dependency, after adjusting for age, gender, and
BMI. Consequently, physical exercise should be promoted and focused to circumvent the gait speed decline associated with
age in older people with sarcopenia.
Keywords Gait speed; Sarcopenia; Elderly; Functional Capacity; Latin-American
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Introduction
Sarcopenia is an age-related loss of muscle mass and function
in older adults and may favour the appearance of cardiovas-
cular complications or neurodegenerative disorders1,2. While
its prevalence is variable depending on its localization and the
method of evaluation, it is estimated that 29% of older per-
sons in community-dwelling populations and 14–33% in
long-term care populations are affected by sarcopenia.3 In
Colombia, recent results from SABE Bogota study estimated
that sarcopenia affects 11.5% of the older population.4
Sarcopenia is related to several functional comorbidities
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including mobility disorders, risk of falls and fractures, and a
loss of physical independence in activities of daily living
(ADL).5,6 It seems that sarcopenia depends on several
coadjuvant factors such as inﬂammatory processes related
to aging, nutritional status, intramuscular fat, and genetics,
in addition to the reduction of physical activity, which is a cru-
cial precursor of sarcopenia.2,7 In the context of the afore-
mentioned factors, there is evidence to indicate that both
aerobic and resistance training promote a healthy anti-
inﬂammatory milieu largely through the release of muscle-
derived myokines,8 mitigate mitochondria-related dysfunc-
tion,8 and ameliorates age-related loss of muscle mass and
strength9 as well as functional capacity and physical
performance.10
As a locomotor capacity, gait speed is representative of
neuromuscular quality (morphological and neuronal)1 and a
critical determining factor for healthy aging. Indeed, the Eu-
ropean Working Group on Sarcopenia in Older People has de-
veloped an algorithm including gait speed measurement as
the easiest and most reliable way to determine sarcopenia
in clinical practice,11 and also this has been used to diagnose
functional disability and dependence in older adults.11–13 Cor-
respondingly, the loss of muscle mass and consequently the
declining of gait speed are age associated; for example, in a
4-year follow-up of older Chinese, the percentage decline in
gait speed was 8.2% and 9.0% in men and women,
respectively.14
On the other hand, sarcopenia, resulting from reduced
skeletal muscle mass, is associated with aging.15 Based on
the need for a simpler method of assessing muscle mass in
community-based, and large-scale epidemiological contexts,
several regions (Europe, USA, and Asia) and organizations in-
corporated the use of calf circumference (CC), as a marker of
muscle mass in elderly people in primary care setting11,16–18.
In a Japanese study including 526 participants, CC was
positively correlated with appendicular skeletal muscle and
as a surrogate marker of muscle mass for diagnosing
sarcopenia.19
In addition, the sarcopenia and the impairment of gait
speed are strongly associated to loss of independence in
ADL.20–22 Therefore, these have three factors related to
sarcopenia → declining of gait speed→ loss of independency
in ADL; and between them, a vicious circle is formed. Conse-
quently and taking into account the previous studies, 23,24 the
gait speed seems to be the key factor that can worsen this vi-
cious circle or on the contrary improve it. This possible role of
gait speed is known as a mediator role and can be explore
through mediation analysis. Statistical mediation analysis al-
lows us to understand how an independent variable ‘X’ af-
fects a dependent variable ‘Y’ through the indirect effect of
the mediating variable ‘M’.15 For instance, mediation analysis
could identify if gait speed do and do not mediate these ad-
verse effects of sarcopenia on dependency. This knowledge
could help to adjust physical activity program in older adults,
emphasizing the improvement of gait speed. Accordingly, the
mediator variable ‘M’ (gait speed) may play a role as the me-
diator of the relationship between the antecedent variable ‘X’
(sarcopenia) and the outcome variable ‘Y’ (loss of indepen-
dence)25 (Figure 1).
While it is known that the level of physical ﬁtness affects
independence and that exercise can counteract the detri-
mental effects of sarcopenia, to our knowledge, no studies
have addressed the role of the gait speed in the relationship
between sarcopenia and loss of functional independence.
Here, we hypothesized that gait speed could have an attenu-
ating effect on the relationship between sarcopenia and loss
of independence.
Method
Study design and sample population
The present study is part of the 2015 SABE study survey on
health, well-being, and aging in Latin America and the Carib-
bean. SABE is a multicentre project originally conducted by
the Pan-American Health Organization and supported by
the Epidemiological Ofﬁce of the National Health Ministry in
Bogotá, Colombia (https://www.minsalud.gov.co/). Details
of the survey have been published elsewhere.26
In brief, data collection took place between April and Sep-
tember 2015, and the response proportion ranged from
~62% in urban areas to 77% in rural sites.26 The estimated
sample size was 24 553 individuals, and assuming an 80% re-
sponse the target sample was 30 691 individuals.26 The esti-
mated sample size was 24 553 individuals, and assuming an
80% response the target sample was 30 691 individuals. How-
ever, at ﬁeldwork after implementing several strategies to
achieve the overall sample and prevent nonparticipation, re-
sponse proportion was about 70% and varied by region and
urban/rural distributions. The ﬁnal sample size achieved, in-
cluding 244 municipalities (n = 23 694 older adults) across
Figure 1 Statistical mediation simple diagram.
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all departments (i.e. states) of the country. Of the 23 694 par-
ticipants who took part in SABE Survey, a total of 19 705
remained in the present analysis after excluding participants
without a BMI (n = 1684), ADL (n = 1281), and CC
(n = 1024) values.
Institutional review boards at the two universities involved
in developing the SABE Colombia study [University of Caldas
(ID protocol CBCS-021-14) and University of Valle (ID protocol
09-014 and O11-015)] reviewed and approved the study pro-
tocol, and written informed consent was obtained from each
individual before inclusion and completion of the ﬁrst exami-
nation (including permission to use secondary data and blood
samples). Permission was obtained from the National Health
Ministry in Bogotá, Colombia, to use the publicly available
data for research and teaching purposes (Pontiﬁcia
Universidad Javeriana). The study protocol to the secondary
analysis was approved by the Human Subjects Committee at
the Pontiﬁcia Universidad Javeriana (ID 20/2017-2017/180,
FM-CIE-0459-17). Further details can be obtained from the
website of the National Health Ministry in Bogotá,
Colombia-SABE (https://www.minsalud.gov.co/sites/rid/
Lists/BibliotecaDigital/RIDE/VS/ED/GCFI/doc-metodologia-
sabe.pdf).
Data collection
Body measurement assessments were collected by investiga-
tors trained in standardized measurement methods, previ-
ously trained by research staff from the coordinating
centres (Universities of Caldas and Valle). All information col-
lected were obtained through face-to-face interviews con-
ducted at each site on mobile capture devices (tablets) or
with printed versions of the questionnaire.
Body mass was measured using weighing scales to the
nearest 0.1 kg; height was measured using a stadiometer to
the nearest 0.1 cm, with the body mass index (BMI, kg/m2)
was subsequently derived. We deﬁned sarcopenia according
to CC, as proposed by Rolland et al.,27 as a ‘proxy’ measure
for assessing muscle mass and early identiﬁcation of
sarcopenia in clinical practice, due to the low cost and ease
of application. As described,27 a CC <31 cm is considered to
be indicative of low muscle mass. This cut-off has been rec-
ommended for use in older individuals by the WHO Expert
Committee.28 Thus, CC measures are practical have accept-
able accuracy for estimating sarcopenia when compared with
dual-energy X-ray absorptiometry, the gold standard for body
composition assessment.27 CC was measured at a plane per-
pendicular to the long axis of the calf while the participant
was sitting on chair or standing with foot ﬂat on the ﬂoor
using an inelastic tape measure. Thus, the CC values pre-
sented here combine the results of left-foot and right-foot
subjects, without consideration for lower body dominance.
Gait speed over a distance of 3 m was measured three times,
and the analysis used the shortest time of the three
attempts.
Functional impairment was assessed with an ADL evalua-
tion using a Spanish-adapted version of the physical level
ADL (Barthel Index).29 The items are weighted: a maximum
score of 100 indicates independence, 91–99 minimal depen-
dence, 75–90 mild dependence, 50–74 moderate depen-
dence, 25–49 severe dependence, and 0–24 total
dependence.30 The socio-economic level (I to VI), ethnic group
(indigenous, black ‘mulato’ or Afro-Colombian, white, and
others, mestizo, gitano, etc.), and tobacco smoking (patients
were categorized as those who do not smoke, those who have
never smoked, those who currently smoke, or those who pre-
viously smoked) were recorded. A ‘proxy physical activity’ was
evaluated by the following questions: (i) ‘Have you regularly
exercised, such as jogging or dancing, or performed rigorous
physical activity at least three times a week for the past year?’
(ii) ‘Do you walk at least three times a week between 9 and 20
blocks (1.6 km) without resting?’ And (iii) ‘Do you walk at least
three times a week 8 blocks (0.5 km) without resting?’ Those
participants who responded afﬁrmatively to two of the three
questions were considered physically active. Finally, nutri-
tional status was assessed by using the longer, original version
of the Mini-Nutritional Assessment and mobility disability was
deﬁned as having difﬁculty in walking 400m or climbing a
ﬂight of stairs without resting.26
Statistical analysis
Before statistical analysis was performed, the normality of var-
iables was tested using the Kolmogorov–Smirnov test. The
variables that presented non-uniformity were transformed
via natural logarithm or reciprocal transformation (1/x)
depending on positive or negative skew.31 For the descriptive
analysis of the sample, we used percentages and frequency
distributions for categorical variables, and mean with standard
deviation for continuous quantitative variables. The character-
istics of the participants with and without sarcopenia were
compared with the chi-squared test for categorical variables
and Student’s t-test for continues variables. The association
between sarcopenia condition and gait speed and depen-
dency level was analysed by linear regression using three
separate models. We entered sarcopenia as predictor variable
and gait speed and dependency categories as outcome vari-
ables and three separate models: Model 1 adjusted by sex,
gender, and BMI; Model 2 adjusted by Model 1 + nutritional
status; Model 3 adjusted by Model 2 and mobility disability.
To examine whether gait speed mediated the association
between sarcopenia and dependence components of physical
function, simple mediation models were generated using or-
dinary least squares with the macro PROCESS version 3.2, ad-
justed for age, sex, and BMI. Mediation hypotheses were
tested using the bias-corrected bootstrap method with 5000
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samples to calculate conﬁdence intervals (95%). An indirect
effect was considered signiﬁcant when the conﬁdence inter-
val did not include zero.25
Results
The descriptive characteristics and differences between the
sarcopenia and non-sarcopenia groups are shown in Table 1
. The classiﬁcation of sarcopenia according to the CC criterion
categorized 16.1% of older adults with sarcopenia, with a
higher prevalence of sarcopenia in women than in men. Re-
garding sociodemographic covariates, the results indicated a
higher prevalence of sarcopenia with advanced age and with
low socio-economic level. In total, 80.7% of the participants
with sarcopenia did not achieve the minimum level of recom-
mended physical activity proxy. Finally, BMI was signiﬁcantly
higher in the non-sarcopenia group whereas dependency
was signiﬁcantly higher in the sarcopenia group (19.6% vs.
13.8%).
Table 2 shows the associations between sarcopenia and
gait speed and dependency level. The results from regression
analysis indicate a signiﬁcant association between sarcopenia
and gait speed independently of age, gender, BMI, nutritional
status, and mobility disability. Likewise, the association be-
tween sarcopenia and dependency level is signiﬁcant when
adjusted the regression by age, gender, BMI, and nutritional
status; however, this association is not signiﬁcant when in-
cluded in the model the mobility disability.
Table 1 Sample characteristics stratiﬁed by sarcopenia status
Sample characteristics Sarcopenia (N = 3168) Non-sarcopenia (N = 16 537) Total (N = 19 705) P-value
Female, n (%) 2021 (18.4) 8943 (81.6) 10 964 (55.6) <0.001
Male, n (%) 1147 (13.1) 7594 (86.9) 8741 (44.4)
Age group, n (%)
60–64 621 (10.3) 5393 (89.7) 6014 (30.5) <0.001
65–69 640 (12.8) 4360 (87.2) 5000 (25.4)
70–74 644 (17.3) 3076 (82.7) 3720 (18.9)
75–79 585 (21.7) 2107 (78.3) 2692 (13.7)
80–84 392 (26.5) 1086 (73.5) 1478 (7.5)
85+ 286 (35.7) 515 (64.3) 801 (4.1)
Socio-economic level, n (%)
1 1714 (54.1) 6971 (42.2) 8685 (44.1) <0.001
2 1073 (33.9) 6420 (38.8) 7493 (38.0)
3 309 (9.8) 2654 (89.6) 2963 (15.0)
4 57 (1.8) 383 (2.3) 440 (2.2)
>5 15 (0.5) 109 (0.7) 124 (0.6)
Ethnic group, n (%)
Indigenous 236 (10.3) 1124 (7.8) 1360 (8.1) <0.001
Black 288 (12.6) 1701 (11.8) 1989 (11.9)
White 546 (23.9) 4002 (27.7) 4548 (27.1)
Others (mestizo, gitano/gypsy, etc.). 1212 (53.1) 7646 (52.8) 8858 (52.9)
Smoking status, n (%)
Yes 526 (16.6) 1695 (10.3) 2221 (11.3) <0.001
No 2642 (83.4) 14 840 (89.7) 17 482 (88.7)
Physical activity ‘proxy’, n (%)
Yes 3190 (19.3) 375 (11.8) 3565 (18.1) <0.001
No 13 327 (80.7) 2790 (88.2) 16 117 (81.9)
Mobility disability, n (%)
No 2120 (66.9) 11 810 (71.4) 13 930 (70.7) <0.001
Barely 502 (15.8) 2505 (15.1) 3007 (15.3)
Some problems 275 (8.7) 1138 (6.9) 1413 (7.2)
A lot of problems 249 (7.9) 1008 (6.1) 1257 (6.4)
Cannot walk 400 m, or climb a ﬂight
of stairs without rest.
17 (0.5) 63 (0.4) 92 (0.4)
Body mass index, mean (SD) 22.4 (3.7) 27.9 (4.6) 27.0 (4.9) <0.001
Nutritional status, n (%)
Malnutrition 282 (8.9) 413 (2.5) 650 (3.3) <0.001
Risk of malnutrition 1603 (50.6) 5325 (32.3) 6838 (34.7)
Normal nutritional status 1283 (40.5) 10 782 (65.2) 12 217 (62.0)
Dependency levels, n (%)
Dependency 1 (0.0) 0 (0.0) 1 (0.0) <0.001
Severe 13 (0.4) 6 (0.1) 19 (0.1)
Moderate 250 (7.9) 836 (5.1) 1086 (5.5)
Mild 357 (11.3) 1433 (8.7) 1790 (9.1)
Non-dependency 2547 (80.4) 14 262 (86.2) 16 809 (85.3)
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Figure 2 shows the mediation models used to determine
whether the performance in physical function could mediate
the adverse effect of sarcopenia on dependency. In Figure 2,
the regression a (β = 0.02; P = 0.001) indicated that
sarcopenia leads to lower gait speed, and b (β = 0.25;
P < 0.001) shows a signiﬁcant direct relationship between
higher gait speed and less functional dependence. Also, a di-
rect effect (β = 0.05; P < 0.001) was observed for the ad-
verse outcome of sarcopenia on functional dependence.
Our mediational hypothesis was conﬁrmed because the con-
ﬁdence intervals did not include zero (0.009 to 0.004);
therefore, gait speed has a mediation effect on the relation-
ship between sarcopenia and functional dependence.
Discussion
The major ﬁndings of our analysis were that sarcopenia may
negatively inﬂuence the independence in ADL in older adults,
but this adverse association could be counteracted if physical
function performance does not decline. Therefore, gait speed
may positively inﬂuence the detrimental effect of sarcopenia
for dependency, after adjusting for age, gender, and BMI.
Older adults who present characteristics of sarcopenia but
have a better gait speed than their fewer ﬁt peers will show
better functional dependency in ADL, because the association
between sarcopenia and dependence was mediated for this
physical ﬁtness component. Our results thus contribute to
the current knowledge by providing evidence that presenting
a better proﬁle in gait speed may ameliorate the negative im-
pact of sarcopenia on dependency.
CC is an anthropometric parameter that is closely related to
whole body muscle mass and is known to be associated with
the nutrition status of the elderly population.22 Our ﬁndings
indicate that lower CC, a valid predictor of sarcopenia,18,19
might increase the risk of dependency in older adults. This re-
sult is similar to previous cross-sectional studies in which lower
CC was associated with poor functioning in basic ADL, indicat-
ing the high dependency of these patients and a high necessity
of care.20,32 Our results also suggest that sarcopenia induces a
lower gait speed. Indeed, it is well documented that the dete-
rioration of gait speed related to sarcopenia during aging is
due to quantitative and qualitative changes in muscle struc-
ture and function.1 We also found that the lower the gait
speed, the greater dependency, which is in accord with the lit-
erature on this topic,6,33 in which a lower gait speed is related
to more problems in ADL. Accordingly, physical activity fo-
cused on counteracting the decline in gait speed could prevent
functional dependency. Overall, our ﬁndings are consistent
with previous studies presenting strong evidence on the pre-
ventive role of gait speed on all-cause mortality.24 Conse-
quently, the mediator role of gait speed between sarcopenia
and dependence has robustness.
Our results clearly show the differences between older
adults with sarcopenia and non-sarcopenia in the performance
in gait speed and the level of dependence. As shown in previ-
ous studies, our ﬁndings conﬁrm that sarcopenia results in
lower gait speed18,34 and independence in daily living.6,35 Con-
sequently, the promotion of physical activity in older adults is
key to maintain the muscle mass to prevent the deterioration
of gait speed. In this line, it seems that preventing the
deterioration of gait speed is crucial, because it has been
shown to be the physical function component more related
to sarcopenia, functional independence, vitality, and
frailty22,35–37 and is used as a signiﬁcant predictor of frailty
and all-cause mortality.22,38 Furthermore, recent studies have
Table 2 Associations between sarcopenia and gait speed and depen-
dency in older adults
Outcome variable β P-value 95% CI
Gait speed
Model 1 0.040 <0.001 (0.038 to 0.017)
Model 2 0.021 0.001 (0.033 to 0.009)
Model 3 0.017 0.006 (0.029 to 0.005)
Dependency
Model 1 0.066 <0.001 (0.088 to 0.044)
Model 2 0.017 0.007 (0.055 to 0.009)
Model 3 0.019 0.101 (0.041 to 0.004)
Model 1 = adjusted by sex, age, and body mass index; Model
2 = adjusted by Model 1 + nutritional status; Model 3 = adjusted
by Model 2 + mobility disability.
Figure 2 Gait speed as mediator of the effect of sarcopenia on dependency in activities daily living. BMI, body mass index.
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related a decline in gait speed, sarcopenia, pro-inﬂammatory
biomarkers, and functional dependence,39,40 fostering a vi-
cious cycle that may be broken with physical exercise.9
There are several plausible explanations for our ﬁnding.
First, there was a close relationship between sarcopenia,
physical performance (gait speed), and dependency. Muscle
mass is a metabolic tissue and endocrine organ, and the con-
struction of muscle mass releases several endocrines called
myokines, produced, expressed, and released by muscle ﬁ-
bres under contraction, and exerts both local and pleiotropic
effects.39 In this line, reports of a previous cross-sectional
study show a greater proportion of low muscle density in
older people with a lower CC scores; moreover, an associa-
tion was found between high BMI and increased functional
disability and the presence of comorbidities and coexisting
factors of disability. In addition, reduced muscular strength
is known to be signiﬁcantly and independently associated
with functional impairment, walking speed, mobility tasks,
physical performance, and all-cause mortality in the elderly
population.39,40 Accordingly, gait speed performance, which
is related to muscle mass quality, may be one mechanism
for the mediator role between sarcopenia and dependence.
Our study has several limitations that warrant consider-
ation. First, the cross-sectional design of the study limits the
causality of the ﬁndings and only associations can be drawn,
providing hypotheses that can be veriﬁed in future studies. A
second limitation is the criteria used to establish sarcopenia
and non-sarcopenia groups, since the European Working
Group on Sarcopenia in Older People proposes an algorithm
for sarcopenia case-ﬁnding and not only CC; however, it seems
that CC is a valid and reliable method to diagnose
sarcopenia.18,19 Another limitation that could affect the re-
sults of this study is the level of functional dependence, be-
cause this was assessed through a self-reported
questionnaire.41
To the best of our knowledge, this is the ﬁrst study aimed
at investigating the possible role of gait speed performance in
the relationship between sarcopenia and functional depen-
dence. As previously discussed, there is an adverse effect of
sarcopenia on functional dependence in older adults, and de-
pending on the level of gait speed, this adverse effect could
be aggravated or improved. Thus, gait speed plays a mediator
role between sarcopenia and dependence in ADL.
Conclusions and implications
The relationship between sarcopenia and functional depen-
dence is mediated by gait speed, which can attenuate this
negative impact. Accordingly, promoting physical exercise in
older adults with sarcopenia focused on improving gait speed
should counteract the loss of functional independence associ-
ated with sarcopenia.
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